CA2329506A1 - Alg-2lp, alg-2 like molecules and uses therefor - Google Patents
Alg-2lp, alg-2 like molecules and uses therefor Download PDFInfo
- Publication number
- CA2329506A1 CA2329506A1 CA002329506A CA2329506A CA2329506A1 CA 2329506 A1 CA2329506 A1 CA 2329506A1 CA 002329506 A CA002329506 A CA 002329506A CA 2329506 A CA2329506 A CA 2329506A CA 2329506 A1 CA2329506 A1 CA 2329506A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- protein
- nucleic acid
- amino acid
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101100490849 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) alg-2 gene Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 478
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 367
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 273
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 265
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 265
- 238000003782 apoptosis assay Methods 0.000 claims abstract description 53
- 230000005522 programmed cell death Effects 0.000 claims abstract description 53
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 151
- 238000000034 method Methods 0.000 claims description 111
- 239000012634 fragment Substances 0.000 claims description 94
- 150000001413 amino acids Chemical class 0.000 claims description 64
- 239000013598 vector Substances 0.000 claims description 59
- 239000000523 sample Substances 0.000 claims description 49
- 241000282414 Homo sapiens Species 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 44
- 108020004999 messenger RNA Proteins 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 33
- 108091026890 Coding region Proteins 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 13
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 6
- 239000002853 nucleic acid probe Substances 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000018855 positive regulation of programmed cell death Effects 0.000 claims description 2
- 238000000159 protein binding assay Methods 0.000 claims description 2
- 230000018901 negative regulation of programmed cell death Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 abstract description 53
- 241001465754 Metazoa Species 0.000 abstract description 51
- 239000013604 expression vector Substances 0.000 abstract description 43
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 41
- 102000037865 fusion proteins Human genes 0.000 abstract description 28
- 108020001507 fusion proteins Proteins 0.000 abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 22
- 239000000203 mixture Substances 0.000 abstract description 21
- 230000009261 transgenic effect Effects 0.000 abstract description 21
- 238000003259 recombinant expression Methods 0.000 abstract description 14
- 230000000890 antigenic effect Effects 0.000 abstract description 7
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 243
- 210000004027 cell Anatomy 0.000 description 162
- 125000003729 nucleotide group Chemical group 0.000 description 135
- 239000002773 nucleotide Substances 0.000 description 133
- 108020004414 DNA Proteins 0.000 description 68
- 239000002299 complementary DNA Substances 0.000 description 52
- 230000014509 gene expression Effects 0.000 description 51
- 125000000539 amino acid group Chemical group 0.000 description 44
- 235000001014 amino acid Nutrition 0.000 description 43
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- 229940024606 amino acid Drugs 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 34
- 230000000295 complement effect Effects 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 26
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 23
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 23
- 210000000349 chromosome Anatomy 0.000 description 22
- 239000013615 primer Substances 0.000 description 21
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 20
- 238000009396 hybridization Methods 0.000 description 20
- 230000001105 regulatory effect Effects 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 19
- 108700019146 Transgenes Proteins 0.000 description 18
- 241000282693 Cercopithecidae Species 0.000 description 17
- 239000012472 biological sample Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000035772 mutation Effects 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 15
- 230000004927 fusion Effects 0.000 description 15
- 108010079364 N-glycylalanine Proteins 0.000 description 14
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 14
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 14
- -1 hALG-2LP Chemical class 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 238000012216 screening Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- OISWSORSLQOGFV-AVGNSLFASA-N Arg-Met-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCCN=C(N)N OISWSORSLQOGFV-AVGNSLFASA-N 0.000 description 13
- 210000004408 hybridoma Anatomy 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- JNGHLWWFPGIJER-STQMWFEESA-N Gly-Pro-Tyr Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JNGHLWWFPGIJER-STQMWFEESA-N 0.000 description 11
- MIICYIIBVYQNKE-QEWYBTABSA-N Phe-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N MIICYIIBVYQNKE-QEWYBTABSA-N 0.000 description 11
- 102100034785 Programmed cell death protein 6 Human genes 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
- 210000004958 brain cell Anatomy 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 230000002074 deregulated effect Effects 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 108010087823 glycyltyrosine Proteins 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 10
- 108010070675 Glutathione transferase Proteins 0.000 description 10
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 10
- LZHHZYDPMZEMRX-STQMWFEESA-N Pro-Tyr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O LZHHZYDPMZEMRX-STQMWFEESA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 108010010147 glycylglutamine Proteins 0.000 description 10
- 238000002744 homologous recombination Methods 0.000 description 10
- 230000006801 homologous recombination Effects 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 108090000994 Catalytic RNA Proteins 0.000 description 9
- 102000053642 Catalytic RNA Human genes 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 9
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 9
- 101710089369 Programmed cell death protein 6 Proteins 0.000 description 9
- JWGXUKHIKXZWNG-RYUDHWBXSA-N Tyr-Gly-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O JWGXUKHIKXZWNG-RYUDHWBXSA-N 0.000 description 9
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 9
- 230000004075 alteration Effects 0.000 description 9
- 230000030833 cell death Effects 0.000 description 9
- 239000012707 chemical precursor Substances 0.000 description 9
- 108010060199 cysteinylproline Proteins 0.000 description 9
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 9
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 9
- 210000003917 human chromosome Anatomy 0.000 description 9
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 9
- 108091092562 ribozyme Proteins 0.000 description 9
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 8
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 8
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 description 8
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 description 8
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 8
- IRLYZKKNBFPQBW-XGEHTFHBSA-N Val-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N)O IRLYZKKNBFPQBW-XGEHTFHBSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 201000000050 myeloid neoplasm Diseases 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 8
- 108010031719 prolyl-serine Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 7
- PVQLRJRPUTXFFX-CIUDSAMLSA-N Ala-Met-Gln Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PVQLRJRPUTXFFX-CIUDSAMLSA-N 0.000 description 7
- XVLLUZMFSAYKJV-GUBZILKMSA-N Arg-Asp-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XVLLUZMFSAYKJV-GUBZILKMSA-N 0.000 description 7
- OGUPCHKBOKJFMA-SRVKXCTJSA-N Arg-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N OGUPCHKBOKJFMA-SRVKXCTJSA-N 0.000 description 7
- BFDDUDQCPJWQRQ-IHRRRGAJSA-N Arg-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O BFDDUDQCPJWQRQ-IHRRRGAJSA-N 0.000 description 7
- OLISTMZJGQUOGS-GMOBBJLQSA-N Asn-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N OLISTMZJGQUOGS-GMOBBJLQSA-N 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- OACQOWPRWGNKTP-AVGNSLFASA-N Gln-Tyr-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O OACQOWPRWGNKTP-AVGNSLFASA-N 0.000 description 7
- ATRHMOJQJWPVBQ-DRZSPHRISA-N Glu-Ala-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ATRHMOJQJWPVBQ-DRZSPHRISA-N 0.000 description 7
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 7
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 7
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 7
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 7
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 7
- VAIWUNAAPZZGRI-IHPCNDPISA-N Ser-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CO)N VAIWUNAAPZZGRI-IHPCNDPISA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 108091036066 Three prime untranslated region Proteins 0.000 description 7
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 7
- XEYUMGGWQCIWAR-XVKPBYJWSA-N Val-Gln-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N XEYUMGGWQCIWAR-XVKPBYJWSA-N 0.000 description 7
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 108010012581 phenylalanylglutamate Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 7
- 241000894007 species Species 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- XCVRVWZTXPCYJT-BIIVOSGPSA-N Ala-Asn-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N XCVRVWZTXPCYJT-BIIVOSGPSA-N 0.000 description 6
- JUWQNWXEGDYCIE-YUMQZZPRSA-N Arg-Gln-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O JUWQNWXEGDYCIE-YUMQZZPRSA-N 0.000 description 6
- YKBHOXLMMPZPHQ-GMOBBJLQSA-N Arg-Ile-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O YKBHOXLMMPZPHQ-GMOBBJLQSA-N 0.000 description 6
- BHQQRVARKXWXPP-ACZMJKKPSA-N Asn-Asp-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N BHQQRVARKXWXPP-ACZMJKKPSA-N 0.000 description 6
- RLHANKIRBONJBK-IHRRRGAJSA-N Asn-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N RLHANKIRBONJBK-IHRRRGAJSA-N 0.000 description 6
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 6
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 6
- 108091033380 Coding strand Proteins 0.000 description 6
- ZWNFOZNJYNDNGM-UBHSHLNASA-N Cys-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N ZWNFOZNJYNDNGM-UBHSHLNASA-N 0.000 description 6
- NITLUESFANGEIW-BQBZGAKWSA-N Cys-Pro-Gly Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O NITLUESFANGEIW-BQBZGAKWSA-N 0.000 description 6
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 6
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 6
- KBKGRMNVKPSQIF-XDTLVQLUSA-N Glu-Ala-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KBKGRMNVKPSQIF-XDTLVQLUSA-N 0.000 description 6
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 6
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 6
- 101000617964 Homo sapiens Sorcin Proteins 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 6
- 241000880493 Leptailurus serval Species 0.000 description 6
- YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 6
- ZGUMORRUBUCXEH-AVGNSLFASA-N Leu-Lys-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZGUMORRUBUCXEH-AVGNSLFASA-N 0.000 description 6
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 6
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 6
- WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 description 6
- WPTHAGXMYDRPFD-SRVKXCTJSA-N Met-Lys-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O WPTHAGXMYDRPFD-SRVKXCTJSA-N 0.000 description 6
- LLKWSEXLNFBKIF-CYDGBPFRSA-N Met-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCSC LLKWSEXLNFBKIF-CYDGBPFRSA-N 0.000 description 6
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 6
- AFNJAQVMTIQTCB-DLOVCJGASA-N Phe-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 AFNJAQVMTIQTCB-DLOVCJGASA-N 0.000 description 6
- CYQQWUPHIZVCNY-GUBZILKMSA-N Pro-Arg-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CYQQWUPHIZVCNY-GUBZILKMSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 6
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 6
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 description 6
- RKDFEMGVMMYYNG-WDCWCFNPSA-N Thr-Gln-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O RKDFEMGVMMYYNG-WDCWCFNPSA-N 0.000 description 6
- QARCDOCCDOLJSF-HJPIBITLSA-N Tyr-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QARCDOCCDOLJSF-HJPIBITLSA-N 0.000 description 6
- VPEFOFYNHBWFNQ-UFYCRDLUSA-N Tyr-Pro-Tyr Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 VPEFOFYNHBWFNQ-UFYCRDLUSA-N 0.000 description 6
- KHPLUFDSWGDRHD-SLFFLAALSA-N Tyr-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O KHPLUFDSWGDRHD-SLFFLAALSA-N 0.000 description 6
- DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 description 6
- USXYVSTVPHELAF-RCWTZXSCSA-N Val-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](C(C)C)N)O USXYVSTVPHELAF-RCWTZXSCSA-N 0.000 description 6
- GUIYPEKUEMQBIK-JSGCOSHPSA-N Val-Tyr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(O)=O GUIYPEKUEMQBIK-JSGCOSHPSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 6
- 230000002759 chromosomal effect Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 108010081551 glycylphenylalanine Proteins 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 102000050518 human SRI Human genes 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 108010091871 leucylmethionine Proteins 0.000 description 6
- 108010003700 lysyl aspartic acid Proteins 0.000 description 6
- 238000013507 mapping Methods 0.000 description 6
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 108010018625 phenylalanylarginine Proteins 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 108010071207 serylmethionine Proteins 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108010020532 tyrosyl-proline Proteins 0.000 description 6
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 5
- JEEFEQCRXKPQHC-KKUMJFAQSA-N Asn-Leu-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JEEFEQCRXKPQHC-KKUMJFAQSA-N 0.000 description 5
- DJIMLSXHXKWADV-CIUDSAMLSA-N Asn-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O DJIMLSXHXKWADV-CIUDSAMLSA-N 0.000 description 5
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 5
- LPYPANUXJGFMGV-FXQIFTODSA-N Gln-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N LPYPANUXJGFMGV-FXQIFTODSA-N 0.000 description 5
- BETSEXMYBWCDAE-SZMVWBNQSA-N Gln-Trp-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N BETSEXMYBWCDAE-SZMVWBNQSA-N 0.000 description 5
- JLJLBWDKDRYOPA-RYUDHWBXSA-N Gly-Gln-Tyr Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JLJLBWDKDRYOPA-RYUDHWBXSA-N 0.000 description 5
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 5
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 5
- MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 5
- AKVBOOKXVAMKSS-GUBZILKMSA-N Leu-Ser-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O AKVBOOKXVAMKSS-GUBZILKMSA-N 0.000 description 5
- ZGGVHTQAPHVMKM-IHPCNDPISA-N Leu-Trp-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)O)N ZGGVHTQAPHVMKM-IHPCNDPISA-N 0.000 description 5
- BCRQJDMZQUHQSV-STQMWFEESA-N Met-Gly-Tyr Chemical compound [H]N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BCRQJDMZQUHQSV-STQMWFEESA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- LQZZPNDMYNZPFT-KKUMJFAQSA-N Pro-Gln-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LQZZPNDMYNZPFT-KKUMJFAQSA-N 0.000 description 5
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 5
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 5
- 108010091086 Recombinases Proteins 0.000 description 5
- 102000018120 Recombinases Human genes 0.000 description 5
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 5
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 5
- LHEZGZQRLDBSRR-WDCWCFNPSA-N Thr-Glu-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LHEZGZQRLDBSRR-WDCWCFNPSA-N 0.000 description 5
- 230000001594 aberrant effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 108010050848 glycylleucine Proteins 0.000 description 5
- 108010077515 glycylproline Proteins 0.000 description 5
- 210000004754 hybrid cell Anatomy 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 108010038320 lysylphenylalanine Proteins 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 230000004952 protein activity Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 4
- RXTBLQVXNIECFP-FXQIFTODSA-N Ala-Gln-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RXTBLQVXNIECFP-FXQIFTODSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- DNLQVHBBMPZUGJ-BQBZGAKWSA-N Arg-Ser-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O DNLQVHBBMPZUGJ-BQBZGAKWSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 4
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 4
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 4
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 4
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 4
- 101710089292 Sorcin Proteins 0.000 description 4
- 102100021941 Sorcin Human genes 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 230000003831 deregulation Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YEJQWBFDKKTPNO-UHFFFAOYSA-N 2-[[2-[[1-(2-amino-3-methylbutanoyl)pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-methylbutanoic acid Chemical compound CC(C)C(N)C(=O)N1CCCC1C(=O)NCC(=O)NC(C(C)C)C(O)=O YEJQWBFDKKTPNO-UHFFFAOYSA-N 0.000 description 3
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 3
- WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 3
- QHASENCZLDHBGX-ONGXEEELSA-N Ala-Gly-Phe Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QHASENCZLDHBGX-ONGXEEELSA-N 0.000 description 3
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- MLJZMGIXXMTEPO-UBHSHLNASA-N Asn-Trp-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O MLJZMGIXXMTEPO-UBHSHLNASA-N 0.000 description 3
- JZLFYAAGGYMRIK-BYULHYEWSA-N Asn-Val-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O JZLFYAAGGYMRIK-BYULHYEWSA-N 0.000 description 3
- ZLGKHJHFYSRUBH-FXQIFTODSA-N Asp-Arg-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLGKHJHFYSRUBH-FXQIFTODSA-N 0.000 description 3
- XDGBFDYXZCMYEX-NUMRIWBASA-N Asp-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)O XDGBFDYXZCMYEX-NUMRIWBASA-N 0.000 description 3
- ICZWAZVKLACMKR-CIUDSAMLSA-N Asp-His-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CN=CN1 ICZWAZVKLACMKR-CIUDSAMLSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- VTBGVPWSWJBERH-DCAQKATOSA-N Cys-Leu-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CS)N VTBGVPWSWJBERH-DCAQKATOSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- BJPPYOMRAVLXBY-YUMQZZPRSA-N Gln-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N BJPPYOMRAVLXBY-YUMQZZPRSA-N 0.000 description 3
- MFHVAWMMKZBSRQ-ACZMJKKPSA-N Gln-Ser-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N MFHVAWMMKZBSRQ-ACZMJKKPSA-N 0.000 description 3
- OTQSTOXRUBVWAP-NRPADANISA-N Gln-Ser-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OTQSTOXRUBVWAP-NRPADANISA-N 0.000 description 3
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 3
- YFGONBOFGGWKKY-VHSXEESVSA-N Gly-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)CN)C(=O)O YFGONBOFGGWKKY-VHSXEESVSA-N 0.000 description 3
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 3
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- LLZLRXBTOOFODM-QSFUFRPTSA-N Ile-Asp-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N LLZLRXBTOOFODM-QSFUFRPTSA-N 0.000 description 3
- WLRJHVNFGAOYPS-HJPIBITLSA-N Ile-Ser-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N WLRJHVNFGAOYPS-HJPIBITLSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- DJBCKVNHEIJLQA-GMOBBJLQSA-N Met-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCSC)N DJBCKVNHEIJLQA-GMOBBJLQSA-N 0.000 description 3
- IILAGWCGKJSBGB-IHRRRGAJSA-N Met-Phe-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N IILAGWCGKJSBGB-IHRRRGAJSA-N 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- OPEVYHFJXLCCRT-AVGNSLFASA-N Phe-Gln-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O OPEVYHFJXLCCRT-AVGNSLFASA-N 0.000 description 3
- BSTPNLNKHKBONJ-HTUGSXCWSA-N Phe-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O BSTPNLNKHKBONJ-HTUGSXCWSA-N 0.000 description 3
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 3
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 3
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 3
- GFHOSBYCLACKEK-GUBZILKMSA-N Pro-Pro-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O GFHOSBYCLACKEK-GUBZILKMSA-N 0.000 description 3
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 3
- AEGUWTFAQQWVLC-BQBZGAKWSA-N Ser-Gly-Arg Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEGUWTFAQQWVLC-BQBZGAKWSA-N 0.000 description 3
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 3
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 3
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 description 3
- WNDUPCKKKGSKIQ-CIUDSAMLSA-N Ser-Pro-Gln Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O WNDUPCKKKGSKIQ-CIUDSAMLSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- GRSCONMARGNYHA-PMVMPFDFSA-N Trp-Lys-Phe Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GRSCONMARGNYHA-PMVMPFDFSA-N 0.000 description 3
- AYHSJESDFKREAR-KKUMJFAQSA-N Tyr-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AYHSJESDFKREAR-KKUMJFAQSA-N 0.000 description 3
- PLVVHGFEMSDRET-IHPCNDPISA-N Tyr-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=C(C=C3)O)N PLVVHGFEMSDRET-IHPCNDPISA-N 0.000 description 3
- JLFKWDAZBRYCGX-ZKWXMUAHSA-N Val-Asn-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N JLFKWDAZBRYCGX-ZKWXMUAHSA-N 0.000 description 3
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 108010093581 aspartyl-proline Proteins 0.000 description 3
- 108010092854 aspartyllysine Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000003200 chromosome mapping Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 108010045126 glycyl-tyrosyl-glycine Proteins 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 108010051242 phenylalanylserine Proteins 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 108010079317 prolyl-tyrosine Proteins 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 3
- COEXAQSTZUWMRI-STQMWFEESA-N (2s)-1-[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 COEXAQSTZUWMRI-STQMWFEESA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- TTXMOJWKNRJWQJ-FXQIFTODSA-N Ala-Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N TTXMOJWKNRJWQJ-FXQIFTODSA-N 0.000 description 2
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- GPPIDDWYKJPRES-YDHLFZDLSA-N Asp-Phe-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O GPPIDDWYKJPRES-YDHLFZDLSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- QFJPFPCSXOXMKI-BPUTZDHNSA-N Gln-Gln-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N QFJPFPCSXOXMKI-BPUTZDHNSA-N 0.000 description 2
- SGVGIVDZLSHSEN-RYUDHWBXSA-N Gln-Tyr-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O SGVGIVDZLSHSEN-RYUDHWBXSA-N 0.000 description 2
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 2
- VGBSZQSKQRMLHD-MNXVOIDGSA-N Glu-Leu-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VGBSZQSKQRMLHD-MNXVOIDGSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- GZUKEVBTYNNUQF-WDSKDSINSA-N Gly-Ala-Gln Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GZUKEVBTYNNUQF-WDSKDSINSA-N 0.000 description 2
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 2
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 2
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 2
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 2
- QGDOOCIPHSSADO-STQMWFEESA-N Gly-Met-Phe Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QGDOOCIPHSSADO-STQMWFEESA-N 0.000 description 2
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 2
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 2
- HQSKKSLNLSTONK-JTQLQIEISA-N Gly-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 HQSKKSLNLSTONK-JTQLQIEISA-N 0.000 description 2
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- PZUZIHRPOVVHOT-KBPBESRZSA-N His-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CN=CN1 PZUZIHRPOVVHOT-KBPBESRZSA-N 0.000 description 2
- 101000734646 Homo sapiens Programmed cell death protein 6 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- FQYQMFCIJNWDQZ-CYDGBPFRSA-N Ile-Pro-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 FQYQMFCIJNWDQZ-CYDGBPFRSA-N 0.000 description 2
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 2
- KQFZKDITNUEVFJ-JYJNAYRXSA-N Leu-Phe-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CC=CC=C1 KQFZKDITNUEVFJ-JYJNAYRXSA-N 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- NTYQUVLERIHPMU-HRCADAONSA-N Met-Phe-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N NTYQUVLERIHPMU-HRCADAONSA-N 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- IILUKIJNFMUBNF-IHRRRGAJSA-N Phe-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O IILUKIJNFMUBNF-IHRRRGAJSA-N 0.000 description 2
- NJJBATPLUQHRBM-IHRRRGAJSA-N Phe-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CO)C(=O)O NJJBATPLUQHRBM-IHRRRGAJSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 2
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 2
- TXPUNZXZDVJUJQ-LPEHRKFASA-N Pro-Asn-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N2CCC[C@@H]2C(=O)O TXPUNZXZDVJUJQ-LPEHRKFASA-N 0.000 description 2
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 2
- FEVDNIBDCRKMER-IUCAKERBSA-N Pro-Gly-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@@H]1CCCN1 FEVDNIBDCRKMER-IUCAKERBSA-N 0.000 description 2
- VWXGFAIZUQBBBG-UWVGGRQHSA-N Pro-His-Gly Chemical compound C([C@@H](C(=O)NCC(=O)[O-])NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 VWXGFAIZUQBBBG-UWVGGRQHSA-N 0.000 description 2
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 2
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 2
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 2
- BUYHXYIUQUBEQP-AVGNSLFASA-N Ser-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CO)N BUYHXYIUQUBEQP-AVGNSLFASA-N 0.000 description 2
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 2
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 2
- KPNSNVTUVKSBFL-ZJDVBMNYSA-N Thr-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KPNSNVTUVKSBFL-ZJDVBMNYSA-N 0.000 description 2
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- PNKDNKGMEHJTJQ-BPUTZDHNSA-N Trp-Arg-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N PNKDNKGMEHJTJQ-BPUTZDHNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- BARBHMSSVWPKPZ-IHRRRGAJSA-N Tyr-Asp-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BARBHMSSVWPKPZ-IHRRRGAJSA-N 0.000 description 2
- IJUTXXAXQODRMW-KBPBESRZSA-N Tyr-Gly-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O IJUTXXAXQODRMW-KBPBESRZSA-N 0.000 description 2
- AZGZDDNKFFUDEH-QWRGUYRKSA-N Tyr-Gly-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AZGZDDNKFFUDEH-QWRGUYRKSA-N 0.000 description 2
- QAYSODICXVZUIA-WLTAIBSBSA-N Tyr-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QAYSODICXVZUIA-WLTAIBSBSA-N 0.000 description 2
- YYLHVUCSTXXKBS-IHRRRGAJSA-N Tyr-Pro-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YYLHVUCSTXXKBS-IHRRRGAJSA-N 0.000 description 2
- LVFZXRQQQDTBQH-IRIUXVKKSA-N Tyr-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LVFZXRQQQDTBQH-IRIUXVKKSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002742 combinatorial mutagenesis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 108010068488 methionylphenylalanine Proteins 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- UYHSQVMHSFXUOA-UHFFFAOYSA-N 2-methylthiouracil Chemical compound CSC1=NC=CC(O)=N1 UYHSQVMHSFXUOA-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- LRDIEHDJWYRVPT-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 LRDIEHDJWYRVPT-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- XTPUXCVIDQFHIT-UHFFFAOYSA-N 8-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(N)=C2NC(CCC(C)=C)=NC2=N1 XTPUXCVIDQFHIT-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 101150013604 ACADS gene Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- OKIKVSXTXVVFDV-MMWGEVLESA-N Ala-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N OKIKVSXTXVVFDV-MMWGEVLESA-N 0.000 description 1
- PEIBBAXIKUAYGN-UBHSHLNASA-N Ala-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 PEIBBAXIKUAYGN-UBHSHLNASA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- BVBKBQRPOJFCQM-DCAQKATOSA-N Arg-Asn-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BVBKBQRPOJFCQM-DCAQKATOSA-N 0.000 description 1
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WSWYMRLTJVKRCE-ZLUOBGJFSA-N Asp-Ala-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O WSWYMRLTJVKRCE-ZLUOBGJFSA-N 0.000 description 1
- FAEIQWHBRBWUBN-FXQIFTODSA-N Asp-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N)CN=C(N)N FAEIQWHBRBWUBN-FXQIFTODSA-N 0.000 description 1
- ACEDJCOOPZFUBU-CIUDSAMLSA-N Asp-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N ACEDJCOOPZFUBU-CIUDSAMLSA-N 0.000 description 1
- CTWCFPWFIGRAEP-CIUDSAMLSA-N Asp-Lys-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O CTWCFPWFIGRAEP-CIUDSAMLSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101100080292 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pltp gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000004612 Calcium-Transporting ATPases Human genes 0.000 description 1
- 108010017954 Calcium-Transporting ATPases Proteins 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- MFMDKTLJCUBQIC-MXAVVETBSA-N Cys-Phe-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MFMDKTLJCUBQIC-MXAVVETBSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 description 1
- MAGNEQBFSBREJL-DCAQKATOSA-N Gln-Glu-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N MAGNEQBFSBREJL-DCAQKATOSA-N 0.000 description 1
- XKBASPWPBXNVLQ-WDSKDSINSA-N Gln-Gly-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XKBASPWPBXNVLQ-WDSKDSINSA-N 0.000 description 1
- QBLMTCRYYTVUQY-GUBZILKMSA-N Gln-Leu-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QBLMTCRYYTVUQY-GUBZILKMSA-N 0.000 description 1
- XFAUJGNLHIGXET-AVGNSLFASA-N Gln-Leu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XFAUJGNLHIGXET-AVGNSLFASA-N 0.000 description 1
- ZBKUIQNCRIYVGH-SDDRHHMPSA-N Gln-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZBKUIQNCRIYVGH-SDDRHHMPSA-N 0.000 description 1
- WHVLABLIJYGVEK-QEWYBTABSA-N Gln-Phe-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WHVLABLIJYGVEK-QEWYBTABSA-N 0.000 description 1
- DRNMNLKUUKKPIA-HTUGSXCWSA-N Gln-Phe-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCC(N)=O)C(O)=O DRNMNLKUUKKPIA-HTUGSXCWSA-N 0.000 description 1
- WLRYGVYQFXRJDA-DCAQKATOSA-N Gln-Pro-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 WLRYGVYQFXRJDA-DCAQKATOSA-N 0.000 description 1
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 1
- SBCYJMOOHUDWDA-NUMRIWBASA-N Glu-Asp-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SBCYJMOOHUDWDA-NUMRIWBASA-N 0.000 description 1
- CUPSDFQZTVVTSK-GUBZILKMSA-N Glu-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O CUPSDFQZTVVTSK-GUBZILKMSA-N 0.000 description 1
- XMBSYZWANAQXEV-QWRGUYRKSA-N Glu-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-QWRGUYRKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- YNIMVVJTPWCUJH-KBPBESRZSA-N Gly-His-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YNIMVVJTPWCUJH-KBPBESRZSA-N 0.000 description 1
- BHPQOIPBLYJNAW-NGZCFLSTSA-N Gly-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN BHPQOIPBLYJNAW-NGZCFLSTSA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- YJDALMUYJIENAG-QWRGUYRKSA-N Gly-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN)O YJDALMUYJIENAG-QWRGUYRKSA-N 0.000 description 1
- LYZYGGWCBLBDMC-QWHCGFSZSA-N Gly-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CN)C(=O)O LYZYGGWCBLBDMC-QWHCGFSZSA-N 0.000 description 1
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- GNBHSMFBUNEWCJ-DCAQKATOSA-N His-Pro-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O GNBHSMFBUNEWCJ-DCAQKATOSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- WECYRWOMWSCWNX-XUXIUFHCSA-N Ile-Arg-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O WECYRWOMWSCWNX-XUXIUFHCSA-N 0.000 description 1
- IITVUURPOYGCTD-NAKRPEOUSA-N Ile-Pro-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IITVUURPOYGCTD-NAKRPEOUSA-N 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FGNQZXKVAZIMCI-CIUDSAMLSA-N Leu-Asp-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N FGNQZXKVAZIMCI-CIUDSAMLSA-N 0.000 description 1
- QDSKNVXKLPQNOJ-GVXVVHGQSA-N Leu-Gln-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QDSKNVXKLPQNOJ-GVXVVHGQSA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- SIGZKCWZEBFNAK-QAETUUGQSA-N Leu-Ser-Ser-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SIGZKCWZEBFNAK-QAETUUGQSA-N 0.000 description 1
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 1
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 1
- LMGNWHDWJDIOPK-DKIMLUQUSA-N Lys-Phe-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LMGNWHDWJDIOPK-DKIMLUQUSA-N 0.000 description 1
- QFSYGUMEANRNJE-DCAQKATOSA-N Lys-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N QFSYGUMEANRNJE-DCAQKATOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- GMMLGMFBYCFCCX-KZVJFYERSA-N Met-Thr-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMMLGMFBYCFCCX-KZVJFYERSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100190814 Mus musculus Pltp gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- VHWOBXIWBDWZHK-IHRRRGAJSA-N Phe-Arg-Asp Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 VHWOBXIWBDWZHK-IHRRRGAJSA-N 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- DRVIASBABBMZTF-GUBZILKMSA-N Pro-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@@H]1CCCN1 DRVIASBABBMZTF-GUBZILKMSA-N 0.000 description 1
- FUVBEZJCRMHWEM-FXQIFTODSA-N Pro-Asn-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FUVBEZJCRMHWEM-FXQIFTODSA-N 0.000 description 1
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
- SVXXJYJCRNKDDE-AVGNSLFASA-N Pro-Pro-His Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CN=CN1 SVXXJYJCRNKDDE-AVGNSLFASA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 101000734647 Rattus norvegicus Programmed cell death protein 6 Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- GXXTUIUYTWGPMV-FXQIFTODSA-N Ser-Arg-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O GXXTUIUYTWGPMV-FXQIFTODSA-N 0.000 description 1
- YMAWDPHQVABADW-CIUDSAMLSA-N Ser-Gln-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O YMAWDPHQVABADW-CIUDSAMLSA-N 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- DIPIPFHFLPTCLK-LOKLDPHHSA-N Thr-Gln-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O DIPIPFHFLPTCLK-LOKLDPHHSA-N 0.000 description 1
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 1
- JMGJDTNUMAZNLX-RWRJDSDZSA-N Thr-Glu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JMGJDTNUMAZNLX-RWRJDSDZSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- SMLCYZYQFRTLCO-UWJYBYFXSA-N Tyr-Cys-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O SMLCYZYQFRTLCO-UWJYBYFXSA-N 0.000 description 1
- NKMFRGPKTIEXSK-ULQDDVLXSA-N Tyr-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NKMFRGPKTIEXSK-ULQDDVLXSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- XYBNMHRFAUKPAW-IHRRRGAJSA-N Tyr-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)N XYBNMHRFAUKPAW-IHRRRGAJSA-N 0.000 description 1
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 1
- CFIBZQOLUDURST-IHRRRGAJSA-N Val-Tyr-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CS)C(=O)O)N CFIBZQOLUDURST-IHRRRGAJSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 101150036612 gnl gene Proteins 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007653 larval development Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940076376 protein agonist Drugs 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention provides isolated nucleic acids molecules, designated hALG-2LP, sALG-2LP, and mALG-2LP nucleic acid molecules, which encode proteins involved in the modulation of programmed cell death. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing hALG-2LP, sALG-2LP, and mALG-2LP nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a hALG-2LP, sALG-2LP, and mALG-2LP gene has been introduced or disrupted. The invention still further provides isolated hALG-2LP, sALG-2LP, and mALG-2LP proteins, fusion proteins, antigenic peptides and anti-hALG-2LP, sALG-2LP, and mALG-2LP antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Description
ALG-2LP, ALG-2 LIKE MOLECULES AND USES THEREFOR
Background of the Invention During normal embryonic and adult development of multicellular organisms, cells that are not necessary or deleterious are eliminated by a process referred to as programmed cell death or apoptosis (Elks R.E. et al. (1991) Annual Rev. Cell Biol.
7:663-698). Programmed cell death occurs both in vertebrate and invertebrate species and is characterized by unique morphological alterations, such as cytoplasmic contraction and chromatin condensation, as well as by specific DNA cleavage into oligonucleosomal fragments. Unlike necrosis, programmed cell death or apoptosis is an irreversible process which in most systems appears to depend on the expression of a specific set of novel "death genes". Deregulation of this process contributes to the pathogenesis of several diseases including neurodegenerative disorders, cancer, immunodeficiency, and autoimmune diseases (Thompson C.B. et al. (1995) Science 267:
1456).
Calcium is believed to play an important regulatory function in programmed cell death or apoptosis (Trump B.F. et al. (1992) Curr. Opin. Cell Biol. 4:227-232). Early evidence came from studies which demonstrated that sustained elevation of cytosolic calcium was capable of inducing apoptosis in thymocytes (Durant S. et al. ( 1980) Biochem. Biophys. Res. Commun. 93:385-391). A sustained increase in calcium concentration is capable of activating a number of potentially harmful processes in the cell. Some of these processes include the activation of hydrolytic enzymes, such as phospholipase A2, calcium-activated proteases, and calcium-activated endonucleases;
the destabilization of the cytoskeleton; the disruption of cell junctions leading to decreased or absent cell-cell communication; and the activation of expression of immediate-early genes, such as c-fos, c-jun, and c-myc (Zhong L.T. et al.
(1993) Proc.
Natl. Acad. Sci. USA 90:4533-4573).
Several mechanisms may interact to deregulate intracellular calcium concentration. Initially, such interaction may be organelle specific, e.g., anoxia inhibiting mitochondrial respiration, thapsigargin inhibiting the ER Ca2+-ATPase (Thastrup, O. et al (1990) Proc. Natl. Acad. Sci. USA 87 2466-2470), or activated complement permeabilizing the plasma membrane.
Increased cytosolic ionized sodium concentration can also effect cytosolic calcium concentration because of the importance of Na+/Ca2+ exchange in many cells (Snowdowne, K.W. et al. (1985) J. Biol. Chem. 260, 14998-15007). Increased cytosolic sodium concentration can also result in the increase of pHi through activation of the Na+/H+ exchange. Decreased pHi significantly retards the rate of progression of cell death following injury in a variety of cells, probably by antagonizing Ca2+
mediated effects on phospholipases, proteases, and endonucleases, whereas increased pHi often accelerates the progress toward cell death.
Moreover, activation of membrane receptors by ligand binding and interaction with G proteins often results in activation of PLC-(3 and PLC-y. This in turn mediates, among other things, the formation of inositol 1, 4, 5,-triphosphate (IP3) and 1, 2-diacylglycerol. IP3 in turn, mediates release of Ca2+ from the ER which, through the 1 S formation of a calcium influx factor, can result in increased Ca2+ entry into the cell.
Summary of the Invention This invention provides, at least in part, novel nucleic acid molecules encoding proteins which modulate programmed cell death, e.g., programmed cell death in cells that express these proteins. Examples of nucleic acid molecules encoding such proteins include human ALG-2LP, monkey ALG-2LP, and mouse ALG-2LP, which are also referred to herein as apoptosis linked gene-2 like proteins (ALG-2LP). In a preferred embodiment, the hALG-2LP, sALG-2LP, and mALG-2LP proteins interact with (e.g., bind to) a protein, or a portion or subunit thereof, which is a member of a programmed cell death transduction pathway.
ALG-2 was first identified in a screen for genes involved in apoptosis and has subsequently been shown, in antisense experiments, to be required for cell death induced by fas ligand (Vito P. et al. (1996) Science 271:521-525). ALG-2 comprises 191 amino acids, containing two canonical calcium binding EF-hand structures.
Background of the Invention During normal embryonic and adult development of multicellular organisms, cells that are not necessary or deleterious are eliminated by a process referred to as programmed cell death or apoptosis (Elks R.E. et al. (1991) Annual Rev. Cell Biol.
7:663-698). Programmed cell death occurs both in vertebrate and invertebrate species and is characterized by unique morphological alterations, such as cytoplasmic contraction and chromatin condensation, as well as by specific DNA cleavage into oligonucleosomal fragments. Unlike necrosis, programmed cell death or apoptosis is an irreversible process which in most systems appears to depend on the expression of a specific set of novel "death genes". Deregulation of this process contributes to the pathogenesis of several diseases including neurodegenerative disorders, cancer, immunodeficiency, and autoimmune diseases (Thompson C.B. et al. (1995) Science 267:
1456).
Calcium is believed to play an important regulatory function in programmed cell death or apoptosis (Trump B.F. et al. (1992) Curr. Opin. Cell Biol. 4:227-232). Early evidence came from studies which demonstrated that sustained elevation of cytosolic calcium was capable of inducing apoptosis in thymocytes (Durant S. et al. ( 1980) Biochem. Biophys. Res. Commun. 93:385-391). A sustained increase in calcium concentration is capable of activating a number of potentially harmful processes in the cell. Some of these processes include the activation of hydrolytic enzymes, such as phospholipase A2, calcium-activated proteases, and calcium-activated endonucleases;
the destabilization of the cytoskeleton; the disruption of cell junctions leading to decreased or absent cell-cell communication; and the activation of expression of immediate-early genes, such as c-fos, c-jun, and c-myc (Zhong L.T. et al.
(1993) Proc.
Natl. Acad. Sci. USA 90:4533-4573).
Several mechanisms may interact to deregulate intracellular calcium concentration. Initially, such interaction may be organelle specific, e.g., anoxia inhibiting mitochondrial respiration, thapsigargin inhibiting the ER Ca2+-ATPase (Thastrup, O. et al (1990) Proc. Natl. Acad. Sci. USA 87 2466-2470), or activated complement permeabilizing the plasma membrane.
Increased cytosolic ionized sodium concentration can also effect cytosolic calcium concentration because of the importance of Na+/Ca2+ exchange in many cells (Snowdowne, K.W. et al. (1985) J. Biol. Chem. 260, 14998-15007). Increased cytosolic sodium concentration can also result in the increase of pHi through activation of the Na+/H+ exchange. Decreased pHi significantly retards the rate of progression of cell death following injury in a variety of cells, probably by antagonizing Ca2+
mediated effects on phospholipases, proteases, and endonucleases, whereas increased pHi often accelerates the progress toward cell death.
Moreover, activation of membrane receptors by ligand binding and interaction with G proteins often results in activation of PLC-(3 and PLC-y. This in turn mediates, among other things, the formation of inositol 1, 4, 5,-triphosphate (IP3) and 1, 2-diacylglycerol. IP3 in turn, mediates release of Ca2+ from the ER which, through the 1 S formation of a calcium influx factor, can result in increased Ca2+ entry into the cell.
Summary of the Invention This invention provides, at least in part, novel nucleic acid molecules encoding proteins which modulate programmed cell death, e.g., programmed cell death in cells that express these proteins. Examples of nucleic acid molecules encoding such proteins include human ALG-2LP, monkey ALG-2LP, and mouse ALG-2LP, which are also referred to herein as apoptosis linked gene-2 like proteins (ALG-2LP). In a preferred embodiment, the hALG-2LP, sALG-2LP, and mALG-2LP proteins interact with (e.g., bind to) a protein, or a portion or subunit thereof, which is a member of a programmed cell death transduction pathway.
ALG-2 was first identified in a screen for genes involved in apoptosis and has subsequently been shown, in antisense experiments, to be required for cell death induced by fas ligand (Vito P. et al. (1996) Science 271:521-525). ALG-2 comprises 191 amino acids, containing two canonical calcium binding EF-hand structures.
The presently disclosed proteins have sequence homology with ALG-2 and are therefore likely to participate in similar biological processes, e.g., modulate programmed cell death.
Thus, apoptosis linked gene-2-like protein molecules, e.g., hALG-2LP, sALG-S 2LP, and mALG-2LP, can be used to modulate the activity of programmed cell death pathway related molecules and provide novel therapeutic approaches for treatment of disorders characterized by deregulated programmed cell death. Examples of disorders characterized by deregulated programmed cell death include neurodegenerative disorders, e.g., Alzheimer's disease, dementias related to Alzheimer's disease (such as Pick's disease), Parkinson's and other Lewy diffuse body diseases, multiple sclerosis, amyotrophic lateral sclerosis, progressive supranuclear palsy, epilepsy, Jakob-Creutzfieldt disease, or AIDS related dementia; or proliferative disorders, e.g., cancer such as chronic lymphocytic leukemia or colorectal cancer.
Furthermore, as they are involved in programmed cell death, hALG-2LP, sALG-1 S 2LP, or mALG-2LP genes containing genetic lesions can be detected in order to diagnose a disorder characterized by aberrant or abnormal hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid expression or hALG-2LP, sALG-2LP, or mALG-2LP protein activity, e.g., a neurodegenerative disorder.
Moreover, another aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs) comprising a nucleotide sequence encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein or a biologically active portion thereof, as well as nucleic acid fragments suitable for use as primers or hybridization probes for the detection of hALG-2LP, sALG-2LP, or mALG-2LP-encoding nucleic acid (e.g., mRNA). In particularly preferred embodiments, the isolated nucleic acid molecules 2S comprise the nucleotide sequences of SEQ ID NOs:I, 4 or 7, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number , or the coding region (shown in SEQ ID NOs:3, 6, or 9), or a complement of these nucleotide sequences. In other particularly preferred embodiments, the isolated nucleic acid molecules of the invention comprise a nucleotide sequence which hybridizes to, or is at least 32%, 3S%, 40%, 4S%, SO%, SS%, 60%, 6S%, 70%, 7S%, 80%, 8S%, 90%, 9S%, 98% or more homologous to the entire length of the nucleotide sequences shown in SEQ ID NOs:I, 4, or 7, the entire length of nucleotide sequence of the DNA
insert of the lasmid de osited with ATCC~ as Accession Number p p , or a portion of these nucleotide sequences. In other preferred embodiments, the isolated nucleic acid molecules encode the amino acid sequences of SEQ ID NOs:2, 5, or 8, or an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number . The preferred hALG-2LP, sALG-2LP, or mALG-2LP proteins of the present invention also preferably possess at least one of the activities described herein.
In another embodiment, the isolated nucleic acid molecules encode proteins or portions thereof wherein the proteins or portions thereof include an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NOs:2, 5, or 8, e.g., sufficiently homologous to an amino acid sequence of SEQ ID NOs:2, 5, or 8 such that the proteins or portions thereof maintain at least on the of the activities described herein. Preferably, the proteins or portions thereof encoded by the nucleic acid molecules maintain the ability to modulate a programmed cell death pathway activity.
In one embodiment, the proteins encoded by the nucleic acid molecules are at least 38%, 42%, 44%, 45%, SO%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequences of SEQ ID NOs:2, 5, or 8 (e.g., the entire amino acid sequences of SEQ ID NOs:2, S, or 8) or the amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~
as Accession Number . In another preferred embodiment, the proteins are full length human proteins which are substantially homologous to the entire amino acid sequences of SEQ ID NOs:2, 5, or 8 (encoded by the open reading frames shown in SEQ ID NOs:3, 6, or 9, respectively).
In another preferred embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP
nucleic acid molecule is derived from a mammal, e.g., a human, a monkey, or a mouse, and encodes a protein (e.g., a hALG-2LP, sALG-2LP, or mALG-2LP fusion protein) which includes a calcium binding domain which is at least 42% or more homologous to SEQ ID NO:10, 11, 12, 13, 14, or 15 and has one or more of the following activities: 1) it can interact with a programmed cell death pathway associated molecule, e.g., an ALG--$-2 interacting protein; and 2) it can modulate cell death, e.g., programmed cell death, in a cell, e.g., a brain cell and other cells that express ALG2-LP.
In another embodiment, the isolated nucleic acid molecule is at least 15 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOs:l, 4, or 7, or to the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number . Preferably, the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes a naturally-occurring human hALG-2LP, sALG-2LP, or mALG-2LP, or a biologically active portion thereof. Moreover, given the disclosure herein of a hALG-2LP, sALG-2LP, or mALG-2LP-encoding cDNA sequence (e.g., SEQ ID NOs:l, 4, or 7), antisense nucleic acid molecules (i.e., molecules which are complementary to the coding strand of the hALG-2LP, sALG-2LP, or mALG-2LP cDNA sequence) are also provided by the invention.
Another aspect of the invention pertains to vectors, e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention and host cells into which such vectors have been introduced. In one embodiment, such a host cell is used to produce a hALG-2LP, sALG-2LP, or mALG-2LP protein by culturing the host cell in a suitable medium. If desired, the hALG-2LP, sALG-2LP, or mALG-2LP protein can be then isolated from the medium or the host cell.
Yet another aspect of the invention pertains to transgenic nonhuman animals in which a hALG-2LP, sALG-2LP, or mALG-2LP gene has been introduced or altered.
In one embodiment, the genome of the nonhuman animal has been altered by introduction of a nucleic acid molecule of the invention encoding hALG-2LP, sALG-2LP, or mALG-2LP as a transgene. In another embodiment, an endogenous ALG-2LP gene within the genome of the nonhuman animal has been altered, e.g., functionally disrupted, by homologous recombination.
Still another aspect of the invention pertains to an isolated hALG-2LP, sALG-2LP, or mALG-2LP protein or a portion, e.g., a biologically active portion, thereof. In a preferred embodiment, the isolated hALG-2LP, sALG-2LP, or mALG-2LP protein or portion thereof can modulate programmed cell death in a cell, e.g., a brain cell and other cells that express ALG2-LP. In another preferred embodiment, the isolated hALG-2LP, sALG-2LP, or mALG-2LP protein or portion thereof is sufficiently homologous to an amino acid sequence of SEQ ID N0:2, 5, or 8 such that the protein or portion thereof maintains the ability to modulate programmed cell death in a cell, e.g., a brain cell and S other cells that express ALG2-LP.
In one embodiment, the biologically active portion of the hALG-2LP, sALG-2LP, or mALG-2LP protein includes a domain or motif, preferably a domain or motif which has an activity described herein. The domain can be a calcium binding domain, e.g., an EF hand. If the active portion of the protein which comprises the calcium binding domain is isolated or derived from a mammal, e.g., a human, it is preferred that the calcium binding domain be at least 38%, 42%, 44% 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more homologous to SEQ ID NO:10, 11, 12, 13, 14, or 15. Preferably, the biologically active portion of the hALG-2LP, sALG-2LP, or mALG-2LP protein which includes a calcium binding domain also has one of the following activities: 1 ) it can interact with a programmed cell death pathway associated molecule, e.g., an ALG-2 interacting protein; and 2) it can modulate cell death, e.g., programmed cell death, in a cell, e.g., a brain cell and other cells that express ALG2-LP.
The invention also provides an isolated preparation of a hALG-2LP, sALG-2LP, or mALG-2LP protein. In preferred embodiments, the hALG-2LP, sALG-2LP, or mALG-2LP protein comprises the amino acid sequence of SEQ ID N0:2, 5, or 8 or an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number In another preferred embodiment, the invention pertains to an isolated full length hALG-2LP, sALG-2LP, or mALG-2LP protein which is substantially homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8 (encoded by the open reading frame shown in SEQ ID N0:3, 6, or 9, respectively). In yet another embodiment, the hALG-2LP, sALG-2LP, or mALG-protein is at least 38%, 42%, 44%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8, respectively. In other embodiments, the hALG-2LP, sALG-2LP, or mALG-2LP
protein comprises an amino acid sequence which is at least 42% or more homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8, respectively, and has an one or more WO 99/61459 PCTlUS99/10581 -7_ of the following activities: 1 ) it can interact with a programmed cell death pathway associated molecule, e.g., an ALG-2 interacting protein; and 2) it can modulate cell death, e.g., programmed cell death, in a cell, e.g., a brain cell and other cells that express ALG2-LP.
Alternatively, the isolated hALG-2LP, sALG-2LP, or mALG-2LP protein can comprise an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, or is at least 32%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the entire length of the nucleotide sequence of SEQ ID NO:1, 4, or 7, respectively, or the entire length of the nucleotide sequence of the DNA
insert of the plasmid deposited with ATCC~ as Accession Number , respectively.
Moreover, it is preferred that the forms of hALG-2LP, sALG-2LP, or mALG-2LP
also have one or more of the activities described herein.
The hALG-2LP, sALG-2LP, or mALG-2LP protein (or polypeptide) or a biologically active portion thereof can be operatively linked to a non-hALG-2LP, sALG-2LP, or mALG-2LP polypeptide to form a fusion protein. In addition, the hALG-2LP, sALG-2LP, or mALG-2LP protein or a biologically active portion thereof can be incorporated into a pharmaceutical composition comprising the protein and a pharmaceutically acceptable carrier.
The hALG-2LP, sALG-2LP, or mALG-2LP protein of the invention, or portions or fragments thereof, can be used to prepare anti-hALG-2LP, anti sALG-2LP, or anti mALG-2LP antibodies. Accordingly, the invention also provides an antigenic peptide of hALG-2LP, sALG-2LP, or mALG-2LP which comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID N0:2, 5, or 8, respectively, and encompasses an epitope of hALG-2LP, sALG-2LP, or mALG-2LP such that an antibody raised against the hALG-2LP, sALG-2LP, or mALG-2LP peptide forms a specific immune complex with hALG-2LP, sALG-2LP, or mALG-2LP, respectively. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues. The invention further provides an antibody that specifically binds hALG-2LP, sALG-2LP, or mALG-2LP. In one embodiment, the _g-antibody is monoclonal. In another embodiment, the antibody is coupled to a detectable substance. In yet another embodiment, the antibody is incorporated into a pharmaceutical composition comprising the antibody and a pharmaceutically acceptable Garner.
The invention also pertains to methods for detecting genetic lesions in a hALG-2LP, sALG-2LP, or mALG-2LP gene, thereby determining if a subject with the lesioned gene is at risk for (or is predisposed to have) a disorder characterized by aberrant or abnormal hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid expression or hALG-2LP, sALG-2LP, or mALG-2LP protein activity, e.g., a disorder characterized by deregulated programmed cell death. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by an alteration affecting the integrity of a gene encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein, or the misexpression of the hALG-2LP, sALG-2LP, or mALG-2LP gene.
Another aspect of the invention pertains to methods for detecting the presence of hALG-2LP, sALG-2LP, or mALG-2LP in a biological sample. In a preferred embodiment, the methods involve contacting a biological sample with a compound or an agent capable of detecting hALG-2LP, sALG-2LP, or mALG-2LP protein or hALG-2LP, sALG-2LP, or mALG-2LP mRNA such that the presence of hALG-2LP, sALG-2LP, or mALG-2LP is detected in the biological sample. The compound or agent can be, for example, a labeled or labelable nucleic acid probe capable of hybridizing to hALG-2LP, sALG-2LP, or mALG-2LP mRNA or a labeled or labelable antibody capable of binding to hALG-2LP, sALG-2LP, or mALG-2LP protein. The invention further provides methods for diagnosis of a subject with, for example, a disorder characterized by deregulated programmed cell death, based on detection of hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA. In one embodiment, the method involves contacting a cell or tissue sample (e.g., a brain cell sample) from the subject with an agent capable of detecting hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA, determining the amount of hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA
expressed in the cell or tissue sample, comparing the amount of hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA expressed in the cell or tissue sample to a control sample and forming a diagnosis based on the amount of hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA expressed in the cell or tissue sample as compared to the control sample. Preferably, the cell sample is a brain cell sample. Kits for detecting hALG-2LP, sALG-2LP, or mALG-2LP in a biological sample are also within the scope of the invention.
Brief Description of the Drawings Figure 1 depicts the human ALG-2LP (hALG-2LP) nucleotide (SEQ ID NO:1 ) and amino acid (SEQ ID N0:2) sequence. The coding region without the 5' and 3' untranslated regions of the human ALG-2LP gene is shown in SEQ ID N0:3.
Figure 2 depicts the monkey ALG-2LP (sALG-2LP) nucleotide (SEQ ID N0:4) and amino acid (SEQ ID NO:S) sequence. The coding region without the 5' and 3' untranslated regions of the monkey ALG-2LP gene is shown in SEQ ID N0:6.
Figure 3 depicts the partial marine ALG-2LP (mALG-2LP) nucleotide (SEQ ID
N0:7) and amino acid (SEQ ID N0:8) sequence. The coding region without the 5' and 3' untranslated regions of the marine ALG-2LP gene is shown in SEQ ID N0:9.
Detailed Description of the Invention The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as hALG-2LP, sALG-2LP, and mALG-2LP nucleic acid and protein molecules that are related to proteins which regulate programmed cell death.
As used herein, "programmed cell death" refers to a genetically regulated process involved in the normal development of multicellular organisms. This process occurs in cells destined for removal in a variety of normal situations, including larval development of the nematode c. elegans, insect metamorphosis, development in mammalian embryos including the nephrogenic zone in the developing kidney, and regression or atrophy (e.g., in the prostrate after castration). Programmed cell death can occur following the withdrawal of growth and trophic factors in many cells, nutritional deprivation, hormone treatment, ultraviolet irradiation, and exposure to toxic and infectious agents including reactive oxygen species and phosphatase inhibitors, e.g., okadaic acid, calcium ionphones, and a number of cancer chemotherapeutic agents. For a detailed description of programmed cell death see Trump B.F. et al. (1995) FASEB J.
9: 219-228 and Lee S. (1993) Curr. Opin. Cell Biol. 5: 286-291, the contents of which are incorporated herein by reference. Thus the hALG-2LP, sALG-2LP, and mALG-proteins by participating in a programmed cell death pathway, can modulate a programmed cell death pathway activity and provide novel diagnostic targets and therapeutic agents for disorders characterized by deregulated programmed cell death, particularly in cells that express ALG2-LP.
As used herein, a "disorder characterized by deregulated programmed cell death"
refers to a disorder, disease or condition which is characterized by a deregulation, e.g., an upregulation or a downregulation, of programmed cell death. Programmed cell death deregulation can lead to deregulation of cellular proliferation and/or cell cycle progression. Examples of disorders characterized by deregulated programmed cell death include neurodegenerative disorders, e.g., Alzheimer's disease, dementias related to Alzheimer's disease (such as Pick's disease), Parkinson's and other Lewy diffuse body diseases, multiple sclerosis, amyotrophic lateral sclerosis, progressive supranuclear palsy, epilepsy, Jakob-Creutzfieldt disease, or AIDS related demential; or profilerative disorders, e.g., cancer such as chronic lymphocytic leukemia or colorectal cancer.
An abnormality in the function of hALG-2LP, sALG-2LP, or mALG-2LP
protein can lead to a disorder characterized by deregulated programmed cell death.
Thus, one aspect of the invention pertains to methods for detecting genetic lesions in a hALG-2LP, sALG-2LP, or mALG-2LP gene, to thereby determine if a subject with the lesioned gene is at risk for (or is predisposed to have) a disorder characterized by aberrant or abnormal hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid expression or hALG-2LP, sALG-2LP, or mALG-2LP protein activity, e.g., a disorder characterized by deregulated programmed cell death.
The apoptosis linked gene-2 like protein nucleic acid molecules described herein, e.g., hALG-2LP, sALG-2LP, and mALG-2LP, were identified from human, monkey, and mouse brain cDNA libraries, respectively, using the Blast Algorithm. A
cDNA
library was prepared from mRNA isolated from disected monkey brain striatum. A
homology search of sequences obtained from the cDNA library revealed a cDNA
sequence that had 42% homology (62 of 144 amino acids) with rat ALG-2 protein.
Additional clones from the cDNA library were sequences and multiple sequences were contiged to obtain a full length monkey cDNA sequence, SEQ ID N0:4. The monkey clone was used to screen a human heart cDNA library and a marine whole brain library.
Sequencing of positive clones yielded the human sequence, SEQ ID NO:1, and the partial marine sequence, SEQ ID N0:7.
The nucleotide sequence of hALG-2LP cDNA and the predicted amino acid sequence of the hALG-2LP protein are shown in Figure 1 and in SEQ ID NOs: l and 2, respectively. A plasrnid containing the full length nucleotide sequence encoding human ALG-2LP (with the DNA insert name of ) was deposited with ATCC~ on and assigned Accession Number . This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C.~112.
1 S The hALG-2LP gene, which is approximately 1667 nucleotides in length, encodes a protein having a molecular weight of approximately 32.7 kD and which is approximately 284 amino acid residues in length. The hALG-2LP protein is expressed in all tissues examined (brain, heart, kidney, liver, lung, skeletal muscle, testis, placenta, pancreas, colon, prostate, ovaries, small intestine, and spleen). No expressio was seen in the hypothalamus.
Amino acid residues 127 to 139 and 194-206 of the hALG-2LP protein comprise a region showing homology to a calcium binding domain. As used herein, the term "calcium binding domain" refers to an amino acid domain, e.g., an EF hand (described in, for example, Baimbridge K.G. et al. (1992) TINS 15(8): 303-308, the contents of which are incorporated herein by reference), which is involved in calcium binding.
These EF hands usually have a sequence, which is similar to the consensus sequence:
EO~~00~~ODKDGDG~O~~~EF~~00. (SEQ ID N0:16).
O can be I, L, V or M, and "~" indicates a position with no strongly preferred residue.
Each residue listed is present in more than 25% of sequences, and those underlined are present in more than 80% of sequences.
The nucleotide sequence of the sALG-2LP cDNA and the predicted amino acid sequence of the sALG-2LP protein are shown in Figure 2 and in SEQ ID NOs:4 and 5, respectively. The sALG-2LP gene, which is approximately 1525 nucleotides in length, encodes a protein having a molecular weight of approximately 31.8 kD and which is approximately 277 amino acid residues in length.
The nucleotide sequence of the partial mALG-2LP cDNA and the predicted amino acid sequence of the partial mALG-2LP protein are shown in Figure 3 and in SEQ
ID NOs:7 and 8, respectively. The partial mALG-2LP gene, which is approximately 1362 nucleotides in length, encodes a protein having a molecular weight of approximately 31.5 kD and which is approximately 274 amino acid residues in length.
Various aspects of the invention are described in further detail in the following subsections:
I. Isolated Nucleic Acid Molecules One aspect of the invention pertains to isolated nucleic acid molecules that encode hALG-2LP, sALG-2LP, or mALG-2LP or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify hALG-2LP, sALG-2LP, or mALG-2LP-encoding nucleic acid (e.g., hALG-2LP, sALG-2LP, or mALG-2LP mRNA). As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA
molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or O.I
kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA
of the cell from which the nucleic acid is derived (e.g., a brain cell or other cell that expresses ALG2-LP). Moreover, an "isolated" nucleic acid molecule, such as a cDNA
molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.
A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NOs:l, 4, and 7, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a human, a monkey, or a mouse ALG-2LP cDNA can be isolated from a human, a monkey, or a mouse brain library, respectively, using all or portion of SEQ ID NO:1, 4, or 7 as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:1, 4, or 7 can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon the sequence of SEQ ID NO:1, 4, or 7. For example, mRNA can be isolated from normal brain cells (e.g., by the guanidinium-thiocyanate extraction procedure of Chirgwin et al.
(1979) Biochemistry 18: 5294-5299) and cDNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL). Synthetic oligonucleotide primers for PCR amplification can be designed based upon the nucleotide sequence shown in SEQ ID NO:I, 4, or 7. A
nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR
amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to a hALG-2LP, sALG-2LP, or mALG-2LP nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:1, 4, and 7 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number . The sequence of SEQ ID NO:1 corresponds to the human ALG2-LP
(hALG2-LP) cDNA. This cDNA comprises sequences encoding the hALG-2LP protein (i.e., "the coding region", from nucleotides 30 to 881 of SEQ ID NO:1), as well as 5' untranslated sequences (nucleotides 1-29 of SEQ ID NO:1) and 3' untranslated sequences (nucleotides 882 to 1667 of SEQ ID NO:1). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:1 (e.g., nucleotides 30 to 881, shown separately as SEQ ID N0:3). The sequence of SEQ ID N0:4 corresponds to the monkey ALG-2LP (sALG-2LP) cDNA. This cDNA comprises sequences encoding the sALG-2LP protein (i.e., "the coding region", from nucleotides 10 to 840 of SEQ ID N0:4), as well as 5' untranslated sequences (nucleotides 1-9 of SEQ ID
NO: 4) and 3' untranslated sequences (nucleotides 841 to 1525 of SEQ ID N0:4).
Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID N0:4 (e.g., nucleotides 10 to 840, shown separately as SEQ ID N0:6). The sequence of SEQ ID N0:7 corresponds to the partial mouse ALG-2LP (mALG-2LP) cDNA. This cDNA comprises sequences encoding the partial mALG-2LP protein (i.e., "the coding region", from nucleotides 177 to 998 of SEQ ID N0:7), as well as 5' untranslated sequences (nucleotides 1 to 176 of SEQ ID N0:7) and 3' untranslated sequences (nucleotides 999 to 1362 of SEQ ID N0:7). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID N0:7 (e.g., nucleotides 177 to 998, shown separately as SEQ ID N0:9).
In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1, 4, or 7, the nucleotide sequence of the DNA
insert of the lasmid de osited with ATCC~ as Accession Number p p , or a portion of these nucleotide sequences. A nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO:1, 4, or 7 is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:l, 4, or 7 such that it can hybridize to the nucleotide sequence shown in SEQ ID NO:1, 4, or 7, respectively, thereby forming a stable duplex.
In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least 32%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the nucleotide sequence shown in SEQ ID NO:1, 4, or 7, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number , or a portion of these nucleotide sequences. In an additional preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence shown in SEQ ID NO:1, 4, or 7, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number , or a portion of these nucleotide sequences.
Moreover, the nucleic acid molecule of the invention can comprise only a portion of the coding region of SEQ ID NO:1, 4, or 7, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of hALG-2LP, sALG-2LP, or mALG-2LP. The nucleotide sequence determined from the cloning of the hALG-2LP, sALG-2LP, or mALG-2LP gene from a mammal allows for the generation of probes and primers designed for use in identifying and/or cloning hALG-2LP, sALG-2LP, or mALG-2LP homologues in other cell types, e.g., from other tissues, as well as hALG-2LP, sALG-2LP, or mALG-2LP homologues from other mammals, e.g., rats. The probe/primer typically comprises substantially purified oligonucleotide.
The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50, 75, 100, 150, 200, 300, 400, 500, 520, 540, 550, or 600 consecutive nucleotides of SEQ ID NO:I, 4, or 7 sense, an anti-sense sequence of SEQ ID
NO:1, 4, or 7, or naturally occurring mutants thereof. Primers based on the nucleotide sequence in SEQ ID NO:1, 4, or 7 can be used in PCR reactions to clone hALG-2LP, sALG-2LP, or mALG-2LP homologues. Probes based on the hALG-2LP, sALG-2LP, or mALG
2LP nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a hALG-2LP, sALG-2LP, or mALG-2LP protein, such as by measuring a level of a hALG-2LP, sALG-2LP, or mALG-2LP-encoding nucleic acid in a sample of cells from a subject e.g., detecting hALG-2LP, sALG-2LP, or mALG-2LP mRNA levels or determining whether a genomic hALG-2LP, sALG-2LP, or mALG-2LP gene has been mutated or deleted.
In one embodiment, the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID N0:2, 5, or 8 or an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number such that the protein or portion thereof maintains the ability to modulate a programmed cell death related activity. As used herein, the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain as an amino acid residue in SEQ ID N0:2, 5, or 8) amino acid residues to an amino acid sequence of SEQ ID N0:2, S, or 8 or an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number such that the protein or portion thereof is able to modulate a programmed cell death related activity. In another embodiment, the protein is at least 38%, 42%, 44%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8.
Portions of proteins encoded by the hALG-2LP, sALG-2LP, or mALG-2LP
nucleic acid molecules of the invention are preferably biologically active portions of the hALG-2LP, sALG-2LP, or mALG-2LP proteins. As used herein, the term "biologically active portion of hALG-2LP, sALG-2LP, or mALG-2LP" is intended to include a portion, e.g., a domain/motif, of hALG-2LP, sALG-2LP, or mALG-2LP that has one or more of the following activities: 1 ) it can interact with a programmed cell death pathway associated molecule, e.g., an ALG-2 interacting protein; and 2) it can modulate cell death, e.g., programmed cell death, in a cell, e.g., a brain cell and other cells that express ALG2-LP.
Standard binding assays, e.g., immunoprecipitations and yeast two-hybrid assays as described herein, can be performed to determine the ability of a hALG-2LP, sALG-2LP, or mALG-2LP protein or a biologically active portion thereof to interact with (e.g., bind to) another programmed cell death pathway associated protein, e.g., ALG-2, or portion thereof. To determine whether a hALG-2LP, sALG-2LP, or mALG-2LP
protein or a biologically active portion thereof can modulate programmed cell death in a cell such as a T cell, T cells e.g., T cell hybridomas (3D0) which have been cross-linked with a T cell receptor to induce programmed cell death (as described in Ashwell J. D. et al. (1990) J. Immunol. 144:3326) can be transfected with a nucleic acid encoding the hALG-2LP, sALG-2LP, or mALG-2LP protein or biologically active portion thereof, cloned in, for example, a pLTP vector (as described in Vito P. et al. (1996) Science 271:521-525). The ability of the transfected nucleic acid molecules to protect the recipient cells form cell death can then be monitored.
Additional nucleic acid fragments encoding biologically active portions of hALG-2LP, sALG-2LP, or mALG-2LP can be prepared by isolating a portion of SEQ
ID N0:2, 5, or 8, respectively, expressing the encoded portion of hALG-2LP, sALG-2LP, or mALG-2LP protein or peptide (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of hALG-2LP, sALG-2LP, or mALG-protein or peptide.
The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1, 4, or 7 (and portions thereof] due to degeneracy of the genetic code and thus encode the same hALG-2LP, sALG-2LP, or mALG-2LP protein as that encoded by the nucleotide sequence shown in SEQ ID
NO:1, 4, or 7, respectively. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID N0:2, 5, or 8 or a protein having an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~
as Accession Number . In a still further embodiment, the nucleic acid molecule of the invention encodes a full length human protein which is substantially homologous to the amino acid sequence of SEQ ID N0:2, S, or 8 (encoded by the open reading frame shown in SEQ ID N0:3, 6, or 9) or an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number In addition to the hALG-2LP, sALG-2LP, and mALG-2LP nucleotide sequences shown in SEQ ID NOs:I, 4, and 7, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of hALG-2LP, sALG-2LP, and mALG-2LP may exist within a population (e.g., the human IO population). Such genetic polymorphism in the hALG-2LP, sALG-2LP, and mALG-2LP genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein, preferably a mammalian hALG-2LP, sALG-2LP, or mALG-2LP
protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the hALG-2LP, sALG-2LP, or mALG-2LP gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in hALG-2LP, sALG-2LP, or mALG-2LP that are the result of natural allelic variation and that do not alter the functional activity of hALG-2LP, sALG-2LP, or mALG-2LP are intended to be within the scope of the invention. Moreover, nucleic acid molecules encoding hALG-2LP, sALG-2LP, or mALG-2LP proteins from other species, and thus which have a nucleotide sequence which differs from the sequence of SEQ ID NO:1, 4, or 7, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and non-human, non-monkey, or non-marine homologues of the hALG-2LP, sALG-2LP, or mALG-2LP cDNA of the invention can be isolated based on their homology to the hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid disclosed herein using the human cDNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.
Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 4, or 7 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~
as Accession Number . In other embodiments, the nucleic acid is at least 30, 50, 100, 250, 300, 350, 400, 450, 500, 520, 540, 550, or 600 nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60%
homologous to each other typically remain hybridized to each other.
Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biolog~, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C.
Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1, 4, or 7 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring"
nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein). In one embodiment, the nucleic acid encodes a natural human hALG-2LP, sALG-2LP, or mALG-2LP.
In addition to naturally-occurring allelic variants of the hALG-2LP, sALG-2LP, or mALG-2LP sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO:1, 4, or 7, thereby leading to changes in the amino acid sequence of the encoded hALG-2LP, sALG-2LP, or mALG-2LP protein, without altering the functional ability of the hALG-2LP, sALG-2LP, or mALG-2LP protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO: l, 4, or 7. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of hALG-2LP, sALG-2LP, or mA,LG-2LP (e.g., the sequence of SEQ ID N0:2, 5, or 8) without altering the activity of hALG-2LP, sALG-2LP, or mALG-2LP, whereas an "essential" amino acid residue is required for hALG-2LP, sALG-2LP, or mALG-2LP activity. For example, amino acid residues that are conserved among the ALG-2LP proteins of the present invention, are predicted to be particularly unamenable to alteration (e.g., the conserved aspartate, lysine, and glutamate residues present in the EF hand).
Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved in the EF hand) may not be essential for activity and thus are likely to be amenable to alteration without altering hALG-2LP, sALG-2LP, or mALG-2LP activity.
Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding hALG-2LP, sALG-2LP, or mALG-2LP proteins that contain changes in amino acid residues that are not essential for hALG-2LP, sALG-2LP, or mALG-2LP
activity.
Such hALG-2LP, sALG-2LP, or mALG-2LP proteins differ in amino acid sequence from SEQ ID N0:2, 5, or 8, respectively, yet retain at least one of the hALG-2LP, sALG-2LP, or mALG-2LP activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least 38%, 42%, 44%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8 and is capable of modulating programmed cell death.
To determine the percent homology of two amino acid sequences (e.g., SEQ ID
N0:2, 5, or 8 and a mutant form thereof) or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid).
The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence (e.g., SEQ ID
N0:2, 5, or 8) is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (e.g., a mutant form of hALG-2LP, sALG-2LP, or mALG-2LP, respectively), then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., %
homology = # of identical positions/total # of positions x 100).
The comparison of sequences and determination of percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of KarIin and Altschul (1990) Proc. Natl. Acad. Sci. USA
87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid molecules of the invention. BLAST protein searches can also be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the hALG-2LP, sALG-2LP, or mALG-2LP protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST
can be utilized as described in Altschul et al., (1997) Nucleic Acids Res.
25(17):3389-3402.
When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http://www.ncbi.nlm.nih.gov. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN
program (version 2.0) which is part of the GCG sequence alignment software package.
When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
An isolated nucleic acid molecule encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein homologous to the protein of SEQ ID N0:2, 5, or 8, respectively, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1, 4, or 7 such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.
Mutations can be introduced into SEQ ID NO:1, 4, or 7 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues.
A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in hALG-2LP, sALG-2LP, or mALG-2LP is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a hALG-2LP, sALG-2LP, or mALG-2LP coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for a hALG-2LP, sALG-2LP, or mALG-2LP
activity described herein to identify mutants that retain hALG-2LP, sALG-2LP, or mALG-activity. Following mutagenesis of SEQ ID NO:1, 4, or 7, the encoded protein can be expressed recombinantly (e.g., as described in Examples 3 and 4) and the activity of the protein can be determined using, for example, assays described herein.
In addition to the nucleic acid molecules encoding hALG-2LP, sALG-2LP, or mALG-2LP proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA
molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire hALG-2LP, sALG-2LP, or mALG-2LP coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding hALG-2LP, sALG-2LP, or mALG-2LP.
The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues, e.g., the entire coding region of SEQ ID NO:1 comprises nucleotides 30 to 881 (shown separately as SEQ
ID
N0:3), the entire coding region of SEQ ID N0:4 comprises nucleotides 10 to 840 (shown separately as SEQ ID N0:6), and the entire coding region of SEQ ID N0:7 comprises nucleotides 177 to 998 (shown separately as SEQ ID N0:9). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding hALG-2LP, sALG-2LP, or mALG-2LP. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions). An example of an antisense molecule which is complementary to a fragment of the 5' untranslated region of SEQ ID NO:1 and which also includes the start codon is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 20 to 38 of SEQ ID NO:1. This antisense molecule has the following nucleotide sequence: 5' CAGAATCACCATGGCCAGC 3' (SEQ ID
N0:17). An example of an antisense molecule which is complementary to a portion of the 3' untranslated region of SEQ ID NO:1 is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 885 to 905 of SEQ ID NO:1.
This antisense molecule has the following sequence: 5' CCCAACCATCTGTGGAGAGTG 3' (SEQ ID N0:18). An example of an antisense molecule which is complementary to a fragment of the 5' untranslated region of SEQ ID N0:4 and which also includes the start codon is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 1 to 15 of SEQ ID N0:4. This antisense molecule has the following nucleotide sequence: 5' CGCGTGGGCATGGCC 3' (SEQ ID N0:19). An example of an antisense molecule which is complementary to a portion of the 3' untranslated region of SEQ ID N0:4 is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 844 to 862 of SEQ ID N0:4. This antisense molecule has the following sequence: 5' CCCAACCCATCTGTGGAGA 3' (SEQ ID N0:20). An example of an antisense molecule which is complementary to a fragment of the 5' untranslated region of SEQ ID N0:7 and which also includes the start codon is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 170 to 182 of SEQ ID N0:7. This antisense molecule has the following nucleotide sequence: 5' CGGCACGAGCAGC 3' (SEQ ID N0:21 ). An example of an antisense molecule which is complementary to a portion of the 3' untranslated region of SEQ ID
N0:7 is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 992 to 1008 of SEQ ID N0:7. This antisense molecule has the following sequence: 5' GATGCTATGACCCAGCC 3' (SEQ ID N0:22).
Given the coding strand sequences encoding hALG-2LP, sALG-2LP, and S mALG-2LP disclosed herein (e.g., SEQ ID NOs:I, 4, and 7, respectively), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of hALG-2LP, sALG-2LP, or mALG-2LP mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of hALG-2LP, sALG-2LP, or mALG-2LP mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of hALG-2LP, sALG-2LP, or mALG-2LP mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurnng nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modif ed nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), S-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.
Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA
transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA
and/or genomic DNA encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of an antisense nucleic acid 1 S molecule of the invention includes direct injection at a tissue site.
Alternatively, an antisense nucleic acid molecule can be modified to target selected cells and then administered systemically. For example, for systemic administration, an antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen.
The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
In yet another embodiment, the antisense nucleic acid molecule of the invention is an a-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual (3-units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids.
Res. 15:6625-6641 ). The antisense nucleic acid molecule can also comprise a 2'-0-methylribonucleotide (moue et al. (1987) Nucleic Acads Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBSLett. 215:327-330).
In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave hALG-2LP, sALG-2LP, or mALG-2LP mRNA transcripts to thereby inhibit translation of hALG-2LP, sALG-2LP, or mALG-2LP mRNA. A ribozyme having specificity for a hALG-2LP, sALG-2LP, or mALG-2LP-encoding nucleic acid can be designed based upon the nucleotide sequence of a hALG-2LP, sALG-2LP, or mALG-2LP cDNA
disclosed herein (i.e., SEQ ID NO:1, 4, or 7, respectively). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a hALG-2LP, sALG-2LP, or mALG-2LP-encoding mRNA. See, e.g., Cech et al. U.S. Patent No.
4,987,071 and Cech et al. U.S. Patent No. 5,116,742. Alternatively, hALG-2LP, sALG-2LP, or mALG-2LP mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) Science 261:1411-1418.
Alternatively, hALG-2LP, sALG-2LP, or mALG-2LP gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the hALG-2LP, sALG-2LP, or mALG-2LP (e.g., the hALG-2LP, sALG-2LP, or mALG-2LP promoter and/or enhancers) to form triple helical structures that prevent transcription of the hALG-2LP, sALG-2LP, or mALG-2LP gene in target cells. See generally, Helene, C. (1991) Anticancer Drug Des. 6(6):569-84; Helene, C. et al. (1992) Ann. N. Y. Acad. Sci. 660:27-36; and Maher, L.J. ( 1992) Bioassays 14( 12):807-1 S.
II. Recombinant Expression Vectors and Host Cells Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding hALG-2LP, sALG-2LP, or mALG-2LP
(or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the forth of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequences) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.
The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., hALG-2LP, sALG-2LP, or mALG-2LP proteins, mutant forms of hALG-2LP, sALG-2LP, or mALG-2LP, fusion proteins, and the like).
The recombinant expression vectors of the invention can be designed for expression of hALG-2LP, sALG-2LP, or mALG-2LP in prokaryotic or eukaryotic cells.
For example, hALG-2LP, sALG-2LP, or mALG-2LP can be expressed in bacterial cells such as E. coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enrymology 185, Academic Press, San Diego, CA (1990).
Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
Expression of proteins in prokaryotes is most often carried out in E. coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein.
Such fusion vectors typically serve three purposes: 1 ) to increase expression of recombinant protein;
2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.
Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B.
and Johnson, K.S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRITS (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
In one embodiment, the coding sequence of the hALG-2LP, sALG-2LP, or mALG-2LP
is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-hALG-2LP, sALG-2LP, or mALG-2LP. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant hALG-2LP, sALG-2LP, or mALG-2LP unfused to GST can be recovered by cleavage of the fusion protein with thrombin.
Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al. (1988) Gene 69:301-315) and pET l ld (Studier et al. Gene Expression Technology: Methods in Enzymolog~ 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET l ld vector relies on transcription from a T7 gnl0-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident ~, prophage harboring a T7 gnl gene under the transcriptional control of the lacUV 5 promoter.
One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al. (1992) Nucleic Acids Res. 2011-2118).
Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
In another embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP expression vector is a yeast expression vector. Examples of vectors for expression in yeast S. cerivisae include pYepSecl (Baldari, et al. (1987) Embo J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al. (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA).
Alternatively, hALG-2LP, sALG-2LP, or mALG-2LP can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al.
(1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC
(Kaufman et al. (1987) EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements.
For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring 1 S Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific;
Pinkert et al.
(1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBOJ. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) PNAS 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the marine hox promoters (Kessel and Grass (1990) Science 249:374-379) and the a-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to hALG-2LP, sALG-2LP, or mALG-2LP mRNA.
Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA
molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H.
et al., Antisense RNA as a molecular tool for genetic analysis, Reviews -Trends in Genetics, Vol. 1(1) 1986.
Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell"
and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modif cations may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
A host cell can be any prokaryotic or eukaryotic cell. For example, hALG-2LP, sALG-2LP, or mALG-2LP protein can be expressed in bacterial cells such as E.
coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.
Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAF-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A
Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.
For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
Preferred selectable markers include those which confer resistance to drugs, such as 6418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding hALG-2LP, sALG-2LP, or mALG-2LP or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) hALG-2LP, sALG-2LP, or mALG-protein. Accordingly, the invention further provides methods for producing hALG-2LP, sALG-2LP, or mALG-2LP protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding hALG-2LP, sALG-2LP, or mALG-2LP has been introduced) in a suitable medium until hALG-2LP, sALG-2LP, or mALG-2LP is produced. In another embodiment, the method further comprises isolating hALG-2LP, sALG-2LP, or mALG-2LP from the medium or the host cell.
The host cells of the invention can also be used to produce nonhuman transgenic animals. The nonhuman transgenic animals can be used in screening assays designed to identify agents or compounds, e.g., drugs, pharmaceuticals, etc., which are capable of ameliorating detrimental symptoms of selected disorders such as disorders characterized S by deregulated cell death. For example, in one embodiment, a host cell of the invention is a neuronal cell into which hALG-2LP, sALG-2LP, or mALG-2LP-coding sequences have been introduced. Moreover, methods of the invention can be used to create non-human transgenic animals in which exogenous hALG-2LP or sALG-2LP sequences have been introduced into the mouse genome, or homologous recombinant animals in which endogenous sALG-2LP, or mALG-2LP sequences have been altered. Such animals are useful for studying the function and/or activity of hALG-2LP, sALG-2LP, or mALG-2LP and for identifying and/or evaluating modulators of hALG-2LP, sALG-2LP, or mALG-2LP activity. As used herein, a "transgenic animal" is a nonhuman animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include nonhuman primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a nonhuman animal, preferably a mammal, more preferably a mouse, in which an endogenous sALG-2LP, or mALG-2LP gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
A transgenic animal of the invention can be created by introducing hALG-2LP, sALG-2LP, or mA.LG-2LP-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The hALG-2LP, sALG-2LP, or mALG-2LP
cDNA sequence of SEQ ID NO:1, 4, or 7 can be introduced as a transgene into the genome of a nonhuman animal. Alternatively, a non-human, non-monkey, or non-marine homologue of the hALG-2LP, sALG-2LP, or mALG-2LP gene, such as a human hALG-2LP, sALG-2LP, or mALG-2LP gene, can be isolated based on hybridization to the hALG-2LP, sALG-2LP, or mALG-2LP cDNA (described further in subsection I
above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A
tissue-specific regulatory sequences) can be operably linked to the hALG-2LP, sALG-2LP, or mALG-2LP transgene to direct expression of hALG-2LP, sALG-2LP, or mALG-2LP protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos.
4,736,866 and 4,870,009, both by Leder et al., U.S. Patent No. 4,873,191 by Wagner et al. and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the hALG-2LP, sALG-2LP, or mALG-2LP transgene in its genome and/or expression of hALG-2LP, sALG-2LP, or mALG-2LP mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding hALG-2LP, sALG-2LP, or mALG-2LP can further be bred to other transgenic animals carrying other transgenes.
To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a hALG-2LP, sALG-2LP, or mALG-2LP gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the hALG-2LP, sALG-2LP, or mALG-2LP gene. The hALG-2LP, sALG-2LP, or mALG-2LP gene can be a human gene (e.g., from a human genomic clone isolated from a human genomic library screened with the cDNA of SEQ ID NO:1, 4, or 7), but more preferably, is a nonhuman homologue of a human hALG-2LP, sALG-2LP, or mALG-2LP gene. For example, a rat ALG-2LP gene can be isolated from a rat genomic DNA
library using the human ALG-2LP, monkey ALG-2LP, or partial marine ALG-2LP
cDNA of SEQ ID NO:1, 4, or 7 as a probe. The rat ALG-2LP gene then can be used to construct a homologous recombination vector suitable for altering an endogenous ALG-2LP gene in the rat genome. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous ALG-2LP gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out"
vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous ALG-2LP gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous ALG-2LP protein). In the homologous recombination vector, the altered portion of the ALG-2LP gene is flanked at its 5' and 3' ends by additional nucleic acid of the ALG-2LP gene to allow for homologous recombination to occur between the exogenous hALG-2LP, sALG-2LP, or mALG-2LP
gene carried by the vector and an endogenous ALG-2LP gene in an embryonic stem cell.
The additional flanking hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene.
Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see e.g., Thomas, K.R. and Capecchi, M. R. (1987) Cell 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced hALG-2LP, sALG-2LP, or mALG-2LP gene has homologously recombined with the endogenous ALG-2LP gene are selected (see e.g., Li, E. et al. (1992) Cell 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A
chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. ( 1991 ) Current Opinion in Biotechnology 2:823-829 and in PCT International Publication Nos.:
WO
90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al.
In another embodiment, transgenic nonhuman animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the crelloxP recombinase system of bacteriophage Pl. For a description of the crelloxP recombinase system, see, e.g., Lakso et al.
(1992) PNAS
89:6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355. If a crelloxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double"
transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
Clones of the nonhuman transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. (1997) Nature 385:810-813 and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter Go phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.
III. Isolated hALG-2LP, sALG-2LP, and mALG-2LP Proteins and Anti-hALG-2LP, Anti-sALG-2LP, and Anti-mALG-2LP Antibodies Another aspect of the invention pertains to isolated hALG-2LP, sALG-2LP, and mALG-2LP proteins, and biologically active portions thereof, as well as peptide fragments suitable for use as immunogens to raise anti-hALG-2LP, anti-sALG-2LP, and anti-mALG-2LP antibodies. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of hALG-2LP, sALG-2LP, or mALG-2LP protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language "substantially free of cellular material"
includes preparations of hALG-2LP, sALG-2LP, or mALG-2LP protein having less than about 30% (by dry weight) of non-hALG-2LP, sALG-2LP, or mALG-2LP protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-hALG-2LP, sALG-2LP, or mALG-2LP protein, still more preferably less than about 10% of non-hALG-2LP, sALG-2LP, or mALG-2LP protein, and most preferably less than about 5% non-hALG-2LP, sALG-2LP, or mALG-2LP protein. When the hALG-2LP, sALG-2LP, or mALG-2LP protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The language "substantially free of chemical precursors or other chemicals"
includes preparations of hALG-2LP, sALG-2LP, or mALG-2LP protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of hALG-2LP, sALG-2LP, or mALG-2LP protein having less than about 30% (by dry weight) of chemical precursors or non-hALG-2LP, sALG-2LP, or mALG-2LP chemicals, more preferably less than about 20% chemical precursors or non-hALG-2LP, sALG-2LP, or mALG-2LP
chemicals, still more preferably less than about 10% chemical precursors or non-hALG-2LP, sALG-2LP, or mALG-2LP chemicals, and most preferably less than about 5%
chemical precursors or non-hALG-2LP, sALG-2LP, or mALG-2LP chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same animal from which the hALG-2LP, sALG-2LP, or mALG-2LP protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a human ALG-2LP protein in a nonhuman cell.
An isolated hALG-2LP, sALG-2LP, or mALG-2LP protein or a portion thereof of the invention can modulate programmed cell death. In preferred embodiments, the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID N0:2, 5, or 8 such that the protein or portion thereof maintains the ability to modulate programmed cell death. The portion of the protein is preferably a biologically active portion as described herein.
In another preferred embodiment, the hALG-2LP protein (i.e., amino acid residues 1-284 of SEQ
ID N0:2), sALG-2LP protein (i.e., amino acid residues 1-277 of SEQ ID NO:S), or mALG-2LP protein (i.e., amino acid residues 1-274 of SEQ ID N0:8) has an amino acid sequence shown in SEQ ID N0:2, 5, or 8, respectively, or an amino acid sequence which is encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number . In yet another preferred embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence of the DNA insert of the piasmid deposited with ATCC~ as Accession Number . In still another preferred embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP protein has an amino acid sequence which is encoded by a nucleotide sequence that is at least about 32%, 35%, 40%, 45%, SO%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the nucleotide sequence of the DNA insert of the piasmid deposited with ATCC~ as Accession Number . The preferred hALG-2LP, sALG-2LP, or mALG-2LP
proteins of the present invention also preferably possess at least one of the hALG-2LP, sALG-2LP, or mALG-2LP activities described herein. For example, a preferred hALG-2LP, sALG-2LP, or mALG-2LP protein of the present invention includes an amino acid sequence encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number and which can modulate programmed cell death.
In other embodiments, the hALG-2LP, sALG-2LP, or mALG-2LP protein is substantially homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8 and retains the functional activity of the protein of SEQ ID N0:2, S, or 8 yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP protein is a protein which comprises an amino acid sequence which is at least about 38%, 42%, 44%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the entire amino acid sequence of SEQ ID N0:2, 5, or 8 and which has at least one of the hALG-2LP, sALG-2LP, or mALG-2LP activities described herein. In other embodiment, the invention pertains to a full length human protein which is substantially homologous to the amino acid sequence of SEQ ID
N0:2, 5,or8 Biologically active portions of the hALG-2LP, sALG-2LP, or mALG-2LP
protein include peptides comprising amino acid sequences derived from the amino acid sequence of the hALG-2LP, sALG-2LP, or mALG-2LP protein, e.g., the amino acid I 0 sequence shown in SEQ ID N0:2, 5, or 8, respectively or the amino acid sequence of a protein homologous to the hALG-2LP, sALG-2LP, or mALG-2LP protein, which contains less amino acids than the full length hALG-2LP, sALG-2LP, or mALG-2LP
protein or the full length protein which is homologous to the hALG-2LP, sALG-2LP, or mALG-2LP protein, and exhibits at least one activity of the hALG-2LP, sALG-2LP, or mALG-2LP protein. Typically, biologically active portions (peptides, e.g., peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif, e.g., a domain showing homology to a calcium binding domain such as an EF hand, derived from a human and is at least about 38%, 42%, 44%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to SEQ ID NO:10, 11, 12, 13, or 15. Moreover, other biologically active portions, in which other regions of the proteins are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein.
Preferably, the biologically active portions of the hALG-2LP, sALG-2LP, or mALG-2LP protein include one or more selected domains/motifs or portions thereof having biological activity.
hALG-2LP, sALG-2LP, and mALG-2LP proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the hALG-2LP, sALG-2LP, or mALG-2LP protein is expressed in the host cell. The hALG-2LP, sALG-2LP, or mALG-2LP protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, a hALG-2LP, sALG-2LP, or mALG-2LP protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques.
Moreover, native hALG-2LP, sALG-2LP, or mALG-2LP protein can be isolated from cells (e.g., brain cells or other cells that express ALG2-LP) for example using an anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody (described further below).
The invention also provides hALG-2LP, sALG-2LP, or mALG-2LP chimeric or fusion proteins. As used herein, a hALG-2LP, sALG-2LP, or mALG-2LP "chimeric protein" or "fusion protein" comprises a hALG-2LP, sALG-2LP, or mALG-2LP
polypeptide operatively linked to a non-hALG-2LP, sALG-2LP, or mALG-2LP
polypeptide. A "hALG-2LP, sALG-2LP, or mALG-2LP polypeptide" refers to a polypeptide having an amino acid sequence corresponding to hALG-2LP, sALG-2LP, or mALG-2LP, whereas a "non-hALG-2LP, sALG-2LP, or mALG-2LP polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the hALG-2LP, sALG-2LP, or mALG-2LP protein, e.g., a protein which is different from the hALG-2LP, sALG-2LP, or mALG-2LP protein and which is derived from the same or a different organism. Within the fusion protein, the term "operatively linked" is intended to indicate that the hALG-2LP, sALG-2LP, or mALG-2LP polypeptide and the non-hALG-2LP, sALG-2LP, or mALG-2LP
polypeptide are fused in-frame to each other. The non-hALG-2LP, sALG-2LP, or mALG-2LP polypeptide can be fused to the N-terminus or C-terminus of the hALG-2LP, sALG-2LP, or mALG-2LP polypeptide. For example, in one embodiment the fusion protein is a GST-hALG-2LP, GST-sALG-2LP, or GST-rnALG-2LP fusion protein in which the hALG-2LP, sALG-2LP, or mALG-2LP sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant hALG-2LP, sALG-2LP, or mALG-2LP. In another embodiment, the fusion protein is a hALG-2LP, sALG-2LP, or mALG-2LP protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of hALG-2LP, sALG-2LP, or mALG-2LP
can be increased through use of a heterologous signal sequence.
Preferably, a hALG-2LP, sALG-2LP, or mALG-2LP chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-s ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carned out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST
polypeptide). A GST encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the hALG-2LP, sALG-2LP, or mALG-2LP protein.
The present invention also pertains to homologues of the hALG-2LP, sALG-2LP, or mALG-2LP proteins which function as either a hALG-2LP, sALG-2LP, or mALG-2LP agonist (mimetic) or a hALG-2LP, sALG-2LP, or mALG-2LP antagonist.
In a preferred embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP agonists and antagonists stimulate or inhibit, respectively, a subset of the biological activities of the naturally occurring form of the hALG-2LP, sALG-2LP, or mALG-2LP protein. Thus, specific biological effects can be elicited by treatment with a homologue of limited function. In one embodiment, treatment of a subject with a homologue having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurnng form of the hALG-2LP; sALG-2LP, or mALG-2LP protein.
Homologues of the hALG-2LP, sALG-2LP, or mALG-2LP protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the hALG-2LP, sALG-2LP, or mALG-2LP protein. As used herein, the term "homologue" refers to a variant form of the hALG-2LP, sALG-2LP, or mALG-2LP protein which acts as an agonist or antagonist of the activity of the hALG-2LP, sALG-2LP, or mALG-2LP
protein. An agonist of the hALG-2LP, sALG-2LP, or mALG-2LP protein can retain substantially the same, or a subset, of the biological activities of the hALG-2LP, sALG-2LP, or mALG-2LP protein. An antagonist of the hALG-2LP, sALG-2LP, or mALG-2LP protein can inhibit one or more of the activities of the naturally occurring form of the hALG-2LP, sALG-2LP, or mALG-2LP protein, by, for example, competitively binding to a downstream or upstream member of the hALG-2LP, sALG-2LP, or mALG-2LP cascade which includes the hALG-2LP, sALG-2LP, or mALG-2LP protein. Thus, the mammalian hALG-2LP, sALG-2LP, or mALG-2LP protein and homologues thereof of the present invention can be either positive or negative regulators of a programmed cell death transduction pathway activity.
In an alternative embodiment, homologues of the hALG-2LP, sALG-2LP, or mALG-2LP protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the hALG-2LP, sALG-2LP, or mALG-2LP protein for hALG-2LP, sALG-2LP, or mALG-2LP protein agonist or antagonist activity. In one embodiment, a variegated library of hALG-2LP, sALG-2LP, or mALG-2LP variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of hALG-2LP, sALG-2LP, or mALG-variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential hALG-2LP, sALG-2LP, or mALG-2LP sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of hALG-2LP, sALG-2LP, or mALG-2LP sequences therein. There are a variety of methods which can be used to produce libraries of potential hALG-2LP, sALG-2LP, or mALG-2LP homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA
synthesizer, and the synthetic gene then ligated into an appropriate expression vector.
Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential hALG-2LP, sALG-2LP, or mALG-sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu.
Rev.
Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477).
In addition, libraries of fragments of the hALG-2LP, sALG-2LP, or mALG-2LP
protein coding can be used to generate a variegated population of hALG-2LP, sALG-2LP, or mALG-2LP fragments for screening and subsequent selection of homologues of a hALG-2LP, sALG-2LP, or mALG-2LP protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR
fragment of a hALG-2LP, sALG-2LP, or mALG-2LP coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the hALG-2LP, sALG-2LP, or mALG-2LP protein.
Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA
libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of hALG-2LP, sALG-2LP, or mALG-2LP homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected.
Recrusive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify hALG-2LP, sALG-2LP, or mALG-2LP homologues (Arkin and Yourvan (1992) PNAS 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).
In one embodiment, cell based assays can be exploited to analyze a variegated hALG-2LP, sALG-2LP, or mALG-2LP library. For example, a library of expression vectors can be transfected into a cell line, e.g., a T cell hybridoma (3D0) which has been cross-linked with a T cell receptor to induce programmed cell death (as described in Ashwell J. D. et al. ( 1990) J. Immunol. 144:3326). The effect of the hALG-2LP, sALG-2LP, or mALG-2LP mutant on programmed cell death can then be detected, e.g., by monitoring nuclear chromatin changes. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, stimulation of programmed cell death, and the individual clones further characterized.
An isolated hALG-2LP, sALG-2LP, or mALG-2LP protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind hALG-2LP, sALG-2LP, or mALG-2LP using standard techniques for polyclonal and monoclonal antibody preparation. The full-length hALG-2LP, sALG-2LP, or mALG-2LP protein can be used or, alternatively, the invention provides antigenic peptide fragments of hALG-2LP, sALG-2LP, or mALG-2LP for use as immunogens. The antigenic peptide of hALG-2LP, sALG-2LP, or mALG-2LP comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID N0:2, 5, or 8 and encompasses an epitope of hALG-2LP, sALG-2LP, or mALG-2LP such that an antibody raised against the peptide forms a specific immune complex with hALG-2LP, sALG-2LP, or mALG-2LP. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.
Preferred epitopes encompassed by the antigenic peptide are regions of hALG-2LP, sALG-2LP, or mALG-2LP that are located on the surface of the protein, e.g., hydrophilic regions.
A hALG-2LP, sALG-2LP, or mALG-2LP immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed hALG-2LP, sALG-2LP, or mALG-2LP protein or a chemically synthesized hALG-2LP, sALG-2LP, or mALG-2LP peptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic hALG-2LP, sALG-2LP, or mALG-2LP preparation induces a polyclonal anti-hALG-2LP, anti-sALG-2LP, or anti-mALG-2LP antibody response.
Accordingly, another aspect of the invention pertains to anti-hALG-2LP, anti-sALG-2LP, or anti-mALG-2LP antibodies. The term "antibody" as used herein refers to S immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as hALG-2LP, sALG-2LP, or mALG-2LP.
Examples of immunologically active portions of immunoglobulin molecules include Flab) and F(ab')2 fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind hALG-2LP, sALG-2LP, or mALG-2LP. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of hALG-2LP, sALG-2LP, or mALG-2LP. A
monoclonal antibody composition thus typically displays a single binding affinity for a particular hALG-2LP, sALG-2LP, or mALG-2LP protein with which it immunoreacts.
Polyclonal anti-hALG-2LP, sALG-2LP, or mALG-2LP antibodies can be prepared as described above by immunizing a suitable subject with a hALG-2LP, sALG-2LP, or mALG-2LP immunogen. The anti-hALG-2LP, sALG-2LP, or mALG-2LP
antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using in~nobilized hALG-2LP, sALG-2LP, or mALG-2LP. If desired, the antibody molecules directed against hALG-2LP, sALG-2LP, or mALG-2LP can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497) (see also, Brown et al. (1981) J. Immunol. 127:539-46; Brown et al. (1980) J. Biol. Chem .255:4980-83; Yeh et al. (1976) PNAS 76:2927-31; and Yeh et al. (1982) Int. J.
Cancer 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al.
(1983) Immunol Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques.
The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in Monoclonal Antibodies: A New Dimension In Biological Analyses, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) Yale J. Biol. Med., 54:387-402; M. L. Gefter et al. (1977) Somatic Cell Genet.
3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a hALG-2LP, sALG-2LP, or mALG-2LP immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds hALG-2LP, sALG-2LP, or mALG-2LP.
Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-hALG-2LP, sALG-2LP, or mALG-2LP monoclonal antibody (see, e.g., G. Galfre et al. (1977) Nature 266:55052; Gefter et al. Somatic Cell Genet., cited supra; Lerner, Yale J. Biol.
Med., cited supra; Kenneth, Monoclonal Antibodies, cited supra). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, marine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line.
Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS111-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Agl4 myeloma lines.
These myeloma lines are available from ATCC~. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG").
Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind hALG-2LP, sALG-2LP, or mALG-2LP, e.g., using a standard ELISA assay.
Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with hALG-2LP, sALG-2LP, or mALG-2LP to thereby isolate immunoglobulin library members that bind hALG-2LP, sALG-2LP, or mALG-2LP. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No.
9400-O1; and the Stratagene SurfZAPTM Phage Display Kit, Catalog No. 240612).
Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT International Publication No. WO
92/18619; Dower et al. PCT International Publication No. WO 91/17271; Winter et al.
PCT International Publication WO 92/20791; Markland et al. PCT International Publication No. WO 92/15679; Breitling et al. PCT International Publication WO
93/01288; McCafferty et al. PCT International Publication No. WO 92/01047;
Garrard et al. PCT International Publication No. WO 92/09690; Ladner et al. PCT
International Publication No. WO 90/02809; Fuchs et al. (1991) BiolTechnology 9:1370-1372;
Hay et al. (1992) Hum. Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J. Mol.
Biol.
226:889-896; Clarkson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS
89:3576-3580; Garrad et al. (1991) BiolTechnolo~ 9:1373-1377; Hoogenboom et al.
(1991) Nuc. Acid Res. 19:4133-4137; Barbas et al. (1991) PNAS 88:7978-7982;
and McCafferty et al. Nature (1990) 348:552-554.
Additionally, recombinant anti-hALG-2LP, sALG-2LP, or mALG-2LP
antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA
techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187;
Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533;
Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023;
Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) PNAS 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218;
Nishimura et al. (1987) Canc. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-1559); Morrison, S. L. (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214; Winter U.S. Patent 5,225,539;
Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J. Immunol. 141:4053-4060.
An anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody (e.g., monoclonal antibody) can be used to isolate hALG-2LP, sALG-2LP, or mALG-2LP by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody can facilitate the purification of natural hALG-2LP, sALG-2LP, or mALG-2LP from cells and of recombinantly produced hALG-2LP, sALG-2LP, or mALG-2LP expressed in host cells. Moreover, an anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody can be used to detect hALG-2LP, sALG-2LP, or mALG-2LP protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the hALG-2LP, sALG-2LP, or mALG-2LP protein. Anti-hALG-2LP, sALG-2LP, or mALG-2LP antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen.
Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, (3-galactosidase, or acetylcholinesterase;
examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol;
examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I~ 131h 35S or 3H.
IV. Pharmaceutical Compositions The hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid molecules, hALG-2LP, sALG-2LP, or mALG-2LP proteins, and anti-hALG-2LP, sALG-2LP, or mALG-2LP
antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject, e.g., a human. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable Garner. As used herein the language "pharmaceutically acceptable Garner" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention.
Supplementary active compounds can also be incorporated into the compositions.
A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents;
antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable earners include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the 1 S maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a hALG-2LP, sALG-2LP, or mALG-2LP protein or anti-hALG-2LP, anti-sALG-2LP, or anti-mALG-2LP antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Oral compositions generally include an inert diluent or an edible carrier.
They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid Garner for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
Methods for preparation of such formulations will be apparent to those skilled in the art.
The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomai suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) PNAS 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
V. Uses and Methods of the Invention The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in, for example, diagnostic assays. The isolated nucleic S acid molecules of the invention can be used to detect hALG-2LP, sALG-2LP, or mALG-2LP mRNA (e.g., in a biological sample) or a genetic lesion in a hALG-2LP, sALG
2LP, or mALG-2LP gene. In addition, the anti-hALG-2LP, anti-sALG-2LP, or anti mALG-2LP antibodies of the invention can be used to detect and isolate hALG-2LP, sALG-2LP, or mALG-2LP protein and modulate hALG-2LP, sALG-2LP, or mALG
2LP protein activity.
Accordingly, the invention provides a method for detecting the presence of hALG-2LP, sALG-2LP, or mALG-2LP in a biological sample. The method involves contacting the biological sample with a compound or an agent capable of detecting hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA such that the presence of hALG-2LP, sALG-2LP, or mALG-2LP is detected in the biological sample. A
preferred agent for detecting hALG-2LP, sALG-2LP, or mALG-2LP mRNA is a labeled or labelable nucleic acid probe capable of hybridizing to hALG-2LP, sALG-2LP, or mALG-2LP mRNA. The nucleic acid probe can be, for example, the full-length hALG-2LP, sALG-2LP, or mALG-2LP cDNA of SEQ ID NO: 1, 4, or 7, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or S00 nucleotides in length and sufficient to specifically hybridize under stringent conditions to hALG-2LP, sALG-2LP, or mALG-2LP mRNA. A preferred agent for detecting hALG-2LP, sALG-2LP, or mALG-2LP protein is a labeled or labelable antibody capable of binding to hALG-2LP, sALG-2LP, or mALG-2LP protein. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')2) can be used.
The term "labeled or labelable", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled.
Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample"
is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect hALG-2LP, sALG-2LP, or mALG-2LP mRNA or protein in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of hALG-2LP, sALG-2LP, or mALG-2LP mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of hALG-2LP, sALG-2LP, or mALG-2LP protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.
Alternatively, hALG-2LP, sALG-2LP, or mALG-2LP protein can be detected in vivo in a subject by introducing into the subject a labeled anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
1 S The invention also encompasses kits for detecting the presence of hALG-2LP, sALG-2LP, or mALG-2LP in a biological sample. For example, the kit can comprise a labeled or labelable compound or agent capable of detecting hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA in a biological sample; means for determining the amount of hALG-2LP, sALG-2LP, or mALG-2LP in the sample; and means for comparing the amount of hALG-2LP, sALG-2LP, or mALG-2LP in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect hALG-2LP, sALG-2LP, or mALG-mRNA or protein.
The methods of the invention can also be used to detect genetic lesions in a hALG-2LP, sALG-2LP, or mALG-2LP gene, thereby determining if a subject with the lesioned gene is at risk for a disorder, e.g., a disorder characterized by deregulated programmed cell death, characterized by aberrant or abnormal hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid expression or hALG-2LP, sALG-2LP, or mALG-2LP
protein activity as defined herein. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene WO 99/b1459 PCT/US99/10581 encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein, or the misexpression of the hALG-2LP, sALG-2LP, or mALG-2LP gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a hALG-2LP, sALG-2LP, or mALG-2LP gene; 2) an addition of one or more nucleotides to a hALG-2LP, sALG-2LP, or mALG-2LP gene; 3) a substitution of one or more nucleotides of a hALG-2LP, sALG-2LP, or mALG-2LP gene, 4) a chromosomal rearrangement of a hALG-2LP, sALG-2LP, or mALG-2LP gene; 5) an alteration in the level of a messenger RNA transcript of a hALG-2LP, sALG-2LP, or mALG-2LP gene, 6) aberrant modification of a hALG-2LP, sALG-2LP, or mALG-2LP
gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a hALG-2LP, sALG-2LP, or mALG-2LP gene, 8) a non-wild type level of a hALG-2LP, sALG-2LP, or mALG-2LP-protein, 9) allelic loss of a hALG-2LP, sALG-2LP, or mALG-2LP gene, and 10) inappropriate post-translational modification of a hALG-2LP, sALG-2LP, or mALG-2LP-protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a hALG-2LP, sALG-2LP, or mALG-2LP gene.
In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos.
4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al. (1994) PNAS 91:360-364), the latter of which can be particularly useful for detecting point mutations in the hALG-2LP, sALG-2LP, or mALG-2LP-gene (see Abravaya et al. (1995) Nucleic Acids Res .23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specif cally hybridize to a hALG-2LP, sALG-2LP, or mALG-2LP gene under conditions such that hybridization and amplification of the hALG-2LP, sALG-2LP, or mALG-2LP-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample.
In an alternative embodiment, mutations in a hALG-2LP, sALG-2LP, or mALG-2LP gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA.
Moreover, the use of sequence specific ribozymes (see, for example, U.S.
Patent No.
5,498,531 ) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.
In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the hALG-2LP, sALG-2LP, or mALG-2LP
gene and detect mutations by comparing the sequence of the sample hALG-2LP, sALG-2LP, or mALG-2LP with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxam and Gilbert ((1977) PNAS 74:560) or Sanger ((1977) PNAS 74:5463). A variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al. (1996) Adv.
Chromatogr.
36:127-162; and Griffin et al. (i993) Appl. Biochem. Biotechnol. 38:147-159).
Other methods for detecting mutations in the hALG-2LP, sALG-2LP, or mALG-2LP gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al. (1985) Science 230:1242); Cotton et al. (1988) PNAS 85:4397; Saleeba et al. (1992) Meth.
Enzymol.
217:286-295), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al. (1989) PNAS 86:2766; Cotton (1993) Mutat Res 285:125-144; and Hayashi (1992) GenetAnal Tech Appl 9:73-79), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al (1985) Nature 313:495). Examples of other techniques for detecting point mutations include, selective oligonucleotide hybridization, selective amplification, and selective primer extension.
VI. Uses of Partial hALG-2LP, sALG-2LP, and mALG-2LP Sequences Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (a) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (b) identify an individual from a minute biological sample (tissue typing); and (c) aid in forensic identification of a biological sample. These applications are described in the subsections below.
a. Chromosome Mapping Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the hALG-2LP, sALG-2LP, and mALG-2LP, sequences, described herein, can be used to map the location of the hALG-2LP, sALG-2LP, and mALG-2LP genes, respectively, on a chromosome. The mapping of the hALG-2LP, sALG-2LP, and mALG-2LP sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.
Briefly, hALG-2LP, sALG-2LP, and mALG-2LP genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 by in length) from the hALG-2LP, sALG-2LP, and mALG-2LP sequences. Computer analysis of the hALG-2LP, sALG-2LP, and mALG-2LP, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the hALG-2LP, sALG-2LP, and mALG-2LP sequences will yield an amplified fragment.
Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but human cells can, the one human chromosome that contains the gene encoding the needed enzyme, will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio P. et al. (1983) Science 220:919-924). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.
PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the hALG-2LP, sALG-2LP, and mALG-2LP sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a hALG-2LP, sALG-2LP, or mALG-1 S sequence to its chromosome include in situ hybridization (described in Fan, Y. et al.
( 1990) PNAS, 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries.
Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa.
A
pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA
sequence as short as S00 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma et al., Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York 1988).
.__..x. .. ._~~.~~_~..
-59_ Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes.
Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.
Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example, Egeland, J. et al. (1987) Nature, 325:783-787.
Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the hALG-2LP, sALG-2LP, or mALG-2LP
gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.
b. Tissue Typing The hALG-2LP, sALG-2LP, and mALG-2LP sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).
Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the hALG-2LP, sALG-2LP, or mALG-2LP sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.
Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The hALG-2LP, sALG-2LP, or mALG-2LP sequences of the invention 1 S uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals.
The noncoding sequences of SEQ ID NOs:l, 4, and 7, can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOs:3, 6, and 9, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.
If a panel of reagents from hALG-2LP, sALG-2LP, or mALG-2LP sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual.
Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.
c. Use of Partial hALG-2LP, sALG-2LP, and mALG-2LP Sequences in Forensic Biology DNA-based identification techniques can also be used in forensic biology.
Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene.
The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.
The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NOs:I;
4, and 7 are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique.
Examples of polynucleotide reagents include the hALG-2LP, sALG-2LP, and mALG-2LP sequences or portions thereof, e.g., fragments derived from the noncoding regions of SEQ ID NOs:I, 4, and 7, having a length of at least 20 bases, preferably at least 30 bases.
The hALG-2LP, sALG-2LP, and mALG-2LP sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such hALG-2LP, sALG-2LP, and mALG-2LP probes can be used to identify tissue by species and/or by organ type.
WO 99/61459 PCTNS99/105$1 In a similar fashion, these reagents, e.g., hALG-2LP, sALG-2LP, and mALG-2LP primers or probes can be used to screen tissue culture for contamination (i.e. screen for the presence of a mixture of different types of cells in a culture).
This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, and published patent applications cited throughout this application are hereby incorporated by reference.
EXAMPLES
EXAMPLE 1: IDENTIFICATION AND CHARACTERIZATION OF
hALG-2LP, sALG-2LP, and mALG-2LP cDNA
In this example, the hALG-2LP, sALG-2LP, and mALG-2LP nucleic acid molecules were identified by screening appropriate cDNA libraries. An EST
(jlkbc063c04)was first identified in a monkey brain cDNA library using the Sequence Explorer. A mouse EST (jlmba005e01 ) was subsequently identified in a mouse brain cDNA library and two human ESTs were also identified by screening proprietary libraries. The positive clones were sequenced, and the sequences were assembled.
A BLASTNT"' search of the EST database revealed the following ESTs having significant homology to the hALG-2LP cDNA:
EST Database hits Species Base Pairs% Codin Covered Identi ?
Accession # AA569956Human 1149-1630 100 Yes Accession # AA226400Human 1124-1643 100 Yes Accession # W80352Human 1208-1657 99 Yes Accession # AA533187Human 1154-1630 96 Yes Accession # AA633700Human 1160-1 99 Yes Accession # N9S34SHuman 1237-1630 98 Yes Accession # AA431700Human 873-1305 100 Yes Accession # AA311285Human 911-1341 100 Yes Accession # AA643S8SHuman 1202-1629 99.5 Yes Accession # AA0400S8Human 1173-1630 96 Yes A BLASTNT"" search of the EST database revealed the following ESTs having significant homology to the sALG-2LP cDNA:
EST Database hitsSpecies Base Pairs% Coding?
Covered Identi Accession # AA431700Human 84S-1266 96 No Accession # AA311285Human 870-1302 94 No Accession # W26197Human 845-1232 94 No Accession # AA031Human 766-1224 94 No Accession # AA21S228Mouse 13S-67S 90 Yes Accession # AA110246Mouse 13S-67S 90 Yes S
A BLASTNT"" search of the EST database revealed the following ESTs having significant homology to the partial mALG-2LP cDNA:
EST Database hitsSpecies Base Pairs% Coding?
Covered Identi Accession # AA110246Mouse 283-608 99 Yes Accession # AA215228Mouse 296-833 99 Yes Accession # W77580Mouse 664-1000 99 Yes Accession # AA119341Mouse 888-1107 99 Yes EXAMPLE 2: TISSUE EXPRESSION OF THE hALG-2LP, sALG-2LP, and mALG-2LP GENES
Northern Analysis Human, monkey, and mouse multiple tissue northern (MTN) blots, human MTN
I, II, and III blots (Clontech, Palo Alto, CA), containing 2 ###g of poly A+
RNA per lane were probed with hALG-2LP-specific primers (probes). The filters were prehybridized in 10 ml of Express Hyb hybridization solution (Clontech, Palo Alto, CA) at 68°C for 1 hour, after which 100 ng of 32P labeled probe was added.
The probe was generated using the Stratagene Prime-It kit, Catalog Number 300392 (Clontech, Palo Aito, CA). Hybridization was allowed to proceed at 68°C for approximately 2 hours.
The filters were washed in a 0.05% SDS/2X SSC solution for 15 minutes at room temperature and then twice with a 0.1% SDS/O.1X SSC solution for 20 minutes at 50°C
and then exposed to autoradiography film overnight at -80°C with one screen. The human and mouse tissues tested included: brain, heart, kidney, liver, lung, skeletal muscle, spleen, testis, placenta, pancreas, colon, prostate, ovaries, small intestine, and hypothalamus.
There was a strong hybridization to all the tissues tested, except hypothalamus, indicating that ALG-2LP gene transcripts are expressed in these tissues.
EXAMPLE 3: EXPRESSION OF RECOMBINANT hALG-2LP, sALG-2LP, and mALG-2LP PROTEINS IN BACTERIAL CELLS
In this example, hALG-2LP, sALG-2LP, and mALG-2LP are expressed as recombinant glutathione-S-transferase (GST) fusion proteins in E. coli and the fusion proteins are isolated and characterized. Specifically, hALG-2LP, sALG-2LP, and mALG-2LP are fused to GST and these fusion proteins are expressed in E. coli, e.g., strain PEB 199. As hALG-2LP, sALG-2LP, and mALG-2LP are predicted to be 32.7 kD, 31.8 kD, and 31.5 kD, respectively, and GST is predicted to be 26 kD, the fusion proteins are predicted to be 58.7 kD, 57.8 kD, and 57.5 kD in molecular weight, respectively. Expression of the GST-hALG-2LP, -sALG-2LP, and -mALG-2LP fusion proteins in PEB 199 is induced with IPTG. The recombinant fusion proteins are purified from crude bacterial lysates of the induced PEB 199 strain by affinity chromatography on glutathione beads. Using polyacrylamide gel electrophoretic analysis of the proteins purified from the bacterial lysates, the molecular weight of the resultant fusion proteins is determined.
EXAMPLE 4: EXPRESSION OF RECOMBINANT hALG-2LP, sALG-2LP, and mALG-2LP PROTEIN IN COS CELLS
To express the hALG-2LP, sALG-2LP, or mALG-2LP gene in COS cells, the pcDNA/Amp vector by Invitrogen Corporation (San Diego, CA) is used. This vector contains an SV40 origin of replication, an ampicillin resistance gene, an E.
coli replication origin, a CMV promoter followed by a polylinker region, and an SV40 intron and polyadenylation site. A DNA fragment encoding the entire hALG-2LP, sALG-2LP, or mALG-2LP protein and a HA tag (Wilson et al. (1984) Cell 37:767) fused in-frame to its 3' end of the fragment is cloned into the polylinker region of the vector, thereby placing the expression of the recombinant protein under the control of the CMV
promoter.
To construct the plasmid, the hALG-2LP, sALG-2LP, or mALG-2LP DNA
sequence is amplified by PCR using two primers. The 5' primer contains the restriction site of interest followed by approximately twenty nucleotides of the hALG-2LP, sALG-2LP, or mALG-2LP coding sequence starting from the initiation codon; the 3' end WO 99/61459 PCT/US99/105$1 sequence contains complementary sequences to the other restriction site of interest, a translation stop codon, the HA tag and the last 20 nucleotides of the hALG-2LP, sALG-2LP, or mALG-2LP coding sequence. The PCR amplified fragment and the pCDNA/Amp vector are digested with the appropriate restriction enzymes and the vector S is dephosphorylated using the CIAP enzyme (New England Biolabs, Beverly, MA).
Preferably the two restriction sites chosen are different so that the hALG-2LP, sALG-2LP, and mALG-2LP gene is inserted in the correct orientation. The ligation mixture is transformed into E. coli cells (strains HB101, DHSa, SURE, available from Stratagene Cloning Systems, La Jolla, CA, can be used), the transformed culture is plated on ampicillin media plates, and resistant colonies are selected. Plasmid DNA is isolated from transformants and examined by restriction analysis for the presence of the correct fragment.
COS cells are subsequently transfected with the hALG-2LP, sALG-2LP, or mALG-2LP-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium chloride co-precipitation methods, DEAF-dextran-mediated transfection, lipofection, or electroporation. Other suitable methods for transfecting host cells can be found in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual.
2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The expression of the hALG-2LP, sALG-2LP, or mALG-2LP protein is detected by radiolabelling (35S-methionine or 35S-cysteine available from NEN, Boston, MA, can be used) and immunoprecipitation (Harlow, E. and Lane, D.
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988) using an HA specific monoclonal antibody. Briefly, the cells are labelled for 8 hours with 35S-methionine (or 35S-cysteine). The culture media are then collected and the cells are lysed using detergents (RIPA buffer, 150 mM NaCI, 1 % NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH 7.5). Both the cell lysate and the culture media are precipitated with an HA specific monoclonal antibody. Precipitated proteins are then analyzed by SDS-PAGE.
Alternatively, DNA containing the hALG-2LP, sALG-2LP, or mALG-2LP
coding sequence is cloned directly into the polylinker of the pCDNA/Amp vector using the appropriate restriction sites. The resulting plasmid is transfected into COS cells in the manner described above, and the expression of the hALG-2LP, sALG-2LP, or mALG-2LP protein is detected by radiolabelling and immunoprecipitation using a hALG-2LP, sALG-2LP, or mALG-2LP specific monoclonal antibody EXAMPLE 5: CHARACTERIZATION OF hALG-2LP, sALG-2LP, and mALG-2LP PROTEINS
In this example, the amino acid sequences of the hALG-2LP, sALG-2LP, and mALG-2LP proteins were compared to amino acid sequences of known proteins and various motifs were identified.
The hALG-2LP protein, the amino acid sequence of which is shown in Figure 1 (SEQ ID N0:2), is a novel protein which includes 284 amino acid residues.
Amino acid residues 127 to 139 and 194-206 of SEQ ID N0:2 (shown separately as SEQ ID
NO:10 and SEQ ID NO:11, respectively) comprise domains showing high homology to calcium binding domains, e.g., EF hands.
A BLAST search (Altschul et al. (1990) J. Mol. Biol. 215:403) of the protein sequences of human ALG-2LP revealed that hALG-2LP is similar to the following proteins: mouse probable calcium binding protein (Accession No. P12815), human Sorcin {Accession No. P30626), mouse Accession No.50266, mouse calcium binding protein (Accession No. 504970), and Chinese hamster Sorcin (Accession No.P05044).
Human ALG-2LP is 44% identical to mouse probable calcium binding protein (Accession No. P12815) over nucleotides 396-872; 38% identical to human Sorcin (Accession No. P30626) over nucleotides 444-872; 44% identical to mouse Accession No.50266 over nucleotides 396-872; 44% identical to mouse calcium binding protein (Accession No. 504970) over nucleotides 39b-872; and 37% identical to Chinese hamster Sorcin (Accession No.P05044) over nucleotides 444-857, at the amino acid level.
The sALG-2LP protein, the amino acid sequence of which is shown in Figure 2 (SEQ ID NO:S, is a novel protein which includes 277 amino acid residues. Amino acid residues 120 to 132 and 187-199 of SEQ ID NO:S (shown separately as SEQ ID
N0:12 and SEQ ID N0:13, respectively) comprise doamins showing high homology to calcium binding domains, e.g., EF hands.
A BLAST search (Altschul et al. (1990) J. Mol. Biol. 215:403) of the protein sequences of monkey ALG-2LP revealed that sALG-2LP is similar to the following proteins: mouse probable calcium binding protein (Accession No. P1281S), human Sorcin (Accession No. P30626), and Chinese hamster Sorcin (Accession No.POS044).
S Human ALG-2LP is 42% identical to mouse probable calcium binding protein (Accession No. P1281 S) over nucleotides 376-831; 38% identical to human Sorcin (Accession No. P30626) over nucleotides 376-831; and 37% identical to Chinese hamster Sorcin (Accession No.POS044) over nucleotides 403-816, at the amino acid level.
The mALG-2LP protein, the partial amino acid sequence of which is shown in Figure 3 (SEQ ID NO:B, is a novel protein which includes 274 amino acid residues.
Amino acid residues 117 to 129 and 184 to 196 of SEQ ID N0:8 (shown separately as SEQ ID N0:14 and SEQ ID NO:1 S, respectively) comprise domains showing homology to calcium binding domains, e.g., EF hands.
1 S A BLAST search (Altschul et al. (1990) J. Mol. Biol. 215:403) of the protein sequences of partial marine ALG-2LP revealed that mALG-2LP is similar to the following proteins: mouse probable calcium binding protein (Accession No. P
1281 S), mouse calcium binding protein (Accession No. 504970), and human Sorcin (Accession No. P30626). Partial marine ALG-2LP is 4S% identical to mouse probable calcium binding protein (Accession No. P 1281 S) over amino acid residues 11 S-221;
43%
identical to mouse calcium binding protein (Accession No. 504970) over amino acid residues 130-221; and 39% identical to human Sorcin (Accession No. P30626) over amino acid residues 131-227.
2S Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
_1_ SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: MILLENNIUM PHARMACEUTICALS, INC.
(B) STREET: 75 SIDNEY STREET
(C) CITY: CAMBRIDGE
(D) STATE: MASSACHUSETTS
(E) COUNTRY: US
(F) POSTAL CODE: 02139 (G) TELEPHONE:
(H) TELEFAX:
IS (ii) TITLE OF INVENTION: ALG-2LP, ALG-2 LIKE MOLECULES
AND USES THEREFOR
(iii) NUMBER OF SEQUENCES: 22 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: LAHIVE & COCKFIELD, LLP
(B) STREET: 28 STATE STREET
(C) CITY: BOSTON
(D) STATE: MASSACHUSETTS
(E) COUNTRY: US
(F) ZIP: 02109 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B} COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: PCT/US99/
(B) FILING DATE: 13 MAY 1999 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 09/084,749 (B) FILING DATE: 26 MAY 1998 (viii) ATTORNEY/AGENT INFORMATION:
{A) NAME: MANDRAGOURAS, AMY E.
(B) REGISTRATION NUMBER: 36,207 (C) REFERENCE/DOCKET NUMBER: MNI-043PC
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617)227-7400 (B) TELEFAX: (617)742-4214 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1667 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 30..881 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Pro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Gly Pro Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Asn Pro Gly Met Phe Pro Ser Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Gly Pro Tyr Gly Gln Pro Pro Pro Ser Ser Tyr Gly Ala Gln Gln Pro Gly Leu Tyr Gly Gln Gly Gly Ala Pro Pro Asn Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Val Asp Ser Asp His Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Tyr Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu 1?~~AAAAAAAA p~~;AAAAAAAA AAAAAA 16 6 7 (2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 284 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Pro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Gly Pro Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Asn Pro Gly Met Phe Pro Ser Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Gly Pro Tyr Gly Gln Pro Pro Pro Ser Ser Tyr Gly Ala Gln Gln Pro Gly Leu Tyr Gly Gln Gly Gly Ala Pro Pro Asn Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Val Asp Ser Asp His Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Tyr Thr Glu Leu Gln Gln WO 99/b1459 PCT/US99/10581 Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu (2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 852 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..852 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Fro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Gly Pro Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Asn Pro Gly Met Phe Pro Ser Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Gly Pro Tyr Gly Gln Pro Pro Pro Ser Ser Tyr Gly Ala Gln Gln Pro Gly Leu Tyr Gly Gln Gly Gly Ala Pro Pro Asn Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Val Asp Ser Asp His Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Tyr Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu (2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1525 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
( ix) FEATURE
(A) NAME/KEY: CDS
(B) LOCATION: 10..840 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Pro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Tyr Gly Gly Pro Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Sex Pro Gly Met Phe Pro Ser Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Ser Pro Tyr Gly Gln Pro Pro Leu Ser Ser Tyr Gly Ala Gln Gln Pro Gly Pro Tyr Gly Gln Gly Gly Ala Pro Pro Ser Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp _g_ Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp 175 1$0 185 Arg Ser Gly Ser Ile Ser Tyr Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu CAGCCCTGGC ACCGGGAGCA GGTTCTTGTA ATGGAGiTAG TGTCCAGTCA GCTGAGCTCC 1170 (2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 277 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Pro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Tyr Gly Gly Pro Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Ser Pro Gly Met Phe Pro Ser Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Ser Pro Tyr Gly Gln Pro Pro Leu Ser Ser Tyr Gly Ala Gln Gln Pro Gly Pro Tyr Gly Gln Gly Gly Ala Pro Pro Ser Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Tyr Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu (2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 831 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..831 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Pro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Tyr Gly Gly Pro 35 Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Ser Pro Gly Met Phe Pro Sex Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Ser Pro Tyr Gly Gln Pro Pro Leu Ser Ser Tyr Gly Ala Gln Gln Pro Gly Pro Tyr Gly Gln Gly Gly Ala Pro Pro Ser Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly IS Ser Ile Ser Tyr Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu (2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1362 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY; CDS
(B) LOCATION: 177..998 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
Ser Ser Tyr Pro Asn Gly Gln Ser Cys Pro Gly Ala Ala Gly Gln Val Pro Gly Val Pro Pro Gly Gly Tyr Tyr Pro G1y Pro Pro His Gly Gly GIy Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Ala Pro AIa Pro Gly Gly Pro Tyr Gly Tyr Pro Ser Ala Gly Gly Val Pro Ser Gly Thr Pro Ser Gly Pro Tyr Gly Gly Ile Pro Pro Gly Gly Pro Tyr Gly Gln Leu Pro Pro Gly Gly Pro Tyr Gly Thr Gln Pro Gly His Tyr Gly Gln Gly Gly Val Pro Xaa Asn Val Asp Pro Glu Ala Tyr Ser Trp loo 105 110 Phe Gln Ser Val Asp Ala Asp His Ser Gly Tyr Ile Ser Leu Lys Glu Leu Lys Gln Ala Leu Val Asn Ser Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Ala Gly Phe Ser Ala Leu Trp Lys Phe Leu Gln Gln Trp Arg Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Ser Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln PheThr GlnLeuLeu ValSerArg TyrCysAla ArgSer Ala Ile Pro AlaMet GlnLeuAsp CysPheIle LysValCys ThrGln Leu Val LeuThr GluAlaPhe ArgGluLys AspThrA1a ValGln Gly Gln Asn Ile ArgLeu SerPheGlu AspPheVal ThrMetThr AlaSer Arg TCCCTAAAGG
GAGTGGAGCA
CACCAGGGGA
Met Leu (2) INFORMATION FOR SEQ ID N0:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 274 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
Ser Ser Tyr Pro Asn Gly Gln Ser Cys Pro Gly Ala Ala Gly Gln Val Pro Gly Val Pro Pro Gly Gly Tyr Tyr Pro Gly Pro Pro His Gly Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Ala Pro Ala Pro Gly Gly Pro Tyr Gly Tyr Pro Ser Ala Gly Gly Val Pro Ser Gly Thr Pro Ser Gly Pro Tyr Gly Gly Ile Pro Pro Gly Gly Pro Tyr Gly Gln Leu Pro Pro Gly Gly Pro Tyr Gly Thr Gln Pro Gly His Tyr Gly Gln Gly Gly Val Pro Xaa Asn Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Val Asp Ala Asp His Ser Gly Tyr Ile Ser Leu Lys Glu Leu Lys Gln Ala Leu Val Asn Ser Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Ala Gly Phe Ser Ala Leu Trp Lys Phe Leu Gln Gln Trp Arg Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Ser Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Ala Arg Ser Ala Ile Pro Ala Met Gln Leu Asp Cys Phe Ile Lys Val Cys Thr GIn Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu (2) INFORMATION FOR SEQ ID N0:9:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 822 base pairs (B) TYPE: nucleic acid {C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..822 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
Ser Ser Tyr Pro Asn Gly Gln Ser Cys Pro Gly Ala Ala Gly Gln Val Pro Gly Val Pro Pro Gly Gly Tyr Tyr Pro Gly Pro Pro His Gly Gly G1y Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Ala Pro Ala Pro Gly Gly Pro Tyr Gly Tyr Pro Ser Ala Gly Gly Val Pro Ser Gly Thr Pro Ser Gly Pro Tyr Gly Gly Ile Pro Pro Gly Gly Pro Tyr Gly Gln Leu Pro Pro Gly Gly Pro Tyr Gly Thr Gln Pro Gly His Tyr Gly Gln Gly Gly Val Pro Xaa Asn Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Val Asp Ala Asp His Ser Gly Tyr Ile Ser Leu Lys Glu Leu Lys Gln Ala Leu Val Asn Ser Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Ala Gly Phe Ser Ala Leu Trp Lys Phe Leu Gln Gln Trp Arg Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Ser Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser TCC CGG GCT
Pro Gln Phe Thr Gln Leu Leu Val Tyr Cys Ala Arg Ser Ser Arg Ala TTC ATC CTG
Ile Pro Ala Met Gln Leu Asp Cys Lys Val Cys Thr Gln Phe Ile Leu GAA AAG GGC
Gln Val Leu Thr Glu Ala Phe Arg Asp Thr Ala Val Gln Glu Lys Gly TTT GTC AGG
Asn Ile Arg Leu Ser Phe Glu Asp Thr Met Thr Ala Ser Phe Val Arg Met Leu (2) INFORMATION
FOR
SEQ
ID
NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi)SEQUENCE DESCRIPTION: SEQ
ID NO:10:
Asp Ser Asp His Ser Gly Tyr Met Lys Glu Leu Ile Ser (2) INFORMATION
FOR
SEQ
ID
NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi)SEQUENCE DESCRIPTION: SEQ :11:
ID NO
Asp Arg Asp Arg Ser Gly Ser Tyr Thr Glu Leu Ile Ser (2)INFORMATION
FOR
SEQ
ID
N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: N0:12:
SEQ ID
Ser Trp Phe Gln Ser Gly Tyr Ser Met Lys Glu Ile Leu (2)INFORMATION
FOR
SEQ
ID
N0:13:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid {D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: N0:13:
SEQ ID
Asp Arg Asp Arg Ser Gly Ser Ser Tyr Thr Glu Ile Leu (2)INFORMATION
FOR
SEQ
ID
N0:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear {ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: N0:14:
SEQ ID
Asp Ala Asp His Ser Gly Tyr Ser Leu Lys Glu Ile Leu 1 ~ 5 10 (2)INFORMATION
FOR
SEQ
ID
N0:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear {ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID N0:15:
Asp Arg Asp Arg Ser Gly Ser Ile Ser Ser Thr Glu Leu (2) INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID N0:16:
Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Lys Asp Gly Asp Gly Xaa Xaa Xaa Xaa Xaa Glu Phe Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:
(2) INFORMATION FOR SEQ ID N0:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:18:
(2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ N0:19:
ID
15(2) INFORMATION FOR SEQ ID N0:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid 20(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
25(xi) SEQUENCE DESCRIPTION: SEQ N0:20:
ID
(2) INFORMATION FOR SEQ ID N0:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 35{D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDlvA
(xi) SEQUENCE DESCRIPTION: SEQ N0:21:
ID
(2) INFORMATION FOR SEQ ID N0:22:
45(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ N0:22:
ID
Thus, apoptosis linked gene-2-like protein molecules, e.g., hALG-2LP, sALG-S 2LP, and mALG-2LP, can be used to modulate the activity of programmed cell death pathway related molecules and provide novel therapeutic approaches for treatment of disorders characterized by deregulated programmed cell death. Examples of disorders characterized by deregulated programmed cell death include neurodegenerative disorders, e.g., Alzheimer's disease, dementias related to Alzheimer's disease (such as Pick's disease), Parkinson's and other Lewy diffuse body diseases, multiple sclerosis, amyotrophic lateral sclerosis, progressive supranuclear palsy, epilepsy, Jakob-Creutzfieldt disease, or AIDS related dementia; or proliferative disorders, e.g., cancer such as chronic lymphocytic leukemia or colorectal cancer.
Furthermore, as they are involved in programmed cell death, hALG-2LP, sALG-1 S 2LP, or mALG-2LP genes containing genetic lesions can be detected in order to diagnose a disorder characterized by aberrant or abnormal hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid expression or hALG-2LP, sALG-2LP, or mALG-2LP protein activity, e.g., a neurodegenerative disorder.
Moreover, another aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs) comprising a nucleotide sequence encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein or a biologically active portion thereof, as well as nucleic acid fragments suitable for use as primers or hybridization probes for the detection of hALG-2LP, sALG-2LP, or mALG-2LP-encoding nucleic acid (e.g., mRNA). In particularly preferred embodiments, the isolated nucleic acid molecules 2S comprise the nucleotide sequences of SEQ ID NOs:I, 4 or 7, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number , or the coding region (shown in SEQ ID NOs:3, 6, or 9), or a complement of these nucleotide sequences. In other particularly preferred embodiments, the isolated nucleic acid molecules of the invention comprise a nucleotide sequence which hybridizes to, or is at least 32%, 3S%, 40%, 4S%, SO%, SS%, 60%, 6S%, 70%, 7S%, 80%, 8S%, 90%, 9S%, 98% or more homologous to the entire length of the nucleotide sequences shown in SEQ ID NOs:I, 4, or 7, the entire length of nucleotide sequence of the DNA
insert of the lasmid de osited with ATCC~ as Accession Number p p , or a portion of these nucleotide sequences. In other preferred embodiments, the isolated nucleic acid molecules encode the amino acid sequences of SEQ ID NOs:2, 5, or 8, or an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number . The preferred hALG-2LP, sALG-2LP, or mALG-2LP proteins of the present invention also preferably possess at least one of the activities described herein.
In another embodiment, the isolated nucleic acid molecules encode proteins or portions thereof wherein the proteins or portions thereof include an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NOs:2, 5, or 8, e.g., sufficiently homologous to an amino acid sequence of SEQ ID NOs:2, 5, or 8 such that the proteins or portions thereof maintain at least on the of the activities described herein. Preferably, the proteins or portions thereof encoded by the nucleic acid molecules maintain the ability to modulate a programmed cell death pathway activity.
In one embodiment, the proteins encoded by the nucleic acid molecules are at least 38%, 42%, 44%, 45%, SO%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequences of SEQ ID NOs:2, 5, or 8 (e.g., the entire amino acid sequences of SEQ ID NOs:2, S, or 8) or the amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~
as Accession Number . In another preferred embodiment, the proteins are full length human proteins which are substantially homologous to the entire amino acid sequences of SEQ ID NOs:2, 5, or 8 (encoded by the open reading frames shown in SEQ ID NOs:3, 6, or 9, respectively).
In another preferred embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP
nucleic acid molecule is derived from a mammal, e.g., a human, a monkey, or a mouse, and encodes a protein (e.g., a hALG-2LP, sALG-2LP, or mALG-2LP fusion protein) which includes a calcium binding domain which is at least 42% or more homologous to SEQ ID NO:10, 11, 12, 13, 14, or 15 and has one or more of the following activities: 1) it can interact with a programmed cell death pathway associated molecule, e.g., an ALG--$-2 interacting protein; and 2) it can modulate cell death, e.g., programmed cell death, in a cell, e.g., a brain cell and other cells that express ALG2-LP.
In another embodiment, the isolated nucleic acid molecule is at least 15 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOs:l, 4, or 7, or to the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number . Preferably, the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes a naturally-occurring human hALG-2LP, sALG-2LP, or mALG-2LP, or a biologically active portion thereof. Moreover, given the disclosure herein of a hALG-2LP, sALG-2LP, or mALG-2LP-encoding cDNA sequence (e.g., SEQ ID NOs:l, 4, or 7), antisense nucleic acid molecules (i.e., molecules which are complementary to the coding strand of the hALG-2LP, sALG-2LP, or mALG-2LP cDNA sequence) are also provided by the invention.
Another aspect of the invention pertains to vectors, e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention and host cells into which such vectors have been introduced. In one embodiment, such a host cell is used to produce a hALG-2LP, sALG-2LP, or mALG-2LP protein by culturing the host cell in a suitable medium. If desired, the hALG-2LP, sALG-2LP, or mALG-2LP protein can be then isolated from the medium or the host cell.
Yet another aspect of the invention pertains to transgenic nonhuman animals in which a hALG-2LP, sALG-2LP, or mALG-2LP gene has been introduced or altered.
In one embodiment, the genome of the nonhuman animal has been altered by introduction of a nucleic acid molecule of the invention encoding hALG-2LP, sALG-2LP, or mALG-2LP as a transgene. In another embodiment, an endogenous ALG-2LP gene within the genome of the nonhuman animal has been altered, e.g., functionally disrupted, by homologous recombination.
Still another aspect of the invention pertains to an isolated hALG-2LP, sALG-2LP, or mALG-2LP protein or a portion, e.g., a biologically active portion, thereof. In a preferred embodiment, the isolated hALG-2LP, sALG-2LP, or mALG-2LP protein or portion thereof can modulate programmed cell death in a cell, e.g., a brain cell and other cells that express ALG2-LP. In another preferred embodiment, the isolated hALG-2LP, sALG-2LP, or mALG-2LP protein or portion thereof is sufficiently homologous to an amino acid sequence of SEQ ID N0:2, 5, or 8 such that the protein or portion thereof maintains the ability to modulate programmed cell death in a cell, e.g., a brain cell and S other cells that express ALG2-LP.
In one embodiment, the biologically active portion of the hALG-2LP, sALG-2LP, or mALG-2LP protein includes a domain or motif, preferably a domain or motif which has an activity described herein. The domain can be a calcium binding domain, e.g., an EF hand. If the active portion of the protein which comprises the calcium binding domain is isolated or derived from a mammal, e.g., a human, it is preferred that the calcium binding domain be at least 38%, 42%, 44% 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more homologous to SEQ ID NO:10, 11, 12, 13, 14, or 15. Preferably, the biologically active portion of the hALG-2LP, sALG-2LP, or mALG-2LP protein which includes a calcium binding domain also has one of the following activities: 1 ) it can interact with a programmed cell death pathway associated molecule, e.g., an ALG-2 interacting protein; and 2) it can modulate cell death, e.g., programmed cell death, in a cell, e.g., a brain cell and other cells that express ALG2-LP.
The invention also provides an isolated preparation of a hALG-2LP, sALG-2LP, or mALG-2LP protein. In preferred embodiments, the hALG-2LP, sALG-2LP, or mALG-2LP protein comprises the amino acid sequence of SEQ ID N0:2, 5, or 8 or an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number In another preferred embodiment, the invention pertains to an isolated full length hALG-2LP, sALG-2LP, or mALG-2LP protein which is substantially homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8 (encoded by the open reading frame shown in SEQ ID N0:3, 6, or 9, respectively). In yet another embodiment, the hALG-2LP, sALG-2LP, or mALG-protein is at least 38%, 42%, 44%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8, respectively. In other embodiments, the hALG-2LP, sALG-2LP, or mALG-2LP
protein comprises an amino acid sequence which is at least 42% or more homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8, respectively, and has an one or more WO 99/61459 PCTlUS99/10581 -7_ of the following activities: 1 ) it can interact with a programmed cell death pathway associated molecule, e.g., an ALG-2 interacting protein; and 2) it can modulate cell death, e.g., programmed cell death, in a cell, e.g., a brain cell and other cells that express ALG2-LP.
Alternatively, the isolated hALG-2LP, sALG-2LP, or mALG-2LP protein can comprise an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, or is at least 32%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the entire length of the nucleotide sequence of SEQ ID NO:1, 4, or 7, respectively, or the entire length of the nucleotide sequence of the DNA
insert of the plasmid deposited with ATCC~ as Accession Number , respectively.
Moreover, it is preferred that the forms of hALG-2LP, sALG-2LP, or mALG-2LP
also have one or more of the activities described herein.
The hALG-2LP, sALG-2LP, or mALG-2LP protein (or polypeptide) or a biologically active portion thereof can be operatively linked to a non-hALG-2LP, sALG-2LP, or mALG-2LP polypeptide to form a fusion protein. In addition, the hALG-2LP, sALG-2LP, or mALG-2LP protein or a biologically active portion thereof can be incorporated into a pharmaceutical composition comprising the protein and a pharmaceutically acceptable carrier.
The hALG-2LP, sALG-2LP, or mALG-2LP protein of the invention, or portions or fragments thereof, can be used to prepare anti-hALG-2LP, anti sALG-2LP, or anti mALG-2LP antibodies. Accordingly, the invention also provides an antigenic peptide of hALG-2LP, sALG-2LP, or mALG-2LP which comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID N0:2, 5, or 8, respectively, and encompasses an epitope of hALG-2LP, sALG-2LP, or mALG-2LP such that an antibody raised against the hALG-2LP, sALG-2LP, or mALG-2LP peptide forms a specific immune complex with hALG-2LP, sALG-2LP, or mALG-2LP, respectively. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues. The invention further provides an antibody that specifically binds hALG-2LP, sALG-2LP, or mALG-2LP. In one embodiment, the _g-antibody is monoclonal. In another embodiment, the antibody is coupled to a detectable substance. In yet another embodiment, the antibody is incorporated into a pharmaceutical composition comprising the antibody and a pharmaceutically acceptable Garner.
The invention also pertains to methods for detecting genetic lesions in a hALG-2LP, sALG-2LP, or mALG-2LP gene, thereby determining if a subject with the lesioned gene is at risk for (or is predisposed to have) a disorder characterized by aberrant or abnormal hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid expression or hALG-2LP, sALG-2LP, or mALG-2LP protein activity, e.g., a disorder characterized by deregulated programmed cell death. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by an alteration affecting the integrity of a gene encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein, or the misexpression of the hALG-2LP, sALG-2LP, or mALG-2LP gene.
Another aspect of the invention pertains to methods for detecting the presence of hALG-2LP, sALG-2LP, or mALG-2LP in a biological sample. In a preferred embodiment, the methods involve contacting a biological sample with a compound or an agent capable of detecting hALG-2LP, sALG-2LP, or mALG-2LP protein or hALG-2LP, sALG-2LP, or mALG-2LP mRNA such that the presence of hALG-2LP, sALG-2LP, or mALG-2LP is detected in the biological sample. The compound or agent can be, for example, a labeled or labelable nucleic acid probe capable of hybridizing to hALG-2LP, sALG-2LP, or mALG-2LP mRNA or a labeled or labelable antibody capable of binding to hALG-2LP, sALG-2LP, or mALG-2LP protein. The invention further provides methods for diagnosis of a subject with, for example, a disorder characterized by deregulated programmed cell death, based on detection of hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA. In one embodiment, the method involves contacting a cell or tissue sample (e.g., a brain cell sample) from the subject with an agent capable of detecting hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA, determining the amount of hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA
expressed in the cell or tissue sample, comparing the amount of hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA expressed in the cell or tissue sample to a control sample and forming a diagnosis based on the amount of hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA expressed in the cell or tissue sample as compared to the control sample. Preferably, the cell sample is a brain cell sample. Kits for detecting hALG-2LP, sALG-2LP, or mALG-2LP in a biological sample are also within the scope of the invention.
Brief Description of the Drawings Figure 1 depicts the human ALG-2LP (hALG-2LP) nucleotide (SEQ ID NO:1 ) and amino acid (SEQ ID N0:2) sequence. The coding region without the 5' and 3' untranslated regions of the human ALG-2LP gene is shown in SEQ ID N0:3.
Figure 2 depicts the monkey ALG-2LP (sALG-2LP) nucleotide (SEQ ID N0:4) and amino acid (SEQ ID NO:S) sequence. The coding region without the 5' and 3' untranslated regions of the monkey ALG-2LP gene is shown in SEQ ID N0:6.
Figure 3 depicts the partial marine ALG-2LP (mALG-2LP) nucleotide (SEQ ID
N0:7) and amino acid (SEQ ID N0:8) sequence. The coding region without the 5' and 3' untranslated regions of the marine ALG-2LP gene is shown in SEQ ID N0:9.
Detailed Description of the Invention The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as hALG-2LP, sALG-2LP, and mALG-2LP nucleic acid and protein molecules that are related to proteins which regulate programmed cell death.
As used herein, "programmed cell death" refers to a genetically regulated process involved in the normal development of multicellular organisms. This process occurs in cells destined for removal in a variety of normal situations, including larval development of the nematode c. elegans, insect metamorphosis, development in mammalian embryos including the nephrogenic zone in the developing kidney, and regression or atrophy (e.g., in the prostrate after castration). Programmed cell death can occur following the withdrawal of growth and trophic factors in many cells, nutritional deprivation, hormone treatment, ultraviolet irradiation, and exposure to toxic and infectious agents including reactive oxygen species and phosphatase inhibitors, e.g., okadaic acid, calcium ionphones, and a number of cancer chemotherapeutic agents. For a detailed description of programmed cell death see Trump B.F. et al. (1995) FASEB J.
9: 219-228 and Lee S. (1993) Curr. Opin. Cell Biol. 5: 286-291, the contents of which are incorporated herein by reference. Thus the hALG-2LP, sALG-2LP, and mALG-proteins by participating in a programmed cell death pathway, can modulate a programmed cell death pathway activity and provide novel diagnostic targets and therapeutic agents for disorders characterized by deregulated programmed cell death, particularly in cells that express ALG2-LP.
As used herein, a "disorder characterized by deregulated programmed cell death"
refers to a disorder, disease or condition which is characterized by a deregulation, e.g., an upregulation or a downregulation, of programmed cell death. Programmed cell death deregulation can lead to deregulation of cellular proliferation and/or cell cycle progression. Examples of disorders characterized by deregulated programmed cell death include neurodegenerative disorders, e.g., Alzheimer's disease, dementias related to Alzheimer's disease (such as Pick's disease), Parkinson's and other Lewy diffuse body diseases, multiple sclerosis, amyotrophic lateral sclerosis, progressive supranuclear palsy, epilepsy, Jakob-Creutzfieldt disease, or AIDS related demential; or profilerative disorders, e.g., cancer such as chronic lymphocytic leukemia or colorectal cancer.
An abnormality in the function of hALG-2LP, sALG-2LP, or mALG-2LP
protein can lead to a disorder characterized by deregulated programmed cell death.
Thus, one aspect of the invention pertains to methods for detecting genetic lesions in a hALG-2LP, sALG-2LP, or mALG-2LP gene, to thereby determine if a subject with the lesioned gene is at risk for (or is predisposed to have) a disorder characterized by aberrant or abnormal hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid expression or hALG-2LP, sALG-2LP, or mALG-2LP protein activity, e.g., a disorder characterized by deregulated programmed cell death.
The apoptosis linked gene-2 like protein nucleic acid molecules described herein, e.g., hALG-2LP, sALG-2LP, and mALG-2LP, were identified from human, monkey, and mouse brain cDNA libraries, respectively, using the Blast Algorithm. A
cDNA
library was prepared from mRNA isolated from disected monkey brain striatum. A
homology search of sequences obtained from the cDNA library revealed a cDNA
sequence that had 42% homology (62 of 144 amino acids) with rat ALG-2 protein.
Additional clones from the cDNA library were sequences and multiple sequences were contiged to obtain a full length monkey cDNA sequence, SEQ ID N0:4. The monkey clone was used to screen a human heart cDNA library and a marine whole brain library.
Sequencing of positive clones yielded the human sequence, SEQ ID NO:1, and the partial marine sequence, SEQ ID N0:7.
The nucleotide sequence of hALG-2LP cDNA and the predicted amino acid sequence of the hALG-2LP protein are shown in Figure 1 and in SEQ ID NOs: l and 2, respectively. A plasrnid containing the full length nucleotide sequence encoding human ALG-2LP (with the DNA insert name of ) was deposited with ATCC~ on and assigned Accession Number . This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C.~112.
1 S The hALG-2LP gene, which is approximately 1667 nucleotides in length, encodes a protein having a molecular weight of approximately 32.7 kD and which is approximately 284 amino acid residues in length. The hALG-2LP protein is expressed in all tissues examined (brain, heart, kidney, liver, lung, skeletal muscle, testis, placenta, pancreas, colon, prostate, ovaries, small intestine, and spleen). No expressio was seen in the hypothalamus.
Amino acid residues 127 to 139 and 194-206 of the hALG-2LP protein comprise a region showing homology to a calcium binding domain. As used herein, the term "calcium binding domain" refers to an amino acid domain, e.g., an EF hand (described in, for example, Baimbridge K.G. et al. (1992) TINS 15(8): 303-308, the contents of which are incorporated herein by reference), which is involved in calcium binding.
These EF hands usually have a sequence, which is similar to the consensus sequence:
EO~~00~~ODKDGDG~O~~~EF~~00. (SEQ ID N0:16).
O can be I, L, V or M, and "~" indicates a position with no strongly preferred residue.
Each residue listed is present in more than 25% of sequences, and those underlined are present in more than 80% of sequences.
The nucleotide sequence of the sALG-2LP cDNA and the predicted amino acid sequence of the sALG-2LP protein are shown in Figure 2 and in SEQ ID NOs:4 and 5, respectively. The sALG-2LP gene, which is approximately 1525 nucleotides in length, encodes a protein having a molecular weight of approximately 31.8 kD and which is approximately 277 amino acid residues in length.
The nucleotide sequence of the partial mALG-2LP cDNA and the predicted amino acid sequence of the partial mALG-2LP protein are shown in Figure 3 and in SEQ
ID NOs:7 and 8, respectively. The partial mALG-2LP gene, which is approximately 1362 nucleotides in length, encodes a protein having a molecular weight of approximately 31.5 kD and which is approximately 274 amino acid residues in length.
Various aspects of the invention are described in further detail in the following subsections:
I. Isolated Nucleic Acid Molecules One aspect of the invention pertains to isolated nucleic acid molecules that encode hALG-2LP, sALG-2LP, or mALG-2LP or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify hALG-2LP, sALG-2LP, or mALG-2LP-encoding nucleic acid (e.g., hALG-2LP, sALG-2LP, or mALG-2LP mRNA). As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA
molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or O.I
kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA
of the cell from which the nucleic acid is derived (e.g., a brain cell or other cell that expresses ALG2-LP). Moreover, an "isolated" nucleic acid molecule, such as a cDNA
molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.
A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NOs:l, 4, and 7, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a human, a monkey, or a mouse ALG-2LP cDNA can be isolated from a human, a monkey, or a mouse brain library, respectively, using all or portion of SEQ ID NO:1, 4, or 7 as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:1, 4, or 7 can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon the sequence of SEQ ID NO:1, 4, or 7. For example, mRNA can be isolated from normal brain cells (e.g., by the guanidinium-thiocyanate extraction procedure of Chirgwin et al.
(1979) Biochemistry 18: 5294-5299) and cDNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL). Synthetic oligonucleotide primers for PCR amplification can be designed based upon the nucleotide sequence shown in SEQ ID NO:I, 4, or 7. A
nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR
amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to a hALG-2LP, sALG-2LP, or mALG-2LP nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:1, 4, and 7 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number . The sequence of SEQ ID NO:1 corresponds to the human ALG2-LP
(hALG2-LP) cDNA. This cDNA comprises sequences encoding the hALG-2LP protein (i.e., "the coding region", from nucleotides 30 to 881 of SEQ ID NO:1), as well as 5' untranslated sequences (nucleotides 1-29 of SEQ ID NO:1) and 3' untranslated sequences (nucleotides 882 to 1667 of SEQ ID NO:1). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:1 (e.g., nucleotides 30 to 881, shown separately as SEQ ID N0:3). The sequence of SEQ ID N0:4 corresponds to the monkey ALG-2LP (sALG-2LP) cDNA. This cDNA comprises sequences encoding the sALG-2LP protein (i.e., "the coding region", from nucleotides 10 to 840 of SEQ ID N0:4), as well as 5' untranslated sequences (nucleotides 1-9 of SEQ ID
NO: 4) and 3' untranslated sequences (nucleotides 841 to 1525 of SEQ ID N0:4).
Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID N0:4 (e.g., nucleotides 10 to 840, shown separately as SEQ ID N0:6). The sequence of SEQ ID N0:7 corresponds to the partial mouse ALG-2LP (mALG-2LP) cDNA. This cDNA comprises sequences encoding the partial mALG-2LP protein (i.e., "the coding region", from nucleotides 177 to 998 of SEQ ID N0:7), as well as 5' untranslated sequences (nucleotides 1 to 176 of SEQ ID N0:7) and 3' untranslated sequences (nucleotides 999 to 1362 of SEQ ID N0:7). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID N0:7 (e.g., nucleotides 177 to 998, shown separately as SEQ ID N0:9).
In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1, 4, or 7, the nucleotide sequence of the DNA
insert of the lasmid de osited with ATCC~ as Accession Number p p , or a portion of these nucleotide sequences. A nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO:1, 4, or 7 is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:l, 4, or 7 such that it can hybridize to the nucleotide sequence shown in SEQ ID NO:1, 4, or 7, respectively, thereby forming a stable duplex.
In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least 32%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the nucleotide sequence shown in SEQ ID NO:1, 4, or 7, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number , or a portion of these nucleotide sequences. In an additional preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence shown in SEQ ID NO:1, 4, or 7, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number , or a portion of these nucleotide sequences.
Moreover, the nucleic acid molecule of the invention can comprise only a portion of the coding region of SEQ ID NO:1, 4, or 7, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of hALG-2LP, sALG-2LP, or mALG-2LP. The nucleotide sequence determined from the cloning of the hALG-2LP, sALG-2LP, or mALG-2LP gene from a mammal allows for the generation of probes and primers designed for use in identifying and/or cloning hALG-2LP, sALG-2LP, or mALG-2LP homologues in other cell types, e.g., from other tissues, as well as hALG-2LP, sALG-2LP, or mALG-2LP homologues from other mammals, e.g., rats. The probe/primer typically comprises substantially purified oligonucleotide.
The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50, 75, 100, 150, 200, 300, 400, 500, 520, 540, 550, or 600 consecutive nucleotides of SEQ ID NO:I, 4, or 7 sense, an anti-sense sequence of SEQ ID
NO:1, 4, or 7, or naturally occurring mutants thereof. Primers based on the nucleotide sequence in SEQ ID NO:1, 4, or 7 can be used in PCR reactions to clone hALG-2LP, sALG-2LP, or mALG-2LP homologues. Probes based on the hALG-2LP, sALG-2LP, or mALG
2LP nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a hALG-2LP, sALG-2LP, or mALG-2LP protein, such as by measuring a level of a hALG-2LP, sALG-2LP, or mALG-2LP-encoding nucleic acid in a sample of cells from a subject e.g., detecting hALG-2LP, sALG-2LP, or mALG-2LP mRNA levels or determining whether a genomic hALG-2LP, sALG-2LP, or mALG-2LP gene has been mutated or deleted.
In one embodiment, the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID N0:2, 5, or 8 or an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number such that the protein or portion thereof maintains the ability to modulate a programmed cell death related activity. As used herein, the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain as an amino acid residue in SEQ ID N0:2, 5, or 8) amino acid residues to an amino acid sequence of SEQ ID N0:2, S, or 8 or an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number such that the protein or portion thereof is able to modulate a programmed cell death related activity. In another embodiment, the protein is at least 38%, 42%, 44%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8.
Portions of proteins encoded by the hALG-2LP, sALG-2LP, or mALG-2LP
nucleic acid molecules of the invention are preferably biologically active portions of the hALG-2LP, sALG-2LP, or mALG-2LP proteins. As used herein, the term "biologically active portion of hALG-2LP, sALG-2LP, or mALG-2LP" is intended to include a portion, e.g., a domain/motif, of hALG-2LP, sALG-2LP, or mALG-2LP that has one or more of the following activities: 1 ) it can interact with a programmed cell death pathway associated molecule, e.g., an ALG-2 interacting protein; and 2) it can modulate cell death, e.g., programmed cell death, in a cell, e.g., a brain cell and other cells that express ALG2-LP.
Standard binding assays, e.g., immunoprecipitations and yeast two-hybrid assays as described herein, can be performed to determine the ability of a hALG-2LP, sALG-2LP, or mALG-2LP protein or a biologically active portion thereof to interact with (e.g., bind to) another programmed cell death pathway associated protein, e.g., ALG-2, or portion thereof. To determine whether a hALG-2LP, sALG-2LP, or mALG-2LP
protein or a biologically active portion thereof can modulate programmed cell death in a cell such as a T cell, T cells e.g., T cell hybridomas (3D0) which have been cross-linked with a T cell receptor to induce programmed cell death (as described in Ashwell J. D. et al. (1990) J. Immunol. 144:3326) can be transfected with a nucleic acid encoding the hALG-2LP, sALG-2LP, or mALG-2LP protein or biologically active portion thereof, cloned in, for example, a pLTP vector (as described in Vito P. et al. (1996) Science 271:521-525). The ability of the transfected nucleic acid molecules to protect the recipient cells form cell death can then be monitored.
Additional nucleic acid fragments encoding biologically active portions of hALG-2LP, sALG-2LP, or mALG-2LP can be prepared by isolating a portion of SEQ
ID N0:2, 5, or 8, respectively, expressing the encoded portion of hALG-2LP, sALG-2LP, or mALG-2LP protein or peptide (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of hALG-2LP, sALG-2LP, or mALG-protein or peptide.
The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1, 4, or 7 (and portions thereof] due to degeneracy of the genetic code and thus encode the same hALG-2LP, sALG-2LP, or mALG-2LP protein as that encoded by the nucleotide sequence shown in SEQ ID
NO:1, 4, or 7, respectively. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID N0:2, 5, or 8 or a protein having an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~
as Accession Number . In a still further embodiment, the nucleic acid molecule of the invention encodes a full length human protein which is substantially homologous to the amino acid sequence of SEQ ID N0:2, S, or 8 (encoded by the open reading frame shown in SEQ ID N0:3, 6, or 9) or an amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number In addition to the hALG-2LP, sALG-2LP, and mALG-2LP nucleotide sequences shown in SEQ ID NOs:I, 4, and 7, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of hALG-2LP, sALG-2LP, and mALG-2LP may exist within a population (e.g., the human IO population). Such genetic polymorphism in the hALG-2LP, sALG-2LP, and mALG-2LP genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein, preferably a mammalian hALG-2LP, sALG-2LP, or mALG-2LP
protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the hALG-2LP, sALG-2LP, or mALG-2LP gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in hALG-2LP, sALG-2LP, or mALG-2LP that are the result of natural allelic variation and that do not alter the functional activity of hALG-2LP, sALG-2LP, or mALG-2LP are intended to be within the scope of the invention. Moreover, nucleic acid molecules encoding hALG-2LP, sALG-2LP, or mALG-2LP proteins from other species, and thus which have a nucleotide sequence which differs from the sequence of SEQ ID NO:1, 4, or 7, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and non-human, non-monkey, or non-marine homologues of the hALG-2LP, sALG-2LP, or mALG-2LP cDNA of the invention can be isolated based on their homology to the hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid disclosed herein using the human cDNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.
Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 4, or 7 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~
as Accession Number . In other embodiments, the nucleic acid is at least 30, 50, 100, 250, 300, 350, 400, 450, 500, 520, 540, 550, or 600 nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60%
homologous to each other typically remain hybridized to each other.
Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biolog~, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C.
Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1, 4, or 7 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring"
nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein). In one embodiment, the nucleic acid encodes a natural human hALG-2LP, sALG-2LP, or mALG-2LP.
In addition to naturally-occurring allelic variants of the hALG-2LP, sALG-2LP, or mALG-2LP sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO:1, 4, or 7, thereby leading to changes in the amino acid sequence of the encoded hALG-2LP, sALG-2LP, or mALG-2LP protein, without altering the functional ability of the hALG-2LP, sALG-2LP, or mALG-2LP protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO: l, 4, or 7. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of hALG-2LP, sALG-2LP, or mA,LG-2LP (e.g., the sequence of SEQ ID N0:2, 5, or 8) without altering the activity of hALG-2LP, sALG-2LP, or mALG-2LP, whereas an "essential" amino acid residue is required for hALG-2LP, sALG-2LP, or mALG-2LP activity. For example, amino acid residues that are conserved among the ALG-2LP proteins of the present invention, are predicted to be particularly unamenable to alteration (e.g., the conserved aspartate, lysine, and glutamate residues present in the EF hand).
Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved in the EF hand) may not be essential for activity and thus are likely to be amenable to alteration without altering hALG-2LP, sALG-2LP, or mALG-2LP activity.
Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding hALG-2LP, sALG-2LP, or mALG-2LP proteins that contain changes in amino acid residues that are not essential for hALG-2LP, sALG-2LP, or mALG-2LP
activity.
Such hALG-2LP, sALG-2LP, or mALG-2LP proteins differ in amino acid sequence from SEQ ID N0:2, 5, or 8, respectively, yet retain at least one of the hALG-2LP, sALG-2LP, or mALG-2LP activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least 38%, 42%, 44%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8 and is capable of modulating programmed cell death.
To determine the percent homology of two amino acid sequences (e.g., SEQ ID
N0:2, 5, or 8 and a mutant form thereof) or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid).
The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence (e.g., SEQ ID
N0:2, 5, or 8) is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (e.g., a mutant form of hALG-2LP, sALG-2LP, or mALG-2LP, respectively), then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., %
homology = # of identical positions/total # of positions x 100).
The comparison of sequences and determination of percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of KarIin and Altschul (1990) Proc. Natl. Acad. Sci. USA
87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid molecules of the invention. BLAST protein searches can also be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the hALG-2LP, sALG-2LP, or mALG-2LP protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST
can be utilized as described in Altschul et al., (1997) Nucleic Acids Res.
25(17):3389-3402.
When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http://www.ncbi.nlm.nih.gov. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN
program (version 2.0) which is part of the GCG sequence alignment software package.
When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
An isolated nucleic acid molecule encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein homologous to the protein of SEQ ID N0:2, 5, or 8, respectively, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1, 4, or 7 such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.
Mutations can be introduced into SEQ ID NO:1, 4, or 7 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues.
A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in hALG-2LP, sALG-2LP, or mALG-2LP is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a hALG-2LP, sALG-2LP, or mALG-2LP coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for a hALG-2LP, sALG-2LP, or mALG-2LP
activity described herein to identify mutants that retain hALG-2LP, sALG-2LP, or mALG-activity. Following mutagenesis of SEQ ID NO:1, 4, or 7, the encoded protein can be expressed recombinantly (e.g., as described in Examples 3 and 4) and the activity of the protein can be determined using, for example, assays described herein.
In addition to the nucleic acid molecules encoding hALG-2LP, sALG-2LP, or mALG-2LP proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA
molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire hALG-2LP, sALG-2LP, or mALG-2LP coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding hALG-2LP, sALG-2LP, or mALG-2LP.
The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues, e.g., the entire coding region of SEQ ID NO:1 comprises nucleotides 30 to 881 (shown separately as SEQ
ID
N0:3), the entire coding region of SEQ ID N0:4 comprises nucleotides 10 to 840 (shown separately as SEQ ID N0:6), and the entire coding region of SEQ ID N0:7 comprises nucleotides 177 to 998 (shown separately as SEQ ID N0:9). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding hALG-2LP, sALG-2LP, or mALG-2LP. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions). An example of an antisense molecule which is complementary to a fragment of the 5' untranslated region of SEQ ID NO:1 and which also includes the start codon is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 20 to 38 of SEQ ID NO:1. This antisense molecule has the following nucleotide sequence: 5' CAGAATCACCATGGCCAGC 3' (SEQ ID
N0:17). An example of an antisense molecule which is complementary to a portion of the 3' untranslated region of SEQ ID NO:1 is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 885 to 905 of SEQ ID NO:1.
This antisense molecule has the following sequence: 5' CCCAACCATCTGTGGAGAGTG 3' (SEQ ID N0:18). An example of an antisense molecule which is complementary to a fragment of the 5' untranslated region of SEQ ID N0:4 and which also includes the start codon is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 1 to 15 of SEQ ID N0:4. This antisense molecule has the following nucleotide sequence: 5' CGCGTGGGCATGGCC 3' (SEQ ID N0:19). An example of an antisense molecule which is complementary to a portion of the 3' untranslated region of SEQ ID N0:4 is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 844 to 862 of SEQ ID N0:4. This antisense molecule has the following sequence: 5' CCCAACCCATCTGTGGAGA 3' (SEQ ID N0:20). An example of an antisense molecule which is complementary to a fragment of the 5' untranslated region of SEQ ID N0:7 and which also includes the start codon is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 170 to 182 of SEQ ID N0:7. This antisense molecule has the following nucleotide sequence: 5' CGGCACGAGCAGC 3' (SEQ ID N0:21 ). An example of an antisense molecule which is complementary to a portion of the 3' untranslated region of SEQ ID
N0:7 is a nucleic acid molecule which includes nucleotides which are complementary to nucleotides 992 to 1008 of SEQ ID N0:7. This antisense molecule has the following sequence: 5' GATGCTATGACCCAGCC 3' (SEQ ID N0:22).
Given the coding strand sequences encoding hALG-2LP, sALG-2LP, and S mALG-2LP disclosed herein (e.g., SEQ ID NOs:I, 4, and 7, respectively), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of hALG-2LP, sALG-2LP, or mALG-2LP mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of hALG-2LP, sALG-2LP, or mALG-2LP mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of hALG-2LP, sALG-2LP, or mALG-2LP mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurnng nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modif ed nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), S-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.
Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA
transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA
and/or genomic DNA encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of an antisense nucleic acid 1 S molecule of the invention includes direct injection at a tissue site.
Alternatively, an antisense nucleic acid molecule can be modified to target selected cells and then administered systemically. For example, for systemic administration, an antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen.
The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
In yet another embodiment, the antisense nucleic acid molecule of the invention is an a-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual (3-units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids.
Res. 15:6625-6641 ). The antisense nucleic acid molecule can also comprise a 2'-0-methylribonucleotide (moue et al. (1987) Nucleic Acads Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBSLett. 215:327-330).
In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave hALG-2LP, sALG-2LP, or mALG-2LP mRNA transcripts to thereby inhibit translation of hALG-2LP, sALG-2LP, or mALG-2LP mRNA. A ribozyme having specificity for a hALG-2LP, sALG-2LP, or mALG-2LP-encoding nucleic acid can be designed based upon the nucleotide sequence of a hALG-2LP, sALG-2LP, or mALG-2LP cDNA
disclosed herein (i.e., SEQ ID NO:1, 4, or 7, respectively). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a hALG-2LP, sALG-2LP, or mALG-2LP-encoding mRNA. See, e.g., Cech et al. U.S. Patent No.
4,987,071 and Cech et al. U.S. Patent No. 5,116,742. Alternatively, hALG-2LP, sALG-2LP, or mALG-2LP mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) Science 261:1411-1418.
Alternatively, hALG-2LP, sALG-2LP, or mALG-2LP gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the hALG-2LP, sALG-2LP, or mALG-2LP (e.g., the hALG-2LP, sALG-2LP, or mALG-2LP promoter and/or enhancers) to form triple helical structures that prevent transcription of the hALG-2LP, sALG-2LP, or mALG-2LP gene in target cells. See generally, Helene, C. (1991) Anticancer Drug Des. 6(6):569-84; Helene, C. et al. (1992) Ann. N. Y. Acad. Sci. 660:27-36; and Maher, L.J. ( 1992) Bioassays 14( 12):807-1 S.
II. Recombinant Expression Vectors and Host Cells Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding hALG-2LP, sALG-2LP, or mALG-2LP
(or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the forth of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequences) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.
The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., hALG-2LP, sALG-2LP, or mALG-2LP proteins, mutant forms of hALG-2LP, sALG-2LP, or mALG-2LP, fusion proteins, and the like).
The recombinant expression vectors of the invention can be designed for expression of hALG-2LP, sALG-2LP, or mALG-2LP in prokaryotic or eukaryotic cells.
For example, hALG-2LP, sALG-2LP, or mALG-2LP can be expressed in bacterial cells such as E. coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enrymology 185, Academic Press, San Diego, CA (1990).
Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
Expression of proteins in prokaryotes is most often carried out in E. coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein.
Such fusion vectors typically serve three purposes: 1 ) to increase expression of recombinant protein;
2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.
Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B.
and Johnson, K.S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRITS (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
In one embodiment, the coding sequence of the hALG-2LP, sALG-2LP, or mALG-2LP
is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-hALG-2LP, sALG-2LP, or mALG-2LP. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant hALG-2LP, sALG-2LP, or mALG-2LP unfused to GST can be recovered by cleavage of the fusion protein with thrombin.
Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al. (1988) Gene 69:301-315) and pET l ld (Studier et al. Gene Expression Technology: Methods in Enzymolog~ 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET l ld vector relies on transcription from a T7 gnl0-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident ~, prophage harboring a T7 gnl gene under the transcriptional control of the lacUV 5 promoter.
One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al. (1992) Nucleic Acids Res. 2011-2118).
Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
In another embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP expression vector is a yeast expression vector. Examples of vectors for expression in yeast S. cerivisae include pYepSecl (Baldari, et al. (1987) Embo J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al. (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA).
Alternatively, hALG-2LP, sALG-2LP, or mALG-2LP can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al.
(1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC
(Kaufman et al. (1987) EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements.
For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring 1 S Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific;
Pinkert et al.
(1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBOJ. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) PNAS 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the marine hox promoters (Kessel and Grass (1990) Science 249:374-379) and the a-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to hALG-2LP, sALG-2LP, or mALG-2LP mRNA.
Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA
molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H.
et al., Antisense RNA as a molecular tool for genetic analysis, Reviews -Trends in Genetics, Vol. 1(1) 1986.
Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell"
and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modif cations may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
A host cell can be any prokaryotic or eukaryotic cell. For example, hALG-2LP, sALG-2LP, or mALG-2LP protein can be expressed in bacterial cells such as E.
coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.
Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAF-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A
Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.
For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
Preferred selectable markers include those which confer resistance to drugs, such as 6418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding hALG-2LP, sALG-2LP, or mALG-2LP or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) hALG-2LP, sALG-2LP, or mALG-protein. Accordingly, the invention further provides methods for producing hALG-2LP, sALG-2LP, or mALG-2LP protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding hALG-2LP, sALG-2LP, or mALG-2LP has been introduced) in a suitable medium until hALG-2LP, sALG-2LP, or mALG-2LP is produced. In another embodiment, the method further comprises isolating hALG-2LP, sALG-2LP, or mALG-2LP from the medium or the host cell.
The host cells of the invention can also be used to produce nonhuman transgenic animals. The nonhuman transgenic animals can be used in screening assays designed to identify agents or compounds, e.g., drugs, pharmaceuticals, etc., which are capable of ameliorating detrimental symptoms of selected disorders such as disorders characterized S by deregulated cell death. For example, in one embodiment, a host cell of the invention is a neuronal cell into which hALG-2LP, sALG-2LP, or mALG-2LP-coding sequences have been introduced. Moreover, methods of the invention can be used to create non-human transgenic animals in which exogenous hALG-2LP or sALG-2LP sequences have been introduced into the mouse genome, or homologous recombinant animals in which endogenous sALG-2LP, or mALG-2LP sequences have been altered. Such animals are useful for studying the function and/or activity of hALG-2LP, sALG-2LP, or mALG-2LP and for identifying and/or evaluating modulators of hALG-2LP, sALG-2LP, or mALG-2LP activity. As used herein, a "transgenic animal" is a nonhuman animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include nonhuman primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a nonhuman animal, preferably a mammal, more preferably a mouse, in which an endogenous sALG-2LP, or mALG-2LP gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
A transgenic animal of the invention can be created by introducing hALG-2LP, sALG-2LP, or mA.LG-2LP-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The hALG-2LP, sALG-2LP, or mALG-2LP
cDNA sequence of SEQ ID NO:1, 4, or 7 can be introduced as a transgene into the genome of a nonhuman animal. Alternatively, a non-human, non-monkey, or non-marine homologue of the hALG-2LP, sALG-2LP, or mALG-2LP gene, such as a human hALG-2LP, sALG-2LP, or mALG-2LP gene, can be isolated based on hybridization to the hALG-2LP, sALG-2LP, or mALG-2LP cDNA (described further in subsection I
above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A
tissue-specific regulatory sequences) can be operably linked to the hALG-2LP, sALG-2LP, or mALG-2LP transgene to direct expression of hALG-2LP, sALG-2LP, or mALG-2LP protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos.
4,736,866 and 4,870,009, both by Leder et al., U.S. Patent No. 4,873,191 by Wagner et al. and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the hALG-2LP, sALG-2LP, or mALG-2LP transgene in its genome and/or expression of hALG-2LP, sALG-2LP, or mALG-2LP mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding hALG-2LP, sALG-2LP, or mALG-2LP can further be bred to other transgenic animals carrying other transgenes.
To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a hALG-2LP, sALG-2LP, or mALG-2LP gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the hALG-2LP, sALG-2LP, or mALG-2LP gene. The hALG-2LP, sALG-2LP, or mALG-2LP gene can be a human gene (e.g., from a human genomic clone isolated from a human genomic library screened with the cDNA of SEQ ID NO:1, 4, or 7), but more preferably, is a nonhuman homologue of a human hALG-2LP, sALG-2LP, or mALG-2LP gene. For example, a rat ALG-2LP gene can be isolated from a rat genomic DNA
library using the human ALG-2LP, monkey ALG-2LP, or partial marine ALG-2LP
cDNA of SEQ ID NO:1, 4, or 7 as a probe. The rat ALG-2LP gene then can be used to construct a homologous recombination vector suitable for altering an endogenous ALG-2LP gene in the rat genome. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous ALG-2LP gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out"
vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous ALG-2LP gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous ALG-2LP protein). In the homologous recombination vector, the altered portion of the ALG-2LP gene is flanked at its 5' and 3' ends by additional nucleic acid of the ALG-2LP gene to allow for homologous recombination to occur between the exogenous hALG-2LP, sALG-2LP, or mALG-2LP
gene carried by the vector and an endogenous ALG-2LP gene in an embryonic stem cell.
The additional flanking hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene.
Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see e.g., Thomas, K.R. and Capecchi, M. R. (1987) Cell 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced hALG-2LP, sALG-2LP, or mALG-2LP gene has homologously recombined with the endogenous ALG-2LP gene are selected (see e.g., Li, E. et al. (1992) Cell 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A
chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. ( 1991 ) Current Opinion in Biotechnology 2:823-829 and in PCT International Publication Nos.:
WO
90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al.
In another embodiment, transgenic nonhuman animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the crelloxP recombinase system of bacteriophage Pl. For a description of the crelloxP recombinase system, see, e.g., Lakso et al.
(1992) PNAS
89:6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355. If a crelloxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double"
transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
Clones of the nonhuman transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. (1997) Nature 385:810-813 and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter Go phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.
III. Isolated hALG-2LP, sALG-2LP, and mALG-2LP Proteins and Anti-hALG-2LP, Anti-sALG-2LP, and Anti-mALG-2LP Antibodies Another aspect of the invention pertains to isolated hALG-2LP, sALG-2LP, and mALG-2LP proteins, and biologically active portions thereof, as well as peptide fragments suitable for use as immunogens to raise anti-hALG-2LP, anti-sALG-2LP, and anti-mALG-2LP antibodies. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of hALG-2LP, sALG-2LP, or mALG-2LP protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language "substantially free of cellular material"
includes preparations of hALG-2LP, sALG-2LP, or mALG-2LP protein having less than about 30% (by dry weight) of non-hALG-2LP, sALG-2LP, or mALG-2LP protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-hALG-2LP, sALG-2LP, or mALG-2LP protein, still more preferably less than about 10% of non-hALG-2LP, sALG-2LP, or mALG-2LP protein, and most preferably less than about 5% non-hALG-2LP, sALG-2LP, or mALG-2LP protein. When the hALG-2LP, sALG-2LP, or mALG-2LP protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The language "substantially free of chemical precursors or other chemicals"
includes preparations of hALG-2LP, sALG-2LP, or mALG-2LP protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of hALG-2LP, sALG-2LP, or mALG-2LP protein having less than about 30% (by dry weight) of chemical precursors or non-hALG-2LP, sALG-2LP, or mALG-2LP chemicals, more preferably less than about 20% chemical precursors or non-hALG-2LP, sALG-2LP, or mALG-2LP
chemicals, still more preferably less than about 10% chemical precursors or non-hALG-2LP, sALG-2LP, or mALG-2LP chemicals, and most preferably less than about 5%
chemical precursors or non-hALG-2LP, sALG-2LP, or mALG-2LP chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same animal from which the hALG-2LP, sALG-2LP, or mALG-2LP protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a human ALG-2LP protein in a nonhuman cell.
An isolated hALG-2LP, sALG-2LP, or mALG-2LP protein or a portion thereof of the invention can modulate programmed cell death. In preferred embodiments, the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID N0:2, 5, or 8 such that the protein or portion thereof maintains the ability to modulate programmed cell death. The portion of the protein is preferably a biologically active portion as described herein.
In another preferred embodiment, the hALG-2LP protein (i.e., amino acid residues 1-284 of SEQ
ID N0:2), sALG-2LP protein (i.e., amino acid residues 1-277 of SEQ ID NO:S), or mALG-2LP protein (i.e., amino acid residues 1-274 of SEQ ID N0:8) has an amino acid sequence shown in SEQ ID N0:2, 5, or 8, respectively, or an amino acid sequence which is encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number . In yet another preferred embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence of the DNA insert of the piasmid deposited with ATCC~ as Accession Number . In still another preferred embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP protein has an amino acid sequence which is encoded by a nucleotide sequence that is at least about 32%, 35%, 40%, 45%, SO%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the nucleotide sequence of the DNA insert of the piasmid deposited with ATCC~ as Accession Number . The preferred hALG-2LP, sALG-2LP, or mALG-2LP
proteins of the present invention also preferably possess at least one of the hALG-2LP, sALG-2LP, or mALG-2LP activities described herein. For example, a preferred hALG-2LP, sALG-2LP, or mALG-2LP protein of the present invention includes an amino acid sequence encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC~ as Accession Number and which can modulate programmed cell death.
In other embodiments, the hALG-2LP, sALG-2LP, or mALG-2LP protein is substantially homologous to the amino acid sequence of SEQ ID N0:2, 5, or 8 and retains the functional activity of the protein of SEQ ID N0:2, S, or 8 yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP protein is a protein which comprises an amino acid sequence which is at least about 38%, 42%, 44%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the entire amino acid sequence of SEQ ID N0:2, 5, or 8 and which has at least one of the hALG-2LP, sALG-2LP, or mALG-2LP activities described herein. In other embodiment, the invention pertains to a full length human protein which is substantially homologous to the amino acid sequence of SEQ ID
N0:2, 5,or8 Biologically active portions of the hALG-2LP, sALG-2LP, or mALG-2LP
protein include peptides comprising amino acid sequences derived from the amino acid sequence of the hALG-2LP, sALG-2LP, or mALG-2LP protein, e.g., the amino acid I 0 sequence shown in SEQ ID N0:2, 5, or 8, respectively or the amino acid sequence of a protein homologous to the hALG-2LP, sALG-2LP, or mALG-2LP protein, which contains less amino acids than the full length hALG-2LP, sALG-2LP, or mALG-2LP
protein or the full length protein which is homologous to the hALG-2LP, sALG-2LP, or mALG-2LP protein, and exhibits at least one activity of the hALG-2LP, sALG-2LP, or mALG-2LP protein. Typically, biologically active portions (peptides, e.g., peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif, e.g., a domain showing homology to a calcium binding domain such as an EF hand, derived from a human and is at least about 38%, 42%, 44%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to SEQ ID NO:10, 11, 12, 13, or 15. Moreover, other biologically active portions, in which other regions of the proteins are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein.
Preferably, the biologically active portions of the hALG-2LP, sALG-2LP, or mALG-2LP protein include one or more selected domains/motifs or portions thereof having biological activity.
hALG-2LP, sALG-2LP, and mALG-2LP proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the hALG-2LP, sALG-2LP, or mALG-2LP protein is expressed in the host cell. The hALG-2LP, sALG-2LP, or mALG-2LP protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, a hALG-2LP, sALG-2LP, or mALG-2LP protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques.
Moreover, native hALG-2LP, sALG-2LP, or mALG-2LP protein can be isolated from cells (e.g., brain cells or other cells that express ALG2-LP) for example using an anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody (described further below).
The invention also provides hALG-2LP, sALG-2LP, or mALG-2LP chimeric or fusion proteins. As used herein, a hALG-2LP, sALG-2LP, or mALG-2LP "chimeric protein" or "fusion protein" comprises a hALG-2LP, sALG-2LP, or mALG-2LP
polypeptide operatively linked to a non-hALG-2LP, sALG-2LP, or mALG-2LP
polypeptide. A "hALG-2LP, sALG-2LP, or mALG-2LP polypeptide" refers to a polypeptide having an amino acid sequence corresponding to hALG-2LP, sALG-2LP, or mALG-2LP, whereas a "non-hALG-2LP, sALG-2LP, or mALG-2LP polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the hALG-2LP, sALG-2LP, or mALG-2LP protein, e.g., a protein which is different from the hALG-2LP, sALG-2LP, or mALG-2LP protein and which is derived from the same or a different organism. Within the fusion protein, the term "operatively linked" is intended to indicate that the hALG-2LP, sALG-2LP, or mALG-2LP polypeptide and the non-hALG-2LP, sALG-2LP, or mALG-2LP
polypeptide are fused in-frame to each other. The non-hALG-2LP, sALG-2LP, or mALG-2LP polypeptide can be fused to the N-terminus or C-terminus of the hALG-2LP, sALG-2LP, or mALG-2LP polypeptide. For example, in one embodiment the fusion protein is a GST-hALG-2LP, GST-sALG-2LP, or GST-rnALG-2LP fusion protein in which the hALG-2LP, sALG-2LP, or mALG-2LP sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant hALG-2LP, sALG-2LP, or mALG-2LP. In another embodiment, the fusion protein is a hALG-2LP, sALG-2LP, or mALG-2LP protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of hALG-2LP, sALG-2LP, or mALG-2LP
can be increased through use of a heterologous signal sequence.
Preferably, a hALG-2LP, sALG-2LP, or mALG-2LP chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-s ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carned out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST
polypeptide). A GST encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the hALG-2LP, sALG-2LP, or mALG-2LP protein.
The present invention also pertains to homologues of the hALG-2LP, sALG-2LP, or mALG-2LP proteins which function as either a hALG-2LP, sALG-2LP, or mALG-2LP agonist (mimetic) or a hALG-2LP, sALG-2LP, or mALG-2LP antagonist.
In a preferred embodiment, the hALG-2LP, sALG-2LP, or mALG-2LP agonists and antagonists stimulate or inhibit, respectively, a subset of the biological activities of the naturally occurring form of the hALG-2LP, sALG-2LP, or mALG-2LP protein. Thus, specific biological effects can be elicited by treatment with a homologue of limited function. In one embodiment, treatment of a subject with a homologue having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurnng form of the hALG-2LP; sALG-2LP, or mALG-2LP protein.
Homologues of the hALG-2LP, sALG-2LP, or mALG-2LP protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the hALG-2LP, sALG-2LP, or mALG-2LP protein. As used herein, the term "homologue" refers to a variant form of the hALG-2LP, sALG-2LP, or mALG-2LP protein which acts as an agonist or antagonist of the activity of the hALG-2LP, sALG-2LP, or mALG-2LP
protein. An agonist of the hALG-2LP, sALG-2LP, or mALG-2LP protein can retain substantially the same, or a subset, of the biological activities of the hALG-2LP, sALG-2LP, or mALG-2LP protein. An antagonist of the hALG-2LP, sALG-2LP, or mALG-2LP protein can inhibit one or more of the activities of the naturally occurring form of the hALG-2LP, sALG-2LP, or mALG-2LP protein, by, for example, competitively binding to a downstream or upstream member of the hALG-2LP, sALG-2LP, or mALG-2LP cascade which includes the hALG-2LP, sALG-2LP, or mALG-2LP protein. Thus, the mammalian hALG-2LP, sALG-2LP, or mALG-2LP protein and homologues thereof of the present invention can be either positive or negative regulators of a programmed cell death transduction pathway activity.
In an alternative embodiment, homologues of the hALG-2LP, sALG-2LP, or mALG-2LP protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the hALG-2LP, sALG-2LP, or mALG-2LP protein for hALG-2LP, sALG-2LP, or mALG-2LP protein agonist or antagonist activity. In one embodiment, a variegated library of hALG-2LP, sALG-2LP, or mALG-2LP variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of hALG-2LP, sALG-2LP, or mALG-variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential hALG-2LP, sALG-2LP, or mALG-2LP sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of hALG-2LP, sALG-2LP, or mALG-2LP sequences therein. There are a variety of methods which can be used to produce libraries of potential hALG-2LP, sALG-2LP, or mALG-2LP homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA
synthesizer, and the synthetic gene then ligated into an appropriate expression vector.
Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential hALG-2LP, sALG-2LP, or mALG-sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu.
Rev.
Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477).
In addition, libraries of fragments of the hALG-2LP, sALG-2LP, or mALG-2LP
protein coding can be used to generate a variegated population of hALG-2LP, sALG-2LP, or mALG-2LP fragments for screening and subsequent selection of homologues of a hALG-2LP, sALG-2LP, or mALG-2LP protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR
fragment of a hALG-2LP, sALG-2LP, or mALG-2LP coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the hALG-2LP, sALG-2LP, or mALG-2LP protein.
Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA
libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of hALG-2LP, sALG-2LP, or mALG-2LP homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected.
Recrusive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify hALG-2LP, sALG-2LP, or mALG-2LP homologues (Arkin and Yourvan (1992) PNAS 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).
In one embodiment, cell based assays can be exploited to analyze a variegated hALG-2LP, sALG-2LP, or mALG-2LP library. For example, a library of expression vectors can be transfected into a cell line, e.g., a T cell hybridoma (3D0) which has been cross-linked with a T cell receptor to induce programmed cell death (as described in Ashwell J. D. et al. ( 1990) J. Immunol. 144:3326). The effect of the hALG-2LP, sALG-2LP, or mALG-2LP mutant on programmed cell death can then be detected, e.g., by monitoring nuclear chromatin changes. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, stimulation of programmed cell death, and the individual clones further characterized.
An isolated hALG-2LP, sALG-2LP, or mALG-2LP protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind hALG-2LP, sALG-2LP, or mALG-2LP using standard techniques for polyclonal and monoclonal antibody preparation. The full-length hALG-2LP, sALG-2LP, or mALG-2LP protein can be used or, alternatively, the invention provides antigenic peptide fragments of hALG-2LP, sALG-2LP, or mALG-2LP for use as immunogens. The antigenic peptide of hALG-2LP, sALG-2LP, or mALG-2LP comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID N0:2, 5, or 8 and encompasses an epitope of hALG-2LP, sALG-2LP, or mALG-2LP such that an antibody raised against the peptide forms a specific immune complex with hALG-2LP, sALG-2LP, or mALG-2LP. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.
Preferred epitopes encompassed by the antigenic peptide are regions of hALG-2LP, sALG-2LP, or mALG-2LP that are located on the surface of the protein, e.g., hydrophilic regions.
A hALG-2LP, sALG-2LP, or mALG-2LP immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed hALG-2LP, sALG-2LP, or mALG-2LP protein or a chemically synthesized hALG-2LP, sALG-2LP, or mALG-2LP peptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic hALG-2LP, sALG-2LP, or mALG-2LP preparation induces a polyclonal anti-hALG-2LP, anti-sALG-2LP, or anti-mALG-2LP antibody response.
Accordingly, another aspect of the invention pertains to anti-hALG-2LP, anti-sALG-2LP, or anti-mALG-2LP antibodies. The term "antibody" as used herein refers to S immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as hALG-2LP, sALG-2LP, or mALG-2LP.
Examples of immunologically active portions of immunoglobulin molecules include Flab) and F(ab')2 fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind hALG-2LP, sALG-2LP, or mALG-2LP. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of hALG-2LP, sALG-2LP, or mALG-2LP. A
monoclonal antibody composition thus typically displays a single binding affinity for a particular hALG-2LP, sALG-2LP, or mALG-2LP protein with which it immunoreacts.
Polyclonal anti-hALG-2LP, sALG-2LP, or mALG-2LP antibodies can be prepared as described above by immunizing a suitable subject with a hALG-2LP, sALG-2LP, or mALG-2LP immunogen. The anti-hALG-2LP, sALG-2LP, or mALG-2LP
antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using in~nobilized hALG-2LP, sALG-2LP, or mALG-2LP. If desired, the antibody molecules directed against hALG-2LP, sALG-2LP, or mALG-2LP can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497) (see also, Brown et al. (1981) J. Immunol. 127:539-46; Brown et al. (1980) J. Biol. Chem .255:4980-83; Yeh et al. (1976) PNAS 76:2927-31; and Yeh et al. (1982) Int. J.
Cancer 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al.
(1983) Immunol Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques.
The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in Monoclonal Antibodies: A New Dimension In Biological Analyses, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) Yale J. Biol. Med., 54:387-402; M. L. Gefter et al. (1977) Somatic Cell Genet.
3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a hALG-2LP, sALG-2LP, or mALG-2LP immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds hALG-2LP, sALG-2LP, or mALG-2LP.
Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-hALG-2LP, sALG-2LP, or mALG-2LP monoclonal antibody (see, e.g., G. Galfre et al. (1977) Nature 266:55052; Gefter et al. Somatic Cell Genet., cited supra; Lerner, Yale J. Biol.
Med., cited supra; Kenneth, Monoclonal Antibodies, cited supra). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, marine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line.
Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS111-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Agl4 myeloma lines.
These myeloma lines are available from ATCC~. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG").
Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind hALG-2LP, sALG-2LP, or mALG-2LP, e.g., using a standard ELISA assay.
Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with hALG-2LP, sALG-2LP, or mALG-2LP to thereby isolate immunoglobulin library members that bind hALG-2LP, sALG-2LP, or mALG-2LP. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No.
9400-O1; and the Stratagene SurfZAPTM Phage Display Kit, Catalog No. 240612).
Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT International Publication No. WO
92/18619; Dower et al. PCT International Publication No. WO 91/17271; Winter et al.
PCT International Publication WO 92/20791; Markland et al. PCT International Publication No. WO 92/15679; Breitling et al. PCT International Publication WO
93/01288; McCafferty et al. PCT International Publication No. WO 92/01047;
Garrard et al. PCT International Publication No. WO 92/09690; Ladner et al. PCT
International Publication No. WO 90/02809; Fuchs et al. (1991) BiolTechnology 9:1370-1372;
Hay et al. (1992) Hum. Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J. Mol.
Biol.
226:889-896; Clarkson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS
89:3576-3580; Garrad et al. (1991) BiolTechnolo~ 9:1373-1377; Hoogenboom et al.
(1991) Nuc. Acid Res. 19:4133-4137; Barbas et al. (1991) PNAS 88:7978-7982;
and McCafferty et al. Nature (1990) 348:552-554.
Additionally, recombinant anti-hALG-2LP, sALG-2LP, or mALG-2LP
antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA
techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187;
Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533;
Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023;
Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) PNAS 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218;
Nishimura et al. (1987) Canc. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-1559); Morrison, S. L. (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214; Winter U.S. Patent 5,225,539;
Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J. Immunol. 141:4053-4060.
An anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody (e.g., monoclonal antibody) can be used to isolate hALG-2LP, sALG-2LP, or mALG-2LP by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody can facilitate the purification of natural hALG-2LP, sALG-2LP, or mALG-2LP from cells and of recombinantly produced hALG-2LP, sALG-2LP, or mALG-2LP expressed in host cells. Moreover, an anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody can be used to detect hALG-2LP, sALG-2LP, or mALG-2LP protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the hALG-2LP, sALG-2LP, or mALG-2LP protein. Anti-hALG-2LP, sALG-2LP, or mALG-2LP antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen.
Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, (3-galactosidase, or acetylcholinesterase;
examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol;
examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I~ 131h 35S or 3H.
IV. Pharmaceutical Compositions The hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid molecules, hALG-2LP, sALG-2LP, or mALG-2LP proteins, and anti-hALG-2LP, sALG-2LP, or mALG-2LP
antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject, e.g., a human. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable Garner. As used herein the language "pharmaceutically acceptable Garner" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention.
Supplementary active compounds can also be incorporated into the compositions.
A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents;
antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable earners include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the 1 S maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a hALG-2LP, sALG-2LP, or mALG-2LP protein or anti-hALG-2LP, anti-sALG-2LP, or anti-mALG-2LP antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Oral compositions generally include an inert diluent or an edible carrier.
They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid Garner for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
Methods for preparation of such formulations will be apparent to those skilled in the art.
The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomai suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) PNAS 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
V. Uses and Methods of the Invention The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in, for example, diagnostic assays. The isolated nucleic S acid molecules of the invention can be used to detect hALG-2LP, sALG-2LP, or mALG-2LP mRNA (e.g., in a biological sample) or a genetic lesion in a hALG-2LP, sALG
2LP, or mALG-2LP gene. In addition, the anti-hALG-2LP, anti-sALG-2LP, or anti mALG-2LP antibodies of the invention can be used to detect and isolate hALG-2LP, sALG-2LP, or mALG-2LP protein and modulate hALG-2LP, sALG-2LP, or mALG
2LP protein activity.
Accordingly, the invention provides a method for detecting the presence of hALG-2LP, sALG-2LP, or mALG-2LP in a biological sample. The method involves contacting the biological sample with a compound or an agent capable of detecting hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA such that the presence of hALG-2LP, sALG-2LP, or mALG-2LP is detected in the biological sample. A
preferred agent for detecting hALG-2LP, sALG-2LP, or mALG-2LP mRNA is a labeled or labelable nucleic acid probe capable of hybridizing to hALG-2LP, sALG-2LP, or mALG-2LP mRNA. The nucleic acid probe can be, for example, the full-length hALG-2LP, sALG-2LP, or mALG-2LP cDNA of SEQ ID NO: 1, 4, or 7, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or S00 nucleotides in length and sufficient to specifically hybridize under stringent conditions to hALG-2LP, sALG-2LP, or mALG-2LP mRNA. A preferred agent for detecting hALG-2LP, sALG-2LP, or mALG-2LP protein is a labeled or labelable antibody capable of binding to hALG-2LP, sALG-2LP, or mALG-2LP protein. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')2) can be used.
The term "labeled or labelable", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled.
Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample"
is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect hALG-2LP, sALG-2LP, or mALG-2LP mRNA or protein in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of hALG-2LP, sALG-2LP, or mALG-2LP mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of hALG-2LP, sALG-2LP, or mALG-2LP protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.
Alternatively, hALG-2LP, sALG-2LP, or mALG-2LP protein can be detected in vivo in a subject by introducing into the subject a labeled anti-hALG-2LP, sALG-2LP, or mALG-2LP antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
1 S The invention also encompasses kits for detecting the presence of hALG-2LP, sALG-2LP, or mALG-2LP in a biological sample. For example, the kit can comprise a labeled or labelable compound or agent capable of detecting hALG-2LP, sALG-2LP, or mALG-2LP protein or mRNA in a biological sample; means for determining the amount of hALG-2LP, sALG-2LP, or mALG-2LP in the sample; and means for comparing the amount of hALG-2LP, sALG-2LP, or mALG-2LP in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect hALG-2LP, sALG-2LP, or mALG-mRNA or protein.
The methods of the invention can also be used to detect genetic lesions in a hALG-2LP, sALG-2LP, or mALG-2LP gene, thereby determining if a subject with the lesioned gene is at risk for a disorder, e.g., a disorder characterized by deregulated programmed cell death, characterized by aberrant or abnormal hALG-2LP, sALG-2LP, or mALG-2LP nucleic acid expression or hALG-2LP, sALG-2LP, or mALG-2LP
protein activity as defined herein. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene WO 99/b1459 PCT/US99/10581 encoding a hALG-2LP, sALG-2LP, or mALG-2LP protein, or the misexpression of the hALG-2LP, sALG-2LP, or mALG-2LP gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a hALG-2LP, sALG-2LP, or mALG-2LP gene; 2) an addition of one or more nucleotides to a hALG-2LP, sALG-2LP, or mALG-2LP gene; 3) a substitution of one or more nucleotides of a hALG-2LP, sALG-2LP, or mALG-2LP gene, 4) a chromosomal rearrangement of a hALG-2LP, sALG-2LP, or mALG-2LP gene; 5) an alteration in the level of a messenger RNA transcript of a hALG-2LP, sALG-2LP, or mALG-2LP gene, 6) aberrant modification of a hALG-2LP, sALG-2LP, or mALG-2LP
gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a hALG-2LP, sALG-2LP, or mALG-2LP gene, 8) a non-wild type level of a hALG-2LP, sALG-2LP, or mALG-2LP-protein, 9) allelic loss of a hALG-2LP, sALG-2LP, or mALG-2LP gene, and 10) inappropriate post-translational modification of a hALG-2LP, sALG-2LP, or mALG-2LP-protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a hALG-2LP, sALG-2LP, or mALG-2LP gene.
In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos.
4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al. (1994) PNAS 91:360-364), the latter of which can be particularly useful for detecting point mutations in the hALG-2LP, sALG-2LP, or mALG-2LP-gene (see Abravaya et al. (1995) Nucleic Acids Res .23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specif cally hybridize to a hALG-2LP, sALG-2LP, or mALG-2LP gene under conditions such that hybridization and amplification of the hALG-2LP, sALG-2LP, or mALG-2LP-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample.
In an alternative embodiment, mutations in a hALG-2LP, sALG-2LP, or mALG-2LP gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA.
Moreover, the use of sequence specific ribozymes (see, for example, U.S.
Patent No.
5,498,531 ) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.
In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the hALG-2LP, sALG-2LP, or mALG-2LP
gene and detect mutations by comparing the sequence of the sample hALG-2LP, sALG-2LP, or mALG-2LP with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxam and Gilbert ((1977) PNAS 74:560) or Sanger ((1977) PNAS 74:5463). A variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al. (1996) Adv.
Chromatogr.
36:127-162; and Griffin et al. (i993) Appl. Biochem. Biotechnol. 38:147-159).
Other methods for detecting mutations in the hALG-2LP, sALG-2LP, or mALG-2LP gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al. (1985) Science 230:1242); Cotton et al. (1988) PNAS 85:4397; Saleeba et al. (1992) Meth.
Enzymol.
217:286-295), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al. (1989) PNAS 86:2766; Cotton (1993) Mutat Res 285:125-144; and Hayashi (1992) GenetAnal Tech Appl 9:73-79), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al (1985) Nature 313:495). Examples of other techniques for detecting point mutations include, selective oligonucleotide hybridization, selective amplification, and selective primer extension.
VI. Uses of Partial hALG-2LP, sALG-2LP, and mALG-2LP Sequences Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (a) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (b) identify an individual from a minute biological sample (tissue typing); and (c) aid in forensic identification of a biological sample. These applications are described in the subsections below.
a. Chromosome Mapping Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the hALG-2LP, sALG-2LP, and mALG-2LP, sequences, described herein, can be used to map the location of the hALG-2LP, sALG-2LP, and mALG-2LP genes, respectively, on a chromosome. The mapping of the hALG-2LP, sALG-2LP, and mALG-2LP sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.
Briefly, hALG-2LP, sALG-2LP, and mALG-2LP genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 by in length) from the hALG-2LP, sALG-2LP, and mALG-2LP sequences. Computer analysis of the hALG-2LP, sALG-2LP, and mALG-2LP, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the hALG-2LP, sALG-2LP, and mALG-2LP sequences will yield an amplified fragment.
Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but human cells can, the one human chromosome that contains the gene encoding the needed enzyme, will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio P. et al. (1983) Science 220:919-924). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.
PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the hALG-2LP, sALG-2LP, and mALG-2LP sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a hALG-2LP, sALG-2LP, or mALG-1 S sequence to its chromosome include in situ hybridization (described in Fan, Y. et al.
( 1990) PNAS, 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries.
Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa.
A
pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA
sequence as short as S00 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma et al., Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York 1988).
.__..x. .. ._~~.~~_~..
-59_ Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes.
Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.
Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example, Egeland, J. et al. (1987) Nature, 325:783-787.
Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the hALG-2LP, sALG-2LP, or mALG-2LP
gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.
b. Tissue Typing The hALG-2LP, sALG-2LP, and mALG-2LP sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).
Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the hALG-2LP, sALG-2LP, or mALG-2LP sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.
Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The hALG-2LP, sALG-2LP, or mALG-2LP sequences of the invention 1 S uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals.
The noncoding sequences of SEQ ID NOs:l, 4, and 7, can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOs:3, 6, and 9, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.
If a panel of reagents from hALG-2LP, sALG-2LP, or mALG-2LP sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual.
Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.
c. Use of Partial hALG-2LP, sALG-2LP, and mALG-2LP Sequences in Forensic Biology DNA-based identification techniques can also be used in forensic biology.
Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene.
The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.
The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NOs:I;
4, and 7 are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique.
Examples of polynucleotide reagents include the hALG-2LP, sALG-2LP, and mALG-2LP sequences or portions thereof, e.g., fragments derived from the noncoding regions of SEQ ID NOs:I, 4, and 7, having a length of at least 20 bases, preferably at least 30 bases.
The hALG-2LP, sALG-2LP, and mALG-2LP sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such hALG-2LP, sALG-2LP, and mALG-2LP probes can be used to identify tissue by species and/or by organ type.
WO 99/61459 PCTNS99/105$1 In a similar fashion, these reagents, e.g., hALG-2LP, sALG-2LP, and mALG-2LP primers or probes can be used to screen tissue culture for contamination (i.e. screen for the presence of a mixture of different types of cells in a culture).
This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, and published patent applications cited throughout this application are hereby incorporated by reference.
EXAMPLES
EXAMPLE 1: IDENTIFICATION AND CHARACTERIZATION OF
hALG-2LP, sALG-2LP, and mALG-2LP cDNA
In this example, the hALG-2LP, sALG-2LP, and mALG-2LP nucleic acid molecules were identified by screening appropriate cDNA libraries. An EST
(jlkbc063c04)was first identified in a monkey brain cDNA library using the Sequence Explorer. A mouse EST (jlmba005e01 ) was subsequently identified in a mouse brain cDNA library and two human ESTs were also identified by screening proprietary libraries. The positive clones were sequenced, and the sequences were assembled.
A BLASTNT"' search of the EST database revealed the following ESTs having significant homology to the hALG-2LP cDNA:
EST Database hits Species Base Pairs% Codin Covered Identi ?
Accession # AA569956Human 1149-1630 100 Yes Accession # AA226400Human 1124-1643 100 Yes Accession # W80352Human 1208-1657 99 Yes Accession # AA533187Human 1154-1630 96 Yes Accession # AA633700Human 1160-1 99 Yes Accession # N9S34SHuman 1237-1630 98 Yes Accession # AA431700Human 873-1305 100 Yes Accession # AA311285Human 911-1341 100 Yes Accession # AA643S8SHuman 1202-1629 99.5 Yes Accession # AA0400S8Human 1173-1630 96 Yes A BLASTNT"" search of the EST database revealed the following ESTs having significant homology to the sALG-2LP cDNA:
EST Database hitsSpecies Base Pairs% Coding?
Covered Identi Accession # AA431700Human 84S-1266 96 No Accession # AA311285Human 870-1302 94 No Accession # W26197Human 845-1232 94 No Accession # AA031Human 766-1224 94 No Accession # AA21S228Mouse 13S-67S 90 Yes Accession # AA110246Mouse 13S-67S 90 Yes S
A BLASTNT"" search of the EST database revealed the following ESTs having significant homology to the partial mALG-2LP cDNA:
EST Database hitsSpecies Base Pairs% Coding?
Covered Identi Accession # AA110246Mouse 283-608 99 Yes Accession # AA215228Mouse 296-833 99 Yes Accession # W77580Mouse 664-1000 99 Yes Accession # AA119341Mouse 888-1107 99 Yes EXAMPLE 2: TISSUE EXPRESSION OF THE hALG-2LP, sALG-2LP, and mALG-2LP GENES
Northern Analysis Human, monkey, and mouse multiple tissue northern (MTN) blots, human MTN
I, II, and III blots (Clontech, Palo Alto, CA), containing 2 ###g of poly A+
RNA per lane were probed with hALG-2LP-specific primers (probes). The filters were prehybridized in 10 ml of Express Hyb hybridization solution (Clontech, Palo Alto, CA) at 68°C for 1 hour, after which 100 ng of 32P labeled probe was added.
The probe was generated using the Stratagene Prime-It kit, Catalog Number 300392 (Clontech, Palo Aito, CA). Hybridization was allowed to proceed at 68°C for approximately 2 hours.
The filters were washed in a 0.05% SDS/2X SSC solution for 15 minutes at room temperature and then twice with a 0.1% SDS/O.1X SSC solution for 20 minutes at 50°C
and then exposed to autoradiography film overnight at -80°C with one screen. The human and mouse tissues tested included: brain, heart, kidney, liver, lung, skeletal muscle, spleen, testis, placenta, pancreas, colon, prostate, ovaries, small intestine, and hypothalamus.
There was a strong hybridization to all the tissues tested, except hypothalamus, indicating that ALG-2LP gene transcripts are expressed in these tissues.
EXAMPLE 3: EXPRESSION OF RECOMBINANT hALG-2LP, sALG-2LP, and mALG-2LP PROTEINS IN BACTERIAL CELLS
In this example, hALG-2LP, sALG-2LP, and mALG-2LP are expressed as recombinant glutathione-S-transferase (GST) fusion proteins in E. coli and the fusion proteins are isolated and characterized. Specifically, hALG-2LP, sALG-2LP, and mALG-2LP are fused to GST and these fusion proteins are expressed in E. coli, e.g., strain PEB 199. As hALG-2LP, sALG-2LP, and mALG-2LP are predicted to be 32.7 kD, 31.8 kD, and 31.5 kD, respectively, and GST is predicted to be 26 kD, the fusion proteins are predicted to be 58.7 kD, 57.8 kD, and 57.5 kD in molecular weight, respectively. Expression of the GST-hALG-2LP, -sALG-2LP, and -mALG-2LP fusion proteins in PEB 199 is induced with IPTG. The recombinant fusion proteins are purified from crude bacterial lysates of the induced PEB 199 strain by affinity chromatography on glutathione beads. Using polyacrylamide gel electrophoretic analysis of the proteins purified from the bacterial lysates, the molecular weight of the resultant fusion proteins is determined.
EXAMPLE 4: EXPRESSION OF RECOMBINANT hALG-2LP, sALG-2LP, and mALG-2LP PROTEIN IN COS CELLS
To express the hALG-2LP, sALG-2LP, or mALG-2LP gene in COS cells, the pcDNA/Amp vector by Invitrogen Corporation (San Diego, CA) is used. This vector contains an SV40 origin of replication, an ampicillin resistance gene, an E.
coli replication origin, a CMV promoter followed by a polylinker region, and an SV40 intron and polyadenylation site. A DNA fragment encoding the entire hALG-2LP, sALG-2LP, or mALG-2LP protein and a HA tag (Wilson et al. (1984) Cell 37:767) fused in-frame to its 3' end of the fragment is cloned into the polylinker region of the vector, thereby placing the expression of the recombinant protein under the control of the CMV
promoter.
To construct the plasmid, the hALG-2LP, sALG-2LP, or mALG-2LP DNA
sequence is amplified by PCR using two primers. The 5' primer contains the restriction site of interest followed by approximately twenty nucleotides of the hALG-2LP, sALG-2LP, or mALG-2LP coding sequence starting from the initiation codon; the 3' end WO 99/61459 PCT/US99/105$1 sequence contains complementary sequences to the other restriction site of interest, a translation stop codon, the HA tag and the last 20 nucleotides of the hALG-2LP, sALG-2LP, or mALG-2LP coding sequence. The PCR amplified fragment and the pCDNA/Amp vector are digested with the appropriate restriction enzymes and the vector S is dephosphorylated using the CIAP enzyme (New England Biolabs, Beverly, MA).
Preferably the two restriction sites chosen are different so that the hALG-2LP, sALG-2LP, and mALG-2LP gene is inserted in the correct orientation. The ligation mixture is transformed into E. coli cells (strains HB101, DHSa, SURE, available from Stratagene Cloning Systems, La Jolla, CA, can be used), the transformed culture is plated on ampicillin media plates, and resistant colonies are selected. Plasmid DNA is isolated from transformants and examined by restriction analysis for the presence of the correct fragment.
COS cells are subsequently transfected with the hALG-2LP, sALG-2LP, or mALG-2LP-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium chloride co-precipitation methods, DEAF-dextran-mediated transfection, lipofection, or electroporation. Other suitable methods for transfecting host cells can be found in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual.
2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The expression of the hALG-2LP, sALG-2LP, or mALG-2LP protein is detected by radiolabelling (35S-methionine or 35S-cysteine available from NEN, Boston, MA, can be used) and immunoprecipitation (Harlow, E. and Lane, D.
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988) using an HA specific monoclonal antibody. Briefly, the cells are labelled for 8 hours with 35S-methionine (or 35S-cysteine). The culture media are then collected and the cells are lysed using detergents (RIPA buffer, 150 mM NaCI, 1 % NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH 7.5). Both the cell lysate and the culture media are precipitated with an HA specific monoclonal antibody. Precipitated proteins are then analyzed by SDS-PAGE.
Alternatively, DNA containing the hALG-2LP, sALG-2LP, or mALG-2LP
coding sequence is cloned directly into the polylinker of the pCDNA/Amp vector using the appropriate restriction sites. The resulting plasmid is transfected into COS cells in the manner described above, and the expression of the hALG-2LP, sALG-2LP, or mALG-2LP protein is detected by radiolabelling and immunoprecipitation using a hALG-2LP, sALG-2LP, or mALG-2LP specific monoclonal antibody EXAMPLE 5: CHARACTERIZATION OF hALG-2LP, sALG-2LP, and mALG-2LP PROTEINS
In this example, the amino acid sequences of the hALG-2LP, sALG-2LP, and mALG-2LP proteins were compared to amino acid sequences of known proteins and various motifs were identified.
The hALG-2LP protein, the amino acid sequence of which is shown in Figure 1 (SEQ ID N0:2), is a novel protein which includes 284 amino acid residues.
Amino acid residues 127 to 139 and 194-206 of SEQ ID N0:2 (shown separately as SEQ ID
NO:10 and SEQ ID NO:11, respectively) comprise domains showing high homology to calcium binding domains, e.g., EF hands.
A BLAST search (Altschul et al. (1990) J. Mol. Biol. 215:403) of the protein sequences of human ALG-2LP revealed that hALG-2LP is similar to the following proteins: mouse probable calcium binding protein (Accession No. P12815), human Sorcin {Accession No. P30626), mouse Accession No.50266, mouse calcium binding protein (Accession No. 504970), and Chinese hamster Sorcin (Accession No.P05044).
Human ALG-2LP is 44% identical to mouse probable calcium binding protein (Accession No. P12815) over nucleotides 396-872; 38% identical to human Sorcin (Accession No. P30626) over nucleotides 444-872; 44% identical to mouse Accession No.50266 over nucleotides 396-872; 44% identical to mouse calcium binding protein (Accession No. 504970) over nucleotides 39b-872; and 37% identical to Chinese hamster Sorcin (Accession No.P05044) over nucleotides 444-857, at the amino acid level.
The sALG-2LP protein, the amino acid sequence of which is shown in Figure 2 (SEQ ID NO:S, is a novel protein which includes 277 amino acid residues. Amino acid residues 120 to 132 and 187-199 of SEQ ID NO:S (shown separately as SEQ ID
N0:12 and SEQ ID N0:13, respectively) comprise doamins showing high homology to calcium binding domains, e.g., EF hands.
A BLAST search (Altschul et al. (1990) J. Mol. Biol. 215:403) of the protein sequences of monkey ALG-2LP revealed that sALG-2LP is similar to the following proteins: mouse probable calcium binding protein (Accession No. P1281S), human Sorcin (Accession No. P30626), and Chinese hamster Sorcin (Accession No.POS044).
S Human ALG-2LP is 42% identical to mouse probable calcium binding protein (Accession No. P1281 S) over nucleotides 376-831; 38% identical to human Sorcin (Accession No. P30626) over nucleotides 376-831; and 37% identical to Chinese hamster Sorcin (Accession No.POS044) over nucleotides 403-816, at the amino acid level.
The mALG-2LP protein, the partial amino acid sequence of which is shown in Figure 3 (SEQ ID NO:B, is a novel protein which includes 274 amino acid residues.
Amino acid residues 117 to 129 and 184 to 196 of SEQ ID N0:8 (shown separately as SEQ ID N0:14 and SEQ ID NO:1 S, respectively) comprise domains showing homology to calcium binding domains, e.g., EF hands.
1 S A BLAST search (Altschul et al. (1990) J. Mol. Biol. 215:403) of the protein sequences of partial marine ALG-2LP revealed that mALG-2LP is similar to the following proteins: mouse probable calcium binding protein (Accession No. P
1281 S), mouse calcium binding protein (Accession No. 504970), and human Sorcin (Accession No. P30626). Partial marine ALG-2LP is 4S% identical to mouse probable calcium binding protein (Accession No. P 1281 S) over amino acid residues 11 S-221;
43%
identical to mouse calcium binding protein (Accession No. 504970) over amino acid residues 130-221; and 39% identical to human Sorcin (Accession No. P30626) over amino acid residues 131-227.
2S Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
_1_ SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: MILLENNIUM PHARMACEUTICALS, INC.
(B) STREET: 75 SIDNEY STREET
(C) CITY: CAMBRIDGE
(D) STATE: MASSACHUSETTS
(E) COUNTRY: US
(F) POSTAL CODE: 02139 (G) TELEPHONE:
(H) TELEFAX:
IS (ii) TITLE OF INVENTION: ALG-2LP, ALG-2 LIKE MOLECULES
AND USES THEREFOR
(iii) NUMBER OF SEQUENCES: 22 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: LAHIVE & COCKFIELD, LLP
(B) STREET: 28 STATE STREET
(C) CITY: BOSTON
(D) STATE: MASSACHUSETTS
(E) COUNTRY: US
(F) ZIP: 02109 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B} COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: PCT/US99/
(B) FILING DATE: 13 MAY 1999 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 09/084,749 (B) FILING DATE: 26 MAY 1998 (viii) ATTORNEY/AGENT INFORMATION:
{A) NAME: MANDRAGOURAS, AMY E.
(B) REGISTRATION NUMBER: 36,207 (C) REFERENCE/DOCKET NUMBER: MNI-043PC
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617)227-7400 (B) TELEFAX: (617)742-4214 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1667 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 30..881 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Pro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Gly Pro Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Asn Pro Gly Met Phe Pro Ser Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Gly Pro Tyr Gly Gln Pro Pro Pro Ser Ser Tyr Gly Ala Gln Gln Pro Gly Leu Tyr Gly Gln Gly Gly Ala Pro Pro Asn Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Val Asp Ser Asp His Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Tyr Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu 1?~~AAAAAAAA p~~;AAAAAAAA AAAAAA 16 6 7 (2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 284 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Pro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Gly Pro Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Asn Pro Gly Met Phe Pro Ser Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Gly Pro Tyr Gly Gln Pro Pro Pro Ser Ser Tyr Gly Ala Gln Gln Pro Gly Leu Tyr Gly Gln Gly Gly Ala Pro Pro Asn Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Val Asp Ser Asp His Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Tyr Thr Glu Leu Gln Gln WO 99/b1459 PCT/US99/10581 Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu (2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 852 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..852 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Fro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Gly Pro Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Asn Pro Gly Met Phe Pro Ser Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Gly Pro Tyr Gly Gln Pro Pro Pro Ser Ser Tyr Gly Ala Gln Gln Pro Gly Leu Tyr Gly Gln Gly Gly Ala Pro Pro Asn Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Val Asp Ser Asp His Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Tyr Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu (2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1525 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
( ix) FEATURE
(A) NAME/KEY: CDS
(B) LOCATION: 10..840 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Pro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Tyr Gly Gly Pro Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Sex Pro Gly Met Phe Pro Ser Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Ser Pro Tyr Gly Gln Pro Pro Leu Ser Ser Tyr Gly Ala Gln Gln Pro Gly Pro Tyr Gly Gln Gly Gly Ala Pro Pro Ser Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp _g_ Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp 175 1$0 185 Arg Ser Gly Ser Ile Ser Tyr Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu CAGCCCTGGC ACCGGGAGCA GGTTCTTGTA ATGGAGiTAG TGTCCAGTCA GCTGAGCTCC 1170 (2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 277 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Pro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Tyr Gly Gly Pro Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Ser Pro Gly Met Phe Pro Ser Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Ser Pro Tyr Gly Gln Pro Pro Leu Ser Ser Tyr Gly Ala Gln Gln Pro Gly Pro Tyr Gly Gln Gly Gly Ala Pro Pro Ser Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Tyr Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu (2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 831 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..831 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
Met Ala Ser Tyr Pro Tyr Arg Gln Gly Cys Pro Gly Ala Ala Gly Gln Ala Pro Gly Ala Pro Pro Gly Ser Tyr Tyr Pro Gly Pro Pro Asn Ser Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Tyr Gly Gly Pro 35 Ala Pro Gly Gly Pro Tyr Gly Pro Pro Ala Gly Gly Gly Pro Tyr Gly His Pro Ser Pro Gly Met Phe Pro Sex Gly Thr Pro Gly Gly Pro Tyr Gly Gly Ala Ala Pro Gly Ser Pro Tyr Gly Gln Pro Pro Leu Ser Ser Tyr Gly Ala Gln Gln Pro Gly Pro Tyr Gly Gln Gly Gly Ala Pro Pro Ser Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Gly Tyr Ile Ser Met Lys Glu Leu Lys Gln Ala Leu Val Asn Cys Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Tyr Gly Phe Ser Ala Leu Trp Lys Phe Ile Gln Gln Trp Lys Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly IS Ser Ile Ser Tyr Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Pro Arg Ser Ala Asn Pro Ala Met Gln Leu Asp Arg Phe Ile Gln Val Cys Thr Gln Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu (2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1362 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY; CDS
(B) LOCATION: 177..998 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
Ser Ser Tyr Pro Asn Gly Gln Ser Cys Pro Gly Ala Ala Gly Gln Val Pro Gly Val Pro Pro Gly Gly Tyr Tyr Pro G1y Pro Pro His Gly Gly GIy Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Ala Pro AIa Pro Gly Gly Pro Tyr Gly Tyr Pro Ser Ala Gly Gly Val Pro Ser Gly Thr Pro Ser Gly Pro Tyr Gly Gly Ile Pro Pro Gly Gly Pro Tyr Gly Gln Leu Pro Pro Gly Gly Pro Tyr Gly Thr Gln Pro Gly His Tyr Gly Gln Gly Gly Val Pro Xaa Asn Val Asp Pro Glu Ala Tyr Ser Trp loo 105 110 Phe Gln Ser Val Asp Ala Asp His Ser Gly Tyr Ile Ser Leu Lys Glu Leu Lys Gln Ala Leu Val Asn Ser Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Ala Gly Phe Ser Ala Leu Trp Lys Phe Leu Gln Gln Trp Arg Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Ser Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln PheThr GlnLeuLeu ValSerArg TyrCysAla ArgSer Ala Ile Pro AlaMet GlnLeuAsp CysPheIle LysValCys ThrGln Leu Val LeuThr GluAlaPhe ArgGluLys AspThrA1a ValGln Gly Gln Asn Ile ArgLeu SerPheGlu AspPheVal ThrMetThr AlaSer Arg TCCCTAAAGG
GAGTGGAGCA
CACCAGGGGA
Met Leu (2) INFORMATION FOR SEQ ID N0:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 274 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
Ser Ser Tyr Pro Asn Gly Gln Ser Cys Pro Gly Ala Ala Gly Gln Val Pro Gly Val Pro Pro Gly Gly Tyr Tyr Pro Gly Pro Pro His Gly Gly Gly Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Ala Pro Ala Pro Gly Gly Pro Tyr Gly Tyr Pro Ser Ala Gly Gly Val Pro Ser Gly Thr Pro Ser Gly Pro Tyr Gly Gly Ile Pro Pro Gly Gly Pro Tyr Gly Gln Leu Pro Pro Gly Gly Pro Tyr Gly Thr Gln Pro Gly His Tyr Gly Gln Gly Gly Val Pro Xaa Asn Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Val Asp Ala Asp His Ser Gly Tyr Ile Ser Leu Lys Glu Leu Lys Gln Ala Leu Val Asn Ser Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Ala Gly Phe Ser Ala Leu Trp Lys Phe Leu Gln Gln Trp Arg Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Ser Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser Pro Gln Phe Thr Gln Leu Leu Val Ser Arg Tyr Cys Ala Arg Ser Ala Ile Pro Ala Met Gln Leu Asp Cys Phe Ile Lys Val Cys Thr GIn Leu Gln Val Leu Thr Glu Ala Phe Arg Glu Lys Asp Thr Ala Val Gln Gly Asn Ile Arg Leu Ser Phe Glu Asp Phe Val Thr Met Thr Ala Ser Arg Met Leu (2) INFORMATION FOR SEQ ID N0:9:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 822 base pairs (B) TYPE: nucleic acid {C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..822 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
Ser Ser Tyr Pro Asn Gly Gln Ser Cys Pro Gly Ala Ala Gly Gln Val Pro Gly Val Pro Pro Gly Gly Tyr Tyr Pro Gly Pro Pro His Gly Gly G1y Gln Tyr Gly Ser Gly Leu Pro Pro Gly Gly Gly Tyr Gly Ala Pro Ala Pro Gly Gly Pro Tyr Gly Tyr Pro Ser Ala Gly Gly Val Pro Ser Gly Thr Pro Ser Gly Pro Tyr Gly Gly Ile Pro Pro Gly Gly Pro Tyr Gly Gln Leu Pro Pro Gly Gly Pro Tyr Gly Thr Gln Pro Gly His Tyr Gly Gln Gly Gly Val Pro Xaa Asn Val Asp Pro Glu Ala Tyr Ser Trp Phe Gln Ser Val Asp Ala Asp His Ser Gly Tyr Ile Ser Leu Lys Glu Leu Lys Gln Ala Leu Val Asn Ser Asn Trp Ser Ser Phe Asn Asp Glu Thr Cys Leu Met Met Ile Asn Met Phe Asp Lys Thr Lys Ser Gly Arg Ile Asp Val Ala Gly Phe Ser Ala Leu Trp Lys Phe Leu Gln Gln Trp Arg Asn Leu Phe Gln Gln Tyr Asp Arg Asp Arg Ser Gly Ser Ile Ser Ser Thr Glu Leu Gln Gln Ala Leu Ser Gln Met Gly Tyr Asn Leu Ser TCC CGG GCT
Pro Gln Phe Thr Gln Leu Leu Val Tyr Cys Ala Arg Ser Ser Arg Ala TTC ATC CTG
Ile Pro Ala Met Gln Leu Asp Cys Lys Val Cys Thr Gln Phe Ile Leu GAA AAG GGC
Gln Val Leu Thr Glu Ala Phe Arg Asp Thr Ala Val Gln Glu Lys Gly TTT GTC AGG
Asn Ile Arg Leu Ser Phe Glu Asp Thr Met Thr Ala Ser Phe Val Arg Met Leu (2) INFORMATION
FOR
SEQ
ID
NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi)SEQUENCE DESCRIPTION: SEQ
ID NO:10:
Asp Ser Asp His Ser Gly Tyr Met Lys Glu Leu Ile Ser (2) INFORMATION
FOR
SEQ
ID
NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi)SEQUENCE DESCRIPTION: SEQ :11:
ID NO
Asp Arg Asp Arg Ser Gly Ser Tyr Thr Glu Leu Ile Ser (2)INFORMATION
FOR
SEQ
ID
N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: N0:12:
SEQ ID
Ser Trp Phe Gln Ser Gly Tyr Ser Met Lys Glu Ile Leu (2)INFORMATION
FOR
SEQ
ID
N0:13:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid {D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: N0:13:
SEQ ID
Asp Arg Asp Arg Ser Gly Ser Ser Tyr Thr Glu Ile Leu (2)INFORMATION
FOR
SEQ
ID
N0:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear {ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: N0:14:
SEQ ID
Asp Ala Asp His Ser Gly Tyr Ser Leu Lys Glu Ile Leu 1 ~ 5 10 (2)INFORMATION
FOR
SEQ
ID
N0:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear {ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID N0:15:
Asp Arg Asp Arg Ser Gly Ser Ile Ser Ser Thr Glu Leu (2) INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID N0:16:
Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Lys Asp Gly Asp Gly Xaa Xaa Xaa Xaa Xaa Glu Phe Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:
(2) INFORMATION FOR SEQ ID N0:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:18:
(2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ N0:19:
ID
15(2) INFORMATION FOR SEQ ID N0:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid 20(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
25(xi) SEQUENCE DESCRIPTION: SEQ N0:20:
ID
(2) INFORMATION FOR SEQ ID N0:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 35{D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDlvA
(xi) SEQUENCE DESCRIPTION: SEQ N0:21:
ID
(2) INFORMATION FOR SEQ ID N0:22:
45(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ N0:22:
ID
Claims (23)
1. An isolated nucleic acid molecule selected from the group consisting of a) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2;
e) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:5;
f) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:8;
g) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:1 under stringent conditions;
h) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:4 under stringent conditions; and i) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:7 under stringent conditions.
b) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2;
e) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:5;
f) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:8;
g) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:1 under stringent conditions;
h) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:4 under stringent conditions; and i) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:7 under stringent conditions.
2. The nucleic acid molecule of claim 1 further comprising vector nucleic acid sequences.
3. The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous protein.
4. A host cell which contains the nucleic acid molecule of claim 1.
5. The host cell of claim 4 which is a mammalian host cell.
6. A non-human mammalian host cell containing the nucleic acid molecule of claim 1.
7. The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:
a) the coding region of SEQ ID NO:1;
b) the coding region of SEQ ID NO:4; and c) the coding region of SEQ ID NO:7.
a) the coding region of SEQ ID NO:1;
b) the coding region of SEQ ID NO:4; and c) the coding region of SEQ ID NO:7.
8. An isolated protein selected from the group consisting of a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions.
b) a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions.
9. The protein of claim 8 further comprising heterologous amino acid sequences.
10. An antibody which selectively binds to a protein of claim 8.
11. A method for producing a protein selected from the group consisting of:
a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions;
the method comprising the step of culturing the host cell of claim 4 under conditions in which the nucleic acid molecule is expressed.
a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions;
the method comprising the step of culturing the host cell of claim 4 under conditions in which the nucleic acid molecule is expressed.
12. A method for detecting the presence of a protein selected from the group consisting of:
a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions;
in a sample, the method comprising the steps of:
i) contacting the sample with a compound which selectively binds to the protein; and ii) determining whether the compound binds to the protein in the sample.
a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions;
in a sample, the method comprising the steps of:
i) contacting the sample with a compound which selectively binds to the protein; and ii) determining whether the compound binds to the protein in the sample.
13. The method of claim 12, wherein the compound which binds to the protein is an antibody.
14. A kit comprising reagents used for the method of claim 12, wherein the reagents comprise a compound which selectively binds to a protein selected from the group consisting of:
a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions.
a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions.
15. A method for detecting the presence of a nucleic acid molecule selected from the group consisting of:
a) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2;
e) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:5;
f) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:8;
g) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:1 under stringent conditions;
h) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:4 under stringent conditions; and i) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:7 under stringent conditions;
in a sample, the method comprising the steps of:
i) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and ii) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
a) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2;
e) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:5;
f) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:8;
g) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:1 under stringent conditions;
h) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:4 under stringent conditions; and i) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:7 under stringent conditions;
in a sample, the method comprising the steps of:
i) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and ii) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
16. The method of claim 15, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
17. A kit comprising reagents used for the method of claim 15, wherein the reagents comprise a compound which selectively hybridizes to a nucleic acid molecule selected from the group consisting of:
a) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2;
e) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:5;
f) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:8;
g) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:1 under stringent conditions;
h) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:4 under stringent conditions; and i) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:7 under stringent conditions.
a) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a nucleic acid molecule which encodes a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2;
e) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:5;
f) a nucleic acid molecule which encodes a fragment of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:8;
g) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:1 under stringent conditions;
h) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:4 under stringent conditions; and i) a nucleic acid molecule which encodes a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID
NO:7 under stringent conditions.
18. A method for identifying a compound which binds to a protein selected from the group consisting of:
a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b} a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions, the method comprising the steps of:
i) contacting the protein, or a cell expressing the protein with a test compound; and ii) determining whether the protein binds to the test compound.
a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b} a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions, the method comprising the steps of:
i) contacting the protein, or a cell expressing the protein with a test compound; and ii) determining whether the protein binds to the test compound.
19. The method of claim 18, wherein the binding of the test compound to the protein is detected by a method selected from the group consisting of:
a) detection of binding by direct detecting of test compound/protein binding;
b) detection of binding using a competition binding assay;
c) detection of binding using an assay for ALG-2LP activity.
a) detection of binding by direct detecting of test compound/protein binding;
b) detection of binding using a competition binding assay;
c) detection of binding using an assay for ALG-2LP activity.
20. A method for modulating the activity of a protein selected from the group consisting of:
a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 1 S contiguous amino acids of SEQ ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions, the method comprising the steps of:
i) contacting a cell expressing the protein with a compound which binds to the protein in a sufficient concentration to modulate the activity of the protein.
a) a protein comprising the amino acid sequence of SEQ ID NO:2;
b) a protein comprising the amino acid sequence of SEQ ID NO:5;
c) a protein comprising the amino acid sequence of SEQ ID NO:8;
d) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:2, wherein the fragment comprises at least 1 S contiguous amino acids of SEQ ID
NO:2;
e) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:5, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:5;
f) a fragment of a protein comprising the amino acid sequence of SEQ ID
NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ
ID
NO:8;
g) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:2, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 under stringent conditions;
h) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:5, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:4 under stringent conditions; and i) a naturally occurring allelic variant of a protein comprising the amino acid sequence of SEQ ID NO:8, wherein the protein is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 under stringent conditions, the method comprising the steps of:
i) contacting a cell expressing the protein with a compound which binds to the protein in a sufficient concentration to modulate the activity of the protein.
21. The method of claim 20, wherein the activity is modulation of programmed cell death.
22. The method of claim 20, wherein the method results in inhibition of programmed cell death.
23. The method of claim 20, wherein the method results in stimulation of programmed cell death.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8474998A | 1998-05-26 | 1998-05-26 | |
US09/084,749 | 1998-05-26 | ||
PCT/US1999/010581 WO1999061459A1 (en) | 1998-05-26 | 1999-05-13 | Alg-2lp, alg-2 like molecules and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2329506A1 true CA2329506A1 (en) | 1999-12-02 |
Family
ID=22186980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002329506A Abandoned CA2329506A1 (en) | 1998-05-26 | 1999-05-13 | Alg-2lp, alg-2 like molecules and uses therefor |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1082334A1 (en) |
JP (1) | JP2002516335A (en) |
AU (1) | AU3988399A (en) |
CA (1) | CA2329506A1 (en) |
WO (1) | WO1999061459A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763220A (en) * | 1996-12-12 | 1998-06-09 | Incyte Pharmaceuticals, Inc. | Human apoptosis-related calcium-binding protein |
-
1999
- 1999-05-13 AU AU39883/99A patent/AU3988399A/en not_active Abandoned
- 1999-05-13 CA CA002329506A patent/CA2329506A1/en not_active Abandoned
- 1999-05-13 JP JP2000550863A patent/JP2002516335A/en active Pending
- 1999-05-13 EP EP99923016A patent/EP1082334A1/en not_active Withdrawn
- 1999-05-13 WO PCT/US1999/010581 patent/WO1999061459A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU3988399A (en) | 1999-12-13 |
WO1999061459A1 (en) | 1999-12-02 |
JP2002516335A (en) | 2002-06-04 |
EP1082334A1 (en) | 2001-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU747798B2 (en) | G-protein coupled receptors and uses therefor | |
US5882893A (en) | Nucleic acids encoding muscarinic receptors and uses therefor | |
WO1998045467A1 (en) | NOVEL TGF-β PATHWAY GENES | |
US20020119517A1 (en) | Leptin induced genes | |
AU753185B2 (en) | Ligand receptors and uses therefor | |
WO1998054323A1 (en) | The siva genes involved in cd27-mediated apoptosis | |
AU752043B2 (en) | Spoil protein and nucleic acid molecules and uses therefor | |
CA2340796A1 (en) | Novel irap-bp polypeptide and nucleic acid molecules and uses therefor | |
AU3755699A (en) | Novel lrsg protein and nucleic acid molecules and uses therefor | |
AU753279B2 (en) | Novel molecules of the T129-related protein family and uses thereof | |
WO1999050298A1 (en) | GFRα-X, A NOVEL GLIAL-DERIVED NEUROTROPHIC FACTOR RECEPTOR AND USES THEREFOR | |
CA2329506A1 (en) | Alg-2lp, alg-2 like molecules and uses therefor | |
EP1092038A1 (en) | OCT1p, A PROTEIN HAVING HOMOLOGY TO THE ORGANIC AND SUGAR TRANSPORTER FAMILY OF PROTEINS, AND USES THEREOF | |
US6756212B1 (en) | Isolated proteins and nucleic acid molecules having homology to the NIP2 protein and uses thereof | |
US20020004193A1 (en) | Novel MP-7 protein and nucleic acid molecules and uses therefor | |
MXPA00011566A (en) | Alg-2lp, alg-2 like molecules and uses therefor | |
US20030082688A1 (en) | Spoil protein and nucleic acid molecules and uses therefor | |
WO1998008861A1 (en) | Rp compositions and therapeutic and diagnostic uses therefor | |
WO1999054343A2 (en) | Novel molecules of the t139-related protein family and uses thereof | |
WO1999067415A9 (en) | Novel molecules of the t110-related protein family and uses thereof | |
MXPA00007226A (en) | Ligand receptors and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |